Original Article
Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
N Engl J Med 2003; 348:1309-1321April 3, 2003
- Abstract
Background
Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure. We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.
Methods
Patients were randomly assigned to eplerenone (25 mg per day initially, titrated to a maximum of 50 mg per day; 3313 patients) or placebo (3319 patients) in addition to optimal medical therapy. The study continued until 1012 deaths occurred. The primary end points were death from any cause and death from cardiovascular causes or hospitalization for heart failure, acute myocardial infarction, stroke, or ventricular arrhythmia.
Results
During a mean follow-up of 16 months, there were 478 deaths in the eplerenone group and 554 deaths in the placebo group (relative risk, 0.85; 95 percent confidence interval, 0.75 to 0.96; P=0.008). Of these deaths, 407 in the eplerenone group and 483 in the placebo group were attributed to cardiovascular causes (relative risk, 0.83; 95 percent confidence interval, 0.72 to 0.94; P=0.005). The rate of the other primary end point, death from cardiovascular causes or hospitalization for cardiovascular events, was reduced by eplerenone (relative risk, 0.87; 95 percent confidence interval, 0.79 to 0.95; P=0.002), as was the secondary end point of death from any cause or any hospitalization (relative risk, 0.92; 95 percent confidence interval, 0.86 to 0.98; P=0.02). There was also a reduction in the rate of sudden death from cardiac causes (relative risk, 0.79; 95 percent confidence interval, 0.64 to 0.97; P=0.03). The rate of serious hyperkalemia was 5.5 percent in the eplerenone group and 3.9 percent in the placebo group (P=0.002), whereas the rate of hypokalemia was 8.4 percent in the eplerenone group and 13.1 percent in the placebo group (P<0.001).
Conclusions
The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.
Media in This Article
Figure 1
Kaplan–Meier Estimates of the Rate of Death from Any Cause (Panel A), the Rate of Death from Cardiovascular Causes or Hospitalization for Cardiovascular Events (Panel B), and the Rate of Sudden Death from Cardiac Causes (Panel C).Figure 2
Relative Risks of Death from Any Cause (Panel A) and Relative Risks of Death from Cardiovascular Causes or Hospitalization for Cardiovascular Events (Panel B), According to Base-Line Demographic and Clinical Characteristics.Article Activity
- Article
Aldosterone blockade reduces the rate of death due to progressive heart failure and the rate of sudden death from cardiac causes, as well as the rate of hospitalizations for heart failure, among patients with severe heart failure due to systolic left ventricular dysfunction who are being treated with an angiotensin-converting–enzyme (ACE) inhibitor.1 Aldosterone blockade also prevents ventricular remodeling and collagen formation in patients with left ventricular dysfunction after acute myocardial infarction2 and affects a number of pathophysiological mechanisms that are thought to be important in the prognosis of patients with acute myocardial infarction.3-12 Its role in reducing mortality and the rate of hospitalization among patients with acute myocardial infarction complicated by left ventricular dysfunction is uncertain. We therefore designed the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) to test the hypothesis that treatment with eplerenone, an aldosterone blocker that selectively blocks the mineralocorticoid receptor and not glucocorticoid, progesterone, or androgen receptors,13 reduces overall mortality and cardiovascular mortality or hospitalization for cardiovascular events among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure who are receiving optimal medical therapy.
Methods
Study Design and study Population
We conducted a multicenter, international, randomized, double-blind, placebo-controlled trial.14 Patients were randomly assigned to receive eplerenone (25 mg per day) or matching placebo for four weeks, after which the dose of eplerenone was increased to a maximum of 50 mg per day. Randomization was stratified according to clinical site, and schedules were prepared with the use of permuted blocks to ensure the ongoing equivalence of the size of the groups. If at any time during the study the serum potassium concentration was higher than 5.5 mmol per liter, the dose of the study drug was reduced or treatment was temporarily discontinued until the serum potassium concentration fell below 5.5 mmol per liter.
Patients in whom the following criteria were met were eligible for randomization 3 to 14 days after acute myocardial infarction: acute myocardial infarction as documented according to standard criteria; left ventricular dysfunction as documented by a left ventricular ejection fraction of 40 percent or lower on echocardiography, radionuclide angiography, or angiography of the left ventricle after the index acute myocardial infarction and before randomization; and heart failure as documented by the presence of pulmonary rales, chest radiography showing pulmonary venous congestion, or the presence of a third heart sound. In patients with diabetes who met the criteria for left ventricular dysfunction after acute myocardial infarction, symptoms of heart failure did not have to be demonstrated, since such patients have an increased risk of cardiovascular events similar to that of nondiabetic patients with symptoms of heart failure.15 Patients received optimal medical therapy, which could include ACE inhibitors, angiotensin-receptor blockers, diuretics, and beta-blockers, as well as coronary reperfusion therapy.
Important criteria for exclusion were the use of potassium-sparing diuretics, a serum creatinine concentration of more than 2.5 mg per deciliter (220 μmol per liter), and a serum potassium concentration of more than 5.0 mmol per liter before randomization. The institutional review board or ethics committee at each site approved the protocol, and all patients provided written informed consent before enrollment.
Screening and base-line procedures were to be performed during the hospitalization for the index acute myocardial infarction, and follow-up visits occurred at one and four weeks, three months, and every three months thereafter until the termination of the study. The serum potassium concentration was measured 48 hours after the initiation of treatment, at one, four, and five weeks, at all scheduled study visits, and within one week after any change of dose. Information about adverse events and concurrent medications was recorded at every visit. All patients who underwent randomization were followed for vital status and hospitalizations every three months until the termination of the study.
Definition of Study End Points
The two primary end points were time to death from any cause and time to death from cardiovascular causes or first hospitalization for a cardiovascular event, including heart failure, recurrent acute myocardial infarction, stroke, or ventricular arrhythmia. The major secondary end points were death from cardiovascular causes and death from any cause or any hospitalization. All end points were adjudicated by a blinded critical-events committee. Definitions of all adjudicated end points are presented in Supplementary Appendix 1 (available with the full text of this article at http://www.nejm.org).
Statistical Analysis
The two groups were compared in terms of the two primary end points and the secondary end points with the use of Cox proportional-hazards regression. The Cox model included a single covariate corresponding to treatment group and was stratified according to geographic region (Canada and the United States, Latin America, eastern Europe, western Europe, and the rest of the world [including Australia, Israel, New Zealand, South Africa, South Korea, and Taiwan]). The model was used to estimate the relative risk and corresponding 95 percent confidence interval. Time-to-event distributions were summarized with Kaplan–Meier curves. For analyses of mortality, data were censored at the time of loss to follow-up or on the closing date of the study (August 30, 2002). For analyses of death from cardiovascular causes or hospitalization for cardiovascular events, data were censored at the time of death due to noncardiovascular causes, the time of loss to follow-up, or on the closing date of the study. Analyses of the primary and secondary end points were conducted according to the intention-to-treat principle.
The trial was designed to enroll 6200 patients and to continue until 1012 deaths occurred. To maintain an overall type I error rate of 0.05 (two-sided), the rate of death from any cause was tested at the 0.04 level of significance and the rate of death from cardiovascular causes or hospitalization for cardiovascular events was tested at the 0.01 level of significance. With testing at the 0.04 level of significance (two-sided), the study had 88.3 percent power to detect an 18.5 percent difference between the two groups in the rate of death from any cause.16 An external data and safety monitoring board conducted four interim analyses; an alpha level of 0.0001 was the threshold for early termination in the first two interim analyses of mortality from any cause, and an alpha level of 0.001 was the threshold for the last two analyses. Data-base management was performed by a contract research organization. The interim analyses were conducted by an independent statistician for the data and safety monitoring board. All final analyses were conducted by the sponsor. All independent authors had a substantial role in trial design, data accrual, and data interpretation. All had complete access to the data after unblinding.
Subgroup analyses for the two primary end points were performed with a Cox model stratified according to region, with terms for treatment, subgroup, and interaction between treatment and subgroup. For these analyses, measured variables were treated as binary variables, dichotomized at the median value, and also considered as continuous variables.
We also used Cox regression to summarize the time to first hospitalization for a cardiovascular event. For these analyses, data were censored at the time of death. The frequencies of hospitalization for particular causes were analyzed by means of a Cochran–Mantel–Haenszel test, and the relative risk for this analysis was reported as the ratio of the number of hospitalizations per patient in the eplerenone group to the number of hospitalizations per patient in the placebo group. The number of patients who would need to be treated to prevent one event was determined by the method of Altman and Andersen.17
All patients who received at least one dose of the study medication were included in the safety analyses, which included analyses of adverse events, vital signs, and results of clinical laboratory tests. Changes in vital signs and clinical laboratory values were assessed by analysis of covariance, with the base-line value as a covariate. Creatinine clearance was calculated according to the Cockcroft–Gault formula.18 All reported P values are two-sided and are not adjusted for the interim analyses.
Results
Study Patients
A total of 6642 patients underwent randomization at 674 centers in 37 countries between December 27, 1999, and December 31, 2001. A total of 3313 were assigned to placebo, 3319 were assigned to eplerenone, and 10 were excluded from the analysis before unblinding because of problems with the quality of the data at one center. There were no significant differences between the two groups at base line (Table 1Table 1
Base-Line Characteristics of the Patients.). At base line, the majority of patients were receiving standard therapies for acute myocardial infarction complicated by left ventricular dysfunction and heart failure, including ACE inhibitors or angiotensin-receptor blockers (in 87 percent of patients), beta-blockers (in 75 percent), aspirin (in 88 percent), and diuretics (in 60 percent).Twelve patients in each treatment group did not take any study medication. During the study, 1021 patients (493 in the placebo group and 528 in the eplerenone group) permanently discontinued the study medication (median time from randomization to the last dose, 98 days). The most frequent reasons were a request by the patient to withdraw from the study (in 204 patients in the placebo group and 231 in the eplerenone group) and adverse events (in 149 patients in the placebo group and 147 in the eplerenone group). Seventeen patients (7 in the placebo group and 10 in the eplerenone group) had unknown vital status on the closing date of the study (August 30, 2002), and 99 percent of the surviving patients were seen or contacted between August 15 and August 30, 2002. The mean duration of follow-up was 16 months (range, 0 to 33). The mean dose-equivalent of study medication was 43.5 mg in the placebo group and 42.6 mg in the eplerenone group.
End Points
A total of 478 patients in the eplerenone group (14.4 percent) and 554 patients in the placebo group (16.7 percent) died (relative risk, 0.85; P=0.008) (Table 2Table 2
Summary of Primary and Secondary End Points.). Kaplan–Meier estimates of mortality at one year were 11.8 percent in the eplerenone group and 13.6 percent in the placebo group (Figure 1AFigure 1Kaplan–Meier Estimates of the Rate of Death from Any Cause (Panel A), the Rate of Death from Cardiovascular Causes or Hospitalization for Cardiovascular Events (Panel B), and the Rate of Sudden Death from Cardiac Causes (Panel C).). The end point of death from cardiovascular causes or hospitalization for cardiovascular events was reached by 885 patients in the eplerenone group (26.7 percent) and 993 patients in the placebo group (30.0 percent) (relative risk, 0.87; P=0.002) (Figure 1B).A total of 407 deaths in the eplerenone group (12.3 percent of patients) and 483 deaths in the placebo group (14.6 percent of patients) were attributed to cardiovascular causes (relative risk, 0.83; P=0.005). The reduction in cardiovascular mortality was similar for the most common causes — sudden death from cardiac causes, acute myocardial infarction, and heart failure (range of relative risks, 0.79 to 0.82). Of these reductions, the reduction in the risk of sudden death from cardiac causes was statistically significant (relative risk, 0.79; P=0.03) (Table 2 and Figure 1C). There was a relative reduction of 15 percent in the risk of hospitalization for heart failure with eplerenone (relative risk, 0.85; P=0.03), and there were 23 percent fewer episodes of hospitalization for heart failure in the eplerenone group than in the placebo group (relative risk, 0.77; P=0.002). The rate of death from any cause or any hospitalization was 8 percent lower in the eplerenone group than in the placebo group (relative risk, 0.92; P=0.02).
The relative risks for important predefined subgroups are shown in Figure 2Figure 2
Relative Risks of Death from Any Cause (Panel A) and Relative Risks of Death from Cardiovascular Causes or Hospitalization for Cardiovascular Events (Panel B), According to Base-Line Demographic and Clinical Characteristics.. Reductions in the rate of death from any cause and the rate of death from cardiovascular causes or hospitalization for cardiovascular events were consistent among subgroups. Interactions between treatment and some measured variables were significant when they were analyzed as binary variables with median cutoff points (e.g., pulse pressure), but when they were considered as continuous variables, the interactions were no longer significant. The beneficial effect of eplerenone was also consistent across geographic regions (P=0.24 for the interaction of treatment and region for death from any cause, and P=0.94 for the interaction of treatment and region for death from cardiovascular causes or hospitalization for cardiovascular events).Safety
After week 1, the mean systolic and diastolic blood pressure increased in both groups from base line to each time point throughout the remainder of the trial. The magnitude of these increases in the eplerenone group was significantly smaller than that in the placebo group at every point. At one year, the mean blood pressure had increased by 8/4 mm Hg in the placebo group and by 5/3 mm Hg in the eplerenone group (P<0.01). Also at one year, the heart rate had decreased by 6 beats per minute in the placebo group and by 7 beats per minute in the eplerenone group (P=0.32).
At one year, the serum creatinine concentration had increased by 0.02 mg per deciliter (1.8 μmol per liter) in the placebo group and by 0.06 mg per deciliter (5.3 μmol per liter) in the eplerenone group (P<0.001). Potassium levels had increased in both groups at one year (by 0.2 mmol per liter in the placebo group and 0.3 mmol per liter in the eplerenone group, P<0.001). Serious hyperkalemia (serum potassium concentration, ≥6.0 mmol per liter) occurred in 5.5 percent of patients in the eplerenone group, as compared with 3.9 percent of those in the placebo group (P=0.002). For patients who had serious hyperkalemia, the incidence of greater elevations in the potassium concentration was similar in the eplerenone group (0.6 percent with concentrations ≥7 mmol per liter and 0.2 percent with concentrations ≥8 mmol per liter) and in the placebo group (0.5 percent with concentrations ≥7 mmol per liter and 0.1 percent with concentrations ≥8 mmol per liter). Fifteen patients with serious hyperkalemia (12 in the eplerenone group and 3 in the placebo group) were hospitalized for the condition, and one death in the placebo group was attributed to it. In each treatment group, the incidence of hyperkalemia was higher among patients with a lower base-line creatinine clearance (P<0.001 by logistic-regression analysis). Among patients with a base-line creatinine clearance of less than 50 ml per minute, the incidence of serious hyperkalemia was 10.1 percent in the eplerenone group and 5.9 percent in the placebo group (P=0.006). Among patients with a base-line creatinine clearance of 50 ml per minute or more, the corresponding rates were 4.6 percent and 3.5 percent (P=0.04). Patients who had serious hyperkalemia were also more likely than those who did not have serious hyperkalemia to have a serum potassium concentration of more than 5.5 mmol per liter or a calculated creatinine clearance of less than 70 ml per minute at the week 1 visit.
There were no other significant differences between the treatment groups in the number of patients with changes in laboratory variables that met prespecified criteria for abnormally low or high values. Adverse events are described in Table 3Table 3
Adverse Events..Discussion
The addition of eplerenone to optimal treatment at a maximal dose of 50 mg once daily (mean dose, 43 mg per day) in patients assigned to treatment 3 to 14 days (mean, 7) after acute myocardial infarction resulted in additional reductions in overall mortality and the rate of death from cardiovascular causes or hospitalization for cardiovascular events among patients whose acute myocardial infarction was complicated by left ventricular dysfunction and heart failure. There was also a reduction in cardiovascular mortality and the rate of death from any cause or any hospitalization among patients assigned to eplerenone.
One-year mortality among patients assigned to placebo, the majority of whom received an ACE inhibitor or angiotensin-receptor blocker and a beta-blocker, was 13.6 percent. This rate is higher than that in the treatment groups of a recent study of carvedilol in patients with left ventricular dysfunction after acute myocardial infarction (the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction [CAPRICORN] study) and a study of losartan in patients with left ventricular dysfunction after acute myocardial infarction (the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan [OPTIMAAL]),19,20 in which control patients were treated with an ACE inhibitor and a beta-blocker; the higher rate in our study most likely reflects the presence of signs of heart failure, in addition to left ventricular dysfunction, in 90 percent of our patients. Mortality in the placebo group in the current study, however, was lower and the magnitude of the effect of aldosterone blockade was smaller than in the Randomized Aldactone Evaluation Study (RALES), a trial of spironolactone in patients with left ventricular dysfunction and severe chronic heart failure.1 These differences may be attributable to several factors, including the greater use of beta-blockers and a higher base-line left ventricular ejection fraction in the current study. In RALES,1 the mean left ventricular ejection fraction at base line was 25 percent, and patients had New York Heart Association class III or IV heart failure, whereas in the current study in patients with acute myocardial infarction, the mean left ventricular ejection fraction was 33 percent at base line and may have improved after reperfusion, recovery of ventricular stunning, or both. The severity of left ventricular dysfunction,21 the degree of heart failure, and the intensity of background therapy are most likely important factors determining the absolute mortality as well as the effectiveness of therapeutic agents.
The reduction in cardiovascular mortality was in large part due to a 21 percent reduction in the rate of sudden death from cardiac causes. Reductions in the rate of death due to progressive heart failure and acute myocardial infarction were similar but not significant. The reduction in the rate of hospitalization for cardiovascular events was largely due to a 15 percent reduction in the risk of hospitalization for heart failure and a 23 percent reduction in the number of episodes of hospitalization for heart failure. The mechanisms by which eplerenone provides myocardial protection in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure are not completely clear. Effects of aldosterone blockers on plasma volume and electrolyte excretion have been recognized for many years, and although these effects may have contributed to the benefit provided by eplerenone, other nonrenal mechanisms may be equally or more important. Eplerenone reduces coronary vascular inflammation and the risk of subsequent development of interstitial fibrosis in animal models of myocardial disease.22,23 Eplerenone also reduces oxidative stress, improves endothelial dysfunction,4,24 attenuates platelet aggregation,4 decreases activation of matrix metalloproteinases, and improves ventricular remodeling.25 In addition, aldosterone blockade decreases sympathetic drive in rats through direct actions in the brain,26 improves norepinephrine uptake in patients with heart failure,3 and improves heart-rate variability27 — all factors known to have important effects on the risk of sudden death from cardiac causes.
Eplerenone was beneficial in patients who were receiving optimal therapy including an ACE inhibitor or angiotensin-receptor blocker, a beta-blocker, aspirin, a lipid-lowering agent, and coronary reperfusion therapy. Previous experience with regard to the effectiveness of aldosterone blockade in patients with left ventricular dysfunction who are receiving an ACE inhibitor and a beta-blocker is limited, in that in RALES the proportion of patients who were treated with a beta-blocker was only 11 percent.1 This difference in treatments is important, because ACE inhibitors and beta-blockers are considered to represent the current standard of care in patients with left ventricular dysfunction after acute myocardial infarction, and other treatments, including endothelin-receptor antagonists, antibodies against tumor necrosis factor α, and angiotensin-receptor blockers, have not been found to reduce mortality among patients with left ventricular dysfunction and heart failure who are being treated with an ACE inhibitor and a beta-blocker.
We examined a number of predefined subgroups, but our trial was not designed with sufficient power to draw statistical conclusions about individual subgroups. Thus, one should be cautious in interpreting the results of subgroup analyses. There were a few subgroups in which we found a nominally significant interaction with treatment, but no interaction we examined had a significant effect on both primary end points. In general, the beneficial effect of eplerenone on the two primary end points was consistent.
There was an increased incidence of serious hyperkalemia among patients assigned to eplerenone. The risk of serious hyperkalemia was significantly increased among patients who had a decreased creatinine clearance at base line (<50 ml per minute). Although there were no deaths in the eplerenone group that were attributed to hyperkalemia, this finding emphasizes the need to monitor serum potassium and adjust the dose of eplerenone accordingly. We attempted to minimize the risk of hyperkalemia by excluding patients with a base-line serum potassium concentration of more than 5.0 mmol per liter, a base-line serum creatinine concentration of more than 2.5 mg per deciliter, or both. It should, however, be emphasized that in elderly patients, patients with a low body-mass index, or patients with diabetes mellitus, the serum creatinine concentration may not accurately reflect renal function. Determination of creatinine clearance by the Cockcroft–Gault formula, exclusion of patients with moderate-to-severe renal insufficiency, use of a loop diuretic in those with mild renal insufficiency, and adherence to the range of doses used in this study (25 to 50 mg per day) should minimize the risk of hyperkalemia among patients receiving eplerenone and further improve the risk–benefit ratio of this drug. It should also be pointed out that the risk of hypokalemia was more than twice as high as the risk of serious hyperkalemia and that eplerenone significantly reduced this risk.
The rate of discontinuation of blinded treatment due to adverse events and the rates of adverse events other than hyperkalemia and a variety of minor gastrointestinal complications in patients receiving eplerenone were low. In particular, the incidence of gynecomastia and impotence among men in the eplerenone group was no greater than that in the placebo group. This finding differs from the findings in RALES1 and can be attributed to the fact that eplerenone has greater selectivity for the mineralocorticoid receptor than does spironolactone, which also binds to androgen and progesterone receptors. The benefit of eplerenone in reducing the risk of respiratory disorders most likely reflects its reduction of the rate of recurrent heart failure, whereas its benefit in reducing the risk of metabolic and nutritional disorders largely reflects a reduced incidence of hypokalemia and hypoglycemia.
In conclusion, with an estimated number needed to treat of 50 to save one life in one year and an estimated number needed to treat of 33 to prevent one death from cardiovascular causes or one hospitalization for a cardiovascular event in one year, the addition of eplerenone to optimal medical therapy contributes to the continued improvement in survival and hospitalization rates among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.
Supported by a grant from Pharmacia.
Drs. Pitt and Zannad report having served as consultants to Pharmacia.
Source Information
From the University of Michigan, Ann Arbor (B.P.); STICARES, Cardiovascular Research Foundation, Rotterdam, the Netherlands (W.R.); the Centre d'Investigation Clinique de Nancy, Nancy, France (F.Z.); the University of Minnesota, Minneapolis (J.N.); the Fundación Rusculleda, Cordoba, Argentina (F.M.); and Pharmacia, Skokie, Ill. (B.R., R.B., S.H., J.K., M.G.).
Address reprint requests to Dr. Pitt at the Department of Internal Medicine, Division of Cardiology, University of Michigan Medical Center, 3910 Taubman, 1500 E. Medical Center Dr., Ann Arbor, MI 48109-0366, or at bpitt@umich.edu.
Members of the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) Group are listed in the Appendix.
Appendix
The following persons participated in the study: Steering Committee: E. Ambrosioni, J.L. Anderson, E. Apetrei, M. Aschermann, J. Banas, S. Cardoso, A. Caspi, N. Chung, R. Corbalan, H.J. Dargie, R. Dietz, L. Erhardt, A. Garcia-Castillo, M. Gheorghiade, E. Hernandez, O. Hess, K. Jamerson, J. Kjekshus, E. Klug, H. Krum, Y.-T. Lee, N. López, J.-L. López-Sendon, F. Martinez, J. Murin, J. Neaton, J.-C. Nicolau, E. Ostor, A. Parkhomenko, B. Pitt (chair), H. Ross, J. Stepinska, C. Torp-Pedersen, W. Van Mieghem, D.-J. van Veldhuisen, H. White, R.G. Wilcox, R. Willenbrock, Y.-T. Yotov, and F. Zannad. Data and Safety Monitoring Board: J.-P. Boissel, C. Furberg, D. Julian (chair), H. Kulbertus, S. Pocock, and J. Wittes (statistical consultant). Critical Events Committee: A. Battler, J. Blumenfeld, C. Brilla, D. Duprez, M. Fowler, A. Gavazzi, P. Hildebrandt, M. Komajda, J. Korewicki, D. Kosturakis, J.A. Marin-Neto, A. Miller, R. Muñoz Aguilera, R. Oliveri, W. Remme (chair), M. White, and P. Widimsky. Scientific Advisory Board: G. Bakris, A. Castaigne, P. Deedwania, D. Duprez, J.M. Ketelslegers, P. Liu, G. Mancia, J. Nicklas, J.-L. Rouleau, L. Ruilope, S. Sasayama, E. Schiffrin, J. Spertus, A. Struthers, D. Vaughan, M. Weber, and G. Williams (chair). Investigators: Europe — E. Abinader, J. Adams, P.C. Adams, J. Adamus, P. Ahlstrom, H.S. Akesson, N. Akhmedzhanov, S. Alcasena Juango, S. Ali Khan, A. Alonso Garcia, G. Amat, J. Amerena, K.M. Amosova, L. Andreoli, K. Angelo-Nielsen, J. Antonio de Velasco, E. Apetrei, G. Aroutiounov, M. Aschermann, M. Asklund, I. Assmann, M.-C. Aumont, A. Avtandilov, O. Azarin, V. Bada, P. Bakoumov, I. Balazovjech, E. Baldjiev, M. Baluda, J.R. Barrazueta, B. Barsi, Y. Bashir, P.D. Batin, D. Belenky, Y. Belyi, P.E.F. Bendermacher, K. Berget, C. Bergmeier, J. Berning, J.R. Berrazueta-Fernendez, P. Block, G. Boberg, P. Bocek, V. Bohlscheid, I. Bokarev, H. Bolinska, K. Boman, S. Bondarev, T. Bonzel, J.-L. Boreux, M. Borggrefe, M. Borisov, G. Boxho, M. Boyarkin, J. Brachmann, M. Brack, I. Branea, K. Breivik, G.S. Brigden, P.N.A. Bronzwaer, D. Bruce, I. Bruckner, H. Brunvand, A. Bryukhovetski, P. Buser, T. Campbell, A. Campeanu, A. Capucci, E. Carasca, J. Cardoso, M. Carrageta, A. Caspi, S. Cassim, J. Caturla, F. Ceia, B. Cernosek, K. Channer, Z. Chati, P.D. Christensen, N.S. Chung, M. Cinteza, J.G.F. Cleland, M. Cocchieri, P. Commerford, U. Conti, G. Corsini, A. Cortina Liosa, J.-M. Coupez, A. Cribier, J. Csillag, J. Cyran, U. Dahlstrom, A. Dalby, L.J. Dalin, M. Dalkowski, H.J. Dargie, H. Darius, D.M. Datcu, D. David, M. De Myttenaere, E. De Teresa, J. De Velasco, A.G. de Vries, F.R. den Hartog, E. Desjoyaux, A. Dezerbi, J. Dhawan, B. Diaz Molina, K. Dickstein, M. Dorobantu, V. Doschitsin, A. Doubell, P. Dovgalevsky, S.I. Dragulescu, O. Drapkina, O. Dubourg, P.H.J.M. Dunselman, O.I. Dyadyk, Y.V. Dykun, G.V. Dzyak, L.P. Egorova, K. Egstrup, J. Eha, M. Ehrenbergerova, D. El Allaf, A. Elenkova, C.J. Ellis, J.G. Engbers, A.F. Fainyk, G. Falck, R. Fanelli, J. Farre -Mun, J. Favier, G. Ferrari, I. Ferreira, H. Fischer, S. Fotyanov, M.P. Freericks, G. Froeland, E. Galve, M.M. Garcia, A.A. Garcia, L.F. Garnier, G. Gazaryan, C. Georgescu, J. Geraedts, M.G. Glezer, B.I. Goloborodko, B. Goloshchekin, J. Gonsorcik, D. Gotchev, N. Gotcheva, M.G. Gottwik, P. Grande, N. Gratsiansky, E.I. Grishina, L. Groch, A. Gruzdev, D. Guenova, T. Gundersen, I. Hagerman, R. Hambrecht, H. Hammerman, O. Hansen, V. Hansteen, H. Hart, G.F. Hauf, U. Hecker, I. Hegyi, J. Herlitz, D.P. Hertzberger, A.H. Herweijer, G.R. Heyndrickx, L. Hittinger, V. Hoang, H.-P. Hobbach, C. Hofman-Bang, N.J. Holwerda, K.P. Hong, T. Horacek, J. Hormann, J.D. Horowitz, J. Hradec, U. Hurtig, H. Ikram, A. Ioan, W. Jaarsma, L.M. Jadraque, T.J. Jakobsen, K.J. Janicki, D. Jankelow, A. Janosi, P. Jansky, L. Janssens, I. Janzen, P. Jensen, R. Jirmar, Y. Jobic, A. Jones, J. Jonsson, H. Kahles, G. Kaliska, G. Kamensky, L. Kappenberger, J.E. Karlsson, P. Karpati, O.I. Karpenko, Y. Karpov, K. Kawecka-Jaszcz, P.J. Keeling, G. Keren, K. Khalife, M. Khrakovskaya, O.A. Khrustalev, K.K. Klarlund, F.-X. Kleber, E. Klug, W. Koenig, J. Komarek, L.G. Kononenko, K. Konz, Z. Kornacewicz-Jach, V. Kostenko, J. Kotous, I. Kovalsky, P. Kozak, H.U. Kreider-Stempfle, E.P. Kromer, H. Krum, M. Krzeminska-Pakula, K. Kuc, P. Kucera, M. Kurowski, L. Lach, C. Lai, G. Lane, E. Lang, W. Lankes, P.-G. Lankisch, E. Laraudogoitia, J. Larsen, L.-E. Larsson, C. Laruelle, A. Lazar, Y.-T. Lee, A.V. Legkonogov, J. Leitch, W. Lengfelder, C.D. Lescot, B.S. Lewis, P. Lewis, I.A. Libov, N. Liel-Cohen, H.K. Lim, C.-S. Lin, G.C.M. Linssen, C.-P. Liu, D.J.A. Lok, Y.M. Lopatin, E. Lopez De Sa, C. Lotan, N. Lousada, C. Lucas, A. Lucatti, V. Lusov, T.A. Mabin, D.C. MacLeod, W. Maeurer, J.-O. Magnusson, B. Maisch, A. Malinski, M. Maltchougine, P. Manga, S. Mantov, S. Marchi, E. Marcinowska-Suchowierska, F. Marenne, F.S. Maresca, V. Markov, A.T. Marmor, C. Martines, A. Martinez, L. Martin-Jadraque, L.F.R. Martins, R. Martos Ferres, D.A.S.G. Mary, F. Masini, F. Matta, W. Maurer, A.C. Mazzini, K.M.A. McDonald, J.G. Meeder, F. Melandri, J. Melin, C. Menezes, H.R. Michels, L. Missault, V. Mitrovic, P. Mntla, A. Mobilij, A. Mogilevsky, V. Moiseev, M. Mokan, B. Möller, I. Moreira, D. Mouhoub, B. Moura, F. Muders, H. Mudra, J. Munz, J. Murin, W.J. Musial, D.P. Myburgh, N. Naqvi, G. Naumann, S.V. Nazimov, G. Nedelec, S.V. Nedogoda, I. Nielsen, T. Nielsen, P.R. Nierop, G. Nilsson, A. Notaristefano, I.N. Novitsky, I. Nykl, P. Ofner, C. Olariu, H.G. Olbrich, K.G. Oldroyd, N. Olinic, J. Oliveira, T. Omland, J. Orus, D. Owensby, A. Page, K.S. Park, O.M. Parkhomenko, C. Pasotti, M. Pasowicz, P. Pecce, A.C.H. Pell, N.I. Penkov, M. Perez de Juan, H. Perez, M. Petersen, A.A. Petrov, K. Peuhkurinen, X. Philonenko, M. Pieper, B. Pieske, W. Pluta, B. Podzemska, R. Popeye, C. Prost, A. Purcaro, P. Put, V. Radchenko, M. Radoi, A.P. Rae, D. Raev, C. Ramik, S.L. Rasmussen, L. Reisin, B. Renker, V.G. Ribeiro, G. Richardt, I. Riecansky, M. Risenfors, I.A. Rivis, R.H. Robson, R. Rocher, L. Rodriguez Padial, E.L. Rose, S.D. Rosen, T. Rosenfeld, D.B. Rowlands, A. Rozkovec, L. Rudas, L.V. Rudenko, F. Ruiz-Rejon, W. Rutsch, R. Rybar, J. Rybka, H.A. Saetre, I. Sarosi, L.H. Savalle, A. Schmidt, K.P. Schuren, Y. Schwartz, R. Schwinger, J.P. Schwob, D. Scott, U. Sechtem, O. Sela, B. Semrad, M. Senni, N.P. Shilkina, A. Shpektor, J. Silas, A. Sindone, C.J. Sinescu, R. Sipila, J. Sirek, K. Skagen, M. Skura, M. Slanina, S. Slowinski, J. Smid, W. Smielak-Korombel, A. Solodky, R. Spacek, I. Squire, L. Steingo, J. Stepinska, A. Stogowski, G. Storzhakov, R. Striouk, P. Strunge, T. Suter, P. Svitil, K. Swedberg, M. Swidzinski, V.D. Syvolap, J. Sztajzel, S.J. Tahk, A.C. Tans, J.G.M. Tans, R. Targonski, J. Tarjan, F. Tartagni, R. Tchartchoglian, K. Tebloev, R. Teesalu, J.B.L. Ten Kate, P. Terrosu, P.L. Thompson, N.K. Thybo, K. Thygesen, P.A. Tilon, S. Timar, Y. Titkov, O.J. Titlbach, C. Torp-Pedersen, D.T. Torvik, P. Touboul, J.M. Trelawny, R. Trillo Nouche, E. Trochina, R. Trojnar, M.L. Tzekova, D. Tzivoni, V. Vahula, F. Valagussa, M. Valdes, R. Van Der Heijden, J.A.P. Van Der Sloot, J.M.C. Van Hal, L.H.J. Van Kempen, W. Van Mieghem, F.P. Van Rugge, D.J. Van Veldhuisen, B. Van Vlies, L.M. Van Wijk, Y. Vasyuk, M. Vatutin, Z. Vered, W. Vergoni, A. Vertkine, E. Vigholt, A. Vishnevskiy, H.-P. Voegelin, L.M. Voipio-Pulkki, H.-J. Von Mengden, J. Waites, R.D.S. Watson, A.T. Weiss, H.A. Werner, J.C.L. Wesdorp, H. White, P. Wiggers, R.G. Wilcox, P. Wilkinson, A.R. Willems, R. Willenbrock, M. Wirth, D. Wojciechowski, H. Worth, R. Wray, C.-J. Wu, V.V. Yakusevich, S.-P. Yang, N. Yarohno, V.S. Zadionchenko, T. Zaleska, M. Zalewski, F. Zannad, D. Zateyshchikov, E. Zeltin-Abramov, U. Zeymer, R. Zimmermann; Latin America — D.C. Albuquerque, M. Alcaino, O.A. Allall, N. Beer, G. Bortman, R. Botero, J.S. Cardoso, M. Carrageta, E. Carrillo, A.C. Carvalho, R. Castano, F. Ceia, L.A.M. Cesar, E. Chavez, O.R. Coelho, H.R. Colombo, R. Corbalan, H. Doval, O. Dutra, R.A. Franken, L. Gallardo, A. Garcia, J. Garcia, E.A. Gomez, E. Gomez, J. Gonzalez, R.A. Gonzalez, G.V. Greque, L. Guzman, J.C. Haiek, E. Hernandez, M.A. Hominal, J. Isea, F. Lanas, J.L. Leiva, J. Lemus, A. Llancaqueo, N. Lopez, N. Lousada, L.N. Maia, M.F. Maranhao, J.A. Martinez, F.A. Martinez, L. Martins, N. Matadamas, H. Matiz, I. Mendoza, C. Menezes, O. Moises, J.I. Moreira, B. Moura, J.C. Nicolau, J. Nobrega, D. Null, M.S. Oliveira, A.O. Palacios, A. Pazin Filho, S.V. Perrone, L.S. Piegas, J.C. Prieto, A.R. Junior, S. Rassi, V.G. Ribeiro, J.N. Rico, J.M. Rivera, G. Robledo, H. Rodriguez, J. Rosenthal, P.R.F. Rossi, J.F. Saraiva, S. Soifer, A. Sosa Liprandi, H.G. Torres, E. Uruchurtu, R.G. Velasco, J.G. Velasquez, N. Vita, S. Waich, F.R. Zelaya; United States and Canada — N. Abariotis, H. Abdollah, W. Abraham, D. Alaie, W. Allison, A. Ameen, M. Amidi, I. Anand, J.L. Anderson, G.E. Andreae, V. Aquino, W. Ballard, J.S. Banas, S.B. Baron, I. Bata, M.R. Berk, T. Bhesania, P. Binkley, D.C. Booth, D. Borts, L.A. Brookfield, C.S. Brown, K.F. Browne, S.M. Butman, R.C. Capodilupo, D.G. Caralis, K.W. Carr, R. Castan, H. Chadow, G.K. Chalavarya, G.L. Chua, J.A. Cinderella, P. Clavette, B.S. Clemson, T.J. Cohen, H.T. Colfer, C.N. Corder, D.J. Courtade, D.L. Courtney, B. Coutu, F.H. Cucher, W. Czarnecki, K. Danisa, M. D'Astous, I. Dauber, R. Davies, P.C. Deedwania, J.M. Delehanty, D.M. Denny, B.G. Denys, P.J.P. DeYoung, D. Dion, T.J. Donohue, M. El Shahawy, U. Elkayam, J. Escabi, L.K. Essandoh, J.V. Felicetta, D. Fintel, J.M. Fontaine, R.E. Foster, T.A. Frank, K. Gin, M.C. Goldberg, S. Goldman, D. Gossard, G. Gosselin, A.H. Gradman, D. Grandmont, T. Hack, J. Hagar, M. Haikal, S.A. Hall, S. Halpern, H.G. Hanley, G.D. Hanovich, J.L. Hargrove, E.A. Harlamert, T.E. Hastings, W.R. Hathaway, W.H. Haught, G.K. Hilliard, J. Hodsden, W. Hui, W. Hurley, H.M. Ibrahim, S. Jafri, A. Jain, S. Jennison, R.L. Jesse, J. Joseph, J. Kalman, R.P. Karlsberg, R. Khant, M. Koren, E.J. Kosinski, P. Kosolcharoen, W.J. Kostuk, S.M. Kouz, C. Lai, D.E. Langholz, T.H. Le Jemtel, R. Leader, M.-H. Leblanc, H. Lee, S. Lepage, M. Lopez, D.Y. Lu, B.J. Lubelsky, G.J. Luckasen, P.-T.-S. Ma, C.G. MacCallum, E.C. Madu, A.S. Maisel, G.I. Mallis, J.T. Mann, D.R. Marr, F.A. McGrew III, R.J. McKay, B. Mclellan, J. Meisner, T. Meyer, I. Mikati, L.A. Miller, L.W. Miller, G.W. Moe, S.M. Mohiuddin, G.D. Moir, A.W. Morgan, A. Morris, B.J. Murphy, M. Nallasivan, J. Narula, J.M. Nicklas, A.L. Niederman, R. Nitkin, J.H. O'Keefe, K.R. Oken, P.G. O'Neill, R.C. Orchard, W.D. O'Riordan, C.F. Paraboschi, R.I. Patel, G. Pennock, Y. Pesant, D. Phaneuf, D.F. Phillips, J. Plehn, S. Promisloff, A.J. Rajakumar, R. Ramadurai, A. Rashkow, R.A. Rauh, T.M. Rebane, A.L. Riba, C. Richard, J.C. Riddle, G. Ringuette, E. Rivera, S. Rockson, E. Rogers, H. Ross, R. Roux, D. Rupka, A. Saenz, J. Sampson, S.P. Schulman, G. Schuyler, R.F. Sequeira, A.R. Shah, P.K. Shah, S.F. Shakar, Y. Shalev, K.H. Sheikh, U.R. Shettigar, R.M. Siegel, S.L. Sigal, V.N. Singh, C.M. Sotolongo, R.J. Soucier, D.J. Stagaman, W.J. Stephan, M. Stine, W.W. Stoever, J.V. Talano, J. Tam, J.L. Tan, P.H. Tanser, A.S. Taussig, U. Thadani, S.B.H. Timmis, J.R. Timothee, S. Tragoon, B. Tremblay, K.J. Upadhya, N.K. Vijay, L.E. Wagoner, J.L. Walker, W.J. Wickemeyer, G.A. Williams, M.B. Williams, R.E. Williams, A.H. Wiseman, K.J. Wool, M. Yasin, M. Zabalgoitia, S. Zarich, R. Zimmermann, R.P. Zucker.
- References
References
1
Pitt B ,Zannad F ,Remme WJ , et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717
Full Text | Web of Science | Medline2
Rodriguez JA ,Godoy I ,Castro P , et al. Ramipril vs. espironolactona en el remodelamiento ventricular izquierdo post-infarto: randomizado y dobleciego. Rev Med Chile 1997;125:643-652
Web of Science | Medline3
Barr CS ,Lang CC ,Hanson J ,Arnott M ,Kennedy N ,Struthers AD . Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259-1265
CrossRef | Web of Science | Medline4
Bauersachs J ,Heck M ,Fraccarollo D , et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 2002;39:351-358
CrossRef | Web of Science | Medline5
Delyani JA ,Robinson EL ,Rudolph AE . Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 2001;281:H647-H654
Web of Science | Medline6
Farquharson CAJ ,Struthers AD . Spironolactone increases nitric oxide bioavailability, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594-597
Web of Science | Medline7
MacFadyen RJ ,Barr CS ,Struthers AD . Aldosterone blockade reduces collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997;35:30-34
CrossRef | Web of Science | Medline8
Pitt B ,Reichek N ,Metscher B , et al. Efficacy and safety of eplerenone, enalapril, and eplerenone/enalapril combination therapy in patients with left ventricular hypertrophy. Am J Hypertens 2002;15:23A-23A abstract.
CrossRef9
Rocha R ,Martin-Berger C ,Yang P ,Scherrer R ,Delyani J ,McMahon E . Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002;143:4828-4836
CrossRef | Web of Science | Medline10
Schaefer A ,Fraccarollo D ,Hildemann S , et al. Inhibition of platelet activation in congestive heart failure by selective aldosterone receptor antagonism and angiotensin-converting enzyme inhibition. Eur Heart J 2002;23:Suppl:401-401 abstract.
Web of Science11
Wang W . Chronic administration of al-dosterone depresses baroreceptor reflex function in the dog. Hypertension 1994;24:571-575
Web of Science | Medline12
Yee KM ,Pringle SD ,Struthers AD . Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 2001;37:1800-1807
CrossRef | Web of Science | Medline13
de Gasparo M ,Joss U ,Ramjoue HP , et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987;240:650-656
Web of Science | Medline14
Pitt B ,Williams G ,Remme W , et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction: Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001;15:79-87
CrossRef | Web of Science | Medline15
Aronson D ,Rayfield EJ ,Chesebro JH . Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med 1997;126:296-306
Web of Science | Medline16
Shih JH . Sample size calculation for complex clinical trials with survival endpoints. Control Clin Trials 1995;16:395-407
CrossRef | Medline17
Altman DG ,Andersen PK . Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999;319:1492-1495
CrossRef | Web of Science | Medline18
Cockcroft DW ,Gault MH . Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41
CrossRef | Medline19
The CAPRICORN Investigators
CrossRef | Web of Science | Medline20
Dickstein K, Kjekshus J, OPTIMAAL Steering Committee
CrossRef | Web of Science | Medline21
Cleland JG ,Chattopadhyay S ,Khand A ,Houghton T ,Kaye GC . Prevalence and incidence of arrhythmias and sudden death in heart failure. Heart Fail Rev 2002;7:229-242
CrossRef | Medline22
Rocha R ,Rudolph AE ,Frierdich GE , et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002;283:H1802-H1810
Web of Science | Medline23
Sun Y ,Zhang J ,Lu L ,Chen SS ,Quinn MT ,Weber KT . Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002;161:1773-1781
CrossRef | Web of Science | Medline24
Rajagopalan S ,Duquaine D ,King S ,Pitt B ,Patel P . Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002;105:2212-2216
CrossRef | Web of Science | Medline25
Suzuki G ,Morita H ,Mishima T , et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002;106:2967-2972
CrossRef | Web of Science | Medline26
Zhang ZH ,Francis J ,Weiss RM ,Felder RB . The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure. Am J Physiol Heart Circ Physiol 2002;283:H423-H433
Web of Science | Medline27
Korkmaz ME ,Muderrisoglu H ,Ulucam M ,Ozin B . Effects of spironolactone on heart rate variability and left ventricular systolic function in severe ischemic heart failure. Am J Cardiol 2000;86:649-653
CrossRef | Web of Science | Medline
- Citing Articles (1046)
Citing Articles
1
Rajaa F Faris, Marcus Flather, Henry Purcell, Philip A Poole-Wilson, Andrew JS Coats, Rajaa F Faris. 2012. Diuretics for heart failure. .
CrossRef2
Anastasia S. Mihailidou. (2012) Aldosterone in Heart Disease. Current Hypertension Reports
CrossRef3
Christian W. Hamm, Jean-Pierre Bassand, Stefan Agewall, Jeroen Bax, Eric Boersma, Hector Bueno, Pio Caso, Dariusz Dudek, Stephan Gielen, Kurt Huber, Magnus Ohman, Mark C. Petrie, Frank Sonntag, Miguel Sousa Uva, Robert F. Storey, William Wijns, Doron Zahger. (2012) Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. Revista Española de Cardiología 65:2, 173.e1-173.e55
CrossRef4
Massimo Volpe, Silvia Mennuni. (2012) Eplerenone works. Does it matter how?. Expert Review of Cardiovascular Therapy 10:2, 131-133
CrossRef5
Jing-yi Li, Shao-ling Zhang, Meng Ren, Yan-ling Wen, Li Yan, Hua Cheng. (2012) High-sodium intake aggravates myocardial injuries induced by aldosterone via oxidative stress in Sprague-Dawley rats. Acta Pharmacologica Sinica
CrossRef6
Hirotaka Shibata, Hiroshi Itoh. (2012) Mineralocorticoid Receptor-Associated Hypertension and Its Organ Damage: Clinical Relevance for Resistant Hypertension. American Journal of Hypertension
CrossRef7
Toshiaki Nakagaki, Yoshitaka Hirooka, Ryuichi Matsukawa, Masaaki Nishihara, Masatsugu Nakano, Koji Ito, Sumio Hoka, Kenji Sunagawa. (2012) Activation of mineralocorticoid receptors in the rostral ventrolateral medulla is involved in hypertensive mechanisms in stroke-prone spontaneously hypertensive rats. Hypertension Research
CrossRef8
Evangelos P. Daskalopoulos, Ben J.A. Janssen, W. Matthijs Blankesteijn. (2012) Myofibroblasts in the Infarct Area: Concepts and Challenges. Microscopy and Microanalysis1-15
CrossRef9
Decio Armanini, Lorenzo Calò, Cristina Fiore. (2012) Salt and aldosterone do not get along with each other: implication of mineralocorticoid receptors in the profibrotic action of aldosterone. Kidney International 81:1, 118-118
CrossRef10
Jerry M Buysse, I-Zu Huang, Bertram Pitt. (2012) PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Future Cardiology 8:1, 17-28
CrossRef11
Kenneth Dickstein, Judith Bebchuk, Janet Wittes. (2012) The High-Risk Myocardial Infarction Database Initiative. Progress in Cardiovascular Diseases 54:4, 362-366
CrossRef12
Yukiko Ito, Masanori Yoshida, Mikihiro Nakayama, Shoji Tsutaya, Koichiro Ogawa, Harumi Maeda, Misaki Miyata, Yutaka Oiso. (2012) Eplerenone Improved Hypokalemia in a Patient with Gitelman's Syndrome. Internal Medicine 51:1, 83-86
CrossRef13
Ajith P. Nair, Tendoh Timoh, Valentin Fuster. (2012) Contemporary Medical Management of Systolic Heart Failure. Circulation Journal 76:2, 268-277
CrossRef14
Andrew S. Bomback, Philip J. Klemmer. (2012) Mineralocorticoid Receptor Blockade in Chronic Kidney Disease. Blood Purification 33:1-3, 119-124
CrossRef15
J. David Spence. (2012) Lessons From Africa: The Importance of Measuring Plasma Renin and Aldosterone in Resistant Hypertension. Canadian Journal of Cardiology
CrossRef16
Luis Almenar Bonet, Josep Comín Colet, Enrique Pérez de la Sota, Beatriz Díaz Molina. (2012) Insuficiencia cardiaca y trasplante. Revista Española de Cardiología 65, 35-41
CrossRef17
Haissam Haddad, Lisa Mielniczuk, Ross A. Davies. (2012) Recent advances in the management of chronic heart failure. Current Opinion in Cardiology1
CrossRef18
Aurelie Nguyen Dinh Cat, Frederic Jaisser. (2012) Extrarenal effects of aldosterone. Current Opinion in Nephrology and Hypertension1
CrossRef19
Tetsuro Nariai, Katsuya Fujita, Masaya Mori, Seiji Katayama, Seiji Hori, Kazuki Matsui. (2012) Antihypertensive and Cardiorenal Protective Effects of SM-368229, a Novel Mineralocorticoid Receptor Antagonist, in Aldosterone/Salt-Treated Rats. Pharmacology 89:1-2, 44-52
CrossRef20
N Fujimura, K Noma, T Hata, J Soga, T Hidaka, N Idei, Y Fujii, S Mikami, T Maruhashi, Y Iwamoto, Y Kihara, K Chayama, H Kato, J K Liao, Y Higashi. (2011) Mineralocorticoid Receptor Blocker Eplerenone Improves Endothelial Function and Inhibits Rho-Associated Kinase Activity in Patients With Hypertension. Clinical Pharmacology & Therapeutics
CrossRef21
B. Assmus, M. Iwasaki, V. Schachinger, T. Roexe, M. Koyanagi, K. Iekushi, Q. Xu, T. Tonn, E. Seifried, S. Liebner, W. T. Kranert, F. Grunwald, S. Dimmeler, A. M. Zeiher. (2011) Acute myocardial infarction activates progenitor cells and increases Wnt signalling in the bone marrow. European Heart Journal
CrossRef22
Osamu Tsukamoto, Masafumi Kitakaze. (2011) It is Time to Reconsider the Cardiovascular Protection Afforded by RAAS Blockade - Overview of RAAS Systems. Cardiovascular Drugs and Therapy
CrossRef23
Norimichi Koitabashi, David A. Kass. (2011) Reverse remodeling in heart failure—mechanisms and therapeutic opportunities. Nature Reviews Cardiology
CrossRef24
Daniel B. Kramer, Mark E. Josephson. (2011) Expanding the Use of Cardiac Resynchronization Therapy: Words of Caution. Cardiac Electrophysiology Clinics 3:4, 529-537
CrossRef25
E. Franco, I.J. Núñez-Gil, D. Vivas, B. Ruiz Mateos, B. Ibañez, N. Gonzalo, C. Macaya, A. Fernández Ortiz. (2011) Heart failure and non-ST-segment elevation myocardial infarction: A review for a widespread situation. European Journal of Internal Medicine 22:6, 533-540
CrossRef26
Domenic A. Sica. (2011) What is the Role of Aldosterone Excess in Resistant Hypertension and How Should It Be Investigated and Treated?. Current Cardiology Reports 13:6, 520-526
CrossRef27
Alejandro de la Sierra. (2011) Renin–angiotensin system blockade and reduction of cardiovascular risk: future perspectives. Expert Review of Cardiovascular Therapy 9:12, 1585-1591
CrossRef28
Stefano Muzzarelli, Micha Tobias Maeder, Stefan Toggweiler, Hans Rickli, Fabian Nietlispach, Barbara Julius, Thilo Burkard, Matthias Emil Pfisterer, Hans-Peter Brunner-La Rocca. (2011) Frequency and Predictors of Hyperkalemia in Patients ≥60 Years of Age With Heart Failure Undergoing Intense Medical Therapy. The American Journal of Cardiology
CrossRef29
Bertram Pitt. (2011) The Role of Mineralocorticoid Receptor Antagonists in Patients with American College of Cardiology/American Heart Association StageB Heart Failure. Heart Failure Clinics
CrossRef30
Andrew L. Clark. (2011) Almanac 2011: heart failure. The national society journals present selected research that has driven recent advances in clinical cardiology. Revista Portuguesa de Cardiologia 30:12, 941-948
CrossRef31
Farzin Beygui, Jean-Philippe Labbé, Guillaume Cayla, Pierre-Vladimir Ennezat, Pascal Motreff, François Roubille, Johanne Silvain, Olivier Barthélémy, Nicolas Delarche, Eric Van Belle, Jean-Philippe Collet, Gilles Montalescot. (2011) Early mineralocorticoid receptor blockade in primary percutaneous coronary intervention for ST-elevation myocardial infarction is associated with a reduction of life-threatening ventricular arrhythmia. International Journal of Cardiology
CrossRef32
Patrick Collier, Kenneth M. McDonald. (2011) The Role of Renin Angiotensin System Intervention in Stage B Heart Failure. Heart Failure Clinics
CrossRef33
E. de Teresa Galván, J.M. García Pinilla, R. de Teresa Herrera. (2011) Tratamiento de la insuficiencia cardiaca. Medicine - Programa de Formación Médica Continuada Acreditado 10:92, 6240-6248
CrossRef34
Tomoaki Hasui, Nobuyuki Matsunaga, Taiichi Ora, Norio Ohyabu, Nobuhiro Nishigaki, Yoshimi Imura, Yumiko Igata, Hideki Matsui, Takashi Motoyaji, Toshimasa Tanaka, Noriyuki Habuka, Satoshi Sogabe, Midori Ono, Christopher S. Siedem, Tony P. Tang, Cassandra Gauthier, Lisa A. De Meese, Steven A. Boyd, Shoji Fukumoto. (2011) Identification of Benzoxazin-3-one Derivatives as Novel, Potent, and Selective Nonsteroidal Mineralocorticoid Receptor Antagonists. Journal of Medicinal Chemistry111129111224002
CrossRef35
Keisuke Ohtani, Soichiro Usui, Shuichi Kaneko, Shin-ichiro Takashima, Katsunori Kitano, Kanako Yamamoto, Masaki Okajima, Hiroshi Furusho, Masayuki Takamura. (2011) Benidipine reduces ischemia reperfusion-induced systemic oxidative stress through suppression of aldosterone production in mice. Hypertension Research
CrossRef36
Arthur Mark Richards. (2011) Mineralocorticoid receptor antagonists for heart failure. Expert Opinion on Pharmacotherapy1-15
CrossRef37
B Julie He, Mei-ling A Joiner, Madhu V Singh, Elizabeth D Luczak, Paari Dominic Swaminathan, Olha M Koval, William Kutschke, Chantal Allamargot, Jinying Yang, Xiaoqun Guan, Kathy Zimmerman, Isabella M Grumbach, Robert M Weiss, Douglas R Spitz, Curt D Sigmund, W Matthijs Blankesteijn, Stephane Heymans, Peter J Mohler, Mark E Anderson. (2011) Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nature Medicine
CrossRef38
T. Unger, L. Paulis, D. A. Sica. (2011) Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. European Heart Journal 32:22, 2739-2747
CrossRef39
Michael Böhm, Adriaan A. Voors, Jean-Marie Ketelslegers, Stephan H. Schirmer, Eva Turgonyi, Peter Bramlage, Faiez Zannad. (2011) Biomarkers: optimizing treatment guidance in heart failure. Clinical Research in Cardiology 100:11, 973-981
CrossRef40
M. Albaghdadi, M. Gheorghiade, B. Pitt. (2011) Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes. European Heart Journal 32:21, 2626-2633
CrossRef41
Michele Emdin, Luigi Emilio Pastormerlo, Claudio Passino. (2011) The Month After. Journal of the American College of Cardiology 58:19, 1967-1969
CrossRef42
U. Kintscher, R. Kreutz. (2011) Neue Medikamente in der Hypertensiologie. Der Nephrologe 6:6, 504-509
CrossRef43
Esteban López-de-Sá, Angel Martínez, Manuel Anguita, David Dobarro, Manuel Jiménez-Navarro. (2011) Uso de antagonistas de los receptores de aldosterona tras el infarto de miocardio. Datos del registro REICIAM. Revista Española de Cardiología 64:11, 981-987
CrossRef44
Morten Schou, Nana Valeur, Christian Torp-Pedersen, Finn Gustafsson, Lars Køber. (2011) Plasma sodium and mortality risk in patients with myocardial infarction and a low LVEF. European Journal of Clinical Investigation 41:11, 1237-1244
CrossRef45
Patrick Rossignol, Joël Ménard, Renaud Fay, Finn Gustafsson, Bertram Pitt, Faiez Zannad. (2011) Eplerenone Survival Benefits in Heart Failure Patients Post-Myocardial Infarction Are Independent From its Diuretic and Potassium-Sparing Effects. Journal of the American College of Cardiology 58:19, 1958-1966
CrossRef46
Esteban López-de-Sá, Angel Martínez, Manuel Anguita, David Dobarro, Manuel Jiménez-Navarro. (2011) Aldosterone Receptor Antagonist Use After Myocardial Infarction. Data From the REICIAM Registry. Revista Española de Cardiología (English Edition) 64:11, 981-987
CrossRef47
Angela Brown, Becky Captain. (2011) 50 Years of Thiazides: Should Thiazide Diuretics Be Considered Third-Line Hypertension Treatment?. American Journal of Therapeutics 18:6, e244-e254
CrossRef48
D. Craig Brater. (2011) Update in Diuretic Therapy: Clinical Pharmacology. Seminars in Nephrology 31:6, 483-494
CrossRef49
Sidney C. Smith, Emelia J. Benjamin, Robert O. Bonow, Lynne T. Braun, Mark A. Creager, Barry A. Franklin, Raymond J. Gibbons, Scott M. Grundy, Loren F. Hiratzka, Daniel W. Jones, Donald M. Lloyd-Jones, Margo Minissian, Lori Mosca, Eric D. Peterson, Ralph L. Sacco, John Spertus, James H. Stein, Kathryn A. Taubert. (2011) AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. Journal of the American College of Cardiology
CrossRef50
Akshay S. Desai, Eldrin F. Lewis, Rebecca Li, Scott D. Solomon, Susan F. Assmann, Robin Boineau, Nadine Clausell, Rafael Diaz, Jerome L. Fleg, Ivan Gordeev, Sonja McKinlay, Eileen O'Meara, Tamaz Shaburishvili, Bertram Pitt, Marc A. Pfeffer. (2011) Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal
CrossRef51
Prashant D. Bhave, Kurt S. Hoffmayer, Ehrin J. Armstrong, Sonia Garg, Ateet Patel, John S. MacGregor, John C. Stein, Scott Kinlay, Peter Ganz, James M. McCabe. (2011) Predictors of Depressed Left Ventricular Function in Patients Presenting With ST-Elevation Myocardial Infarction. The American Journal of Cardiology
CrossRef52
Jonathan P. Man, Bodh I. Jugdutt. (2011) Systolic heart failure in the elderly: optimizing medical management. Heart Failure Reviews
CrossRef53
Bertram Pitt. (2011) The role of mineralocorticoid receptor antagonists (MRAs) in very old patients with heart failure. Heart Failure Reviews
CrossRef54
Shizuka Aritomi, Tomoyuki Konda, Michihiro Yoshimura. (2011) L/N-type calcium channel blocker suppresses reflex aldosterone production induced by antihypertensive action. Heart and Vessels
CrossRef55
G. de Simone, M. Chinali, G.F. Mureddu, G. Cacciatore, D. Lucci, R. Latini, S. Masson, M. Vanasia, A.P. Maggioni, A. Boccanelli. (2011) Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: The AREA-in-CHF study. Nutrition, Metabolism and Cardiovascular Diseases 21:10, 783-791
CrossRef56
Marieke A. Hillaert, Eef G. Lentjes, Farzin Beygui, Hans Kemperman, Folkert W. Asselbergs, Hendrik M. Nathoe, Pierfrancesco Agostoni, Michiel Voskuil, Fabrice Ivanes, Brigitte Jude, Michel E. Bertrand, Gerard Pasterkamp, Yolanda van der Graaf, Pieter A. Doevendans, Gilles Montalescot, Eric Van Belle. (2011) Measuring and targeting aldosterone and renin in atherosclerosis—A review of clinical data. American Heart Journal 162:4, 585-596
CrossRef57
Simona Maule, Chiara Bertello, Franco Rabbia, Alberto Milan, Paolo Mulatero, Valeria Milazzo, Grazia Papotti, Franco Veglio. (2011) Ventricular repolarization before and after treatment in patients with secondary hypertension due to renal-artery stenosis and primary aldosteronism. Hypertension Research 34:10, 1078-1081
CrossRef58
Andrew Plump, Jeffrey Madwed. (2011) Heart failure drug discovery: Scarred or ready for remodeling?. Journal of Molecular and Cellular Cardiology 51:4, 444-448
CrossRef59
V. Ricchiuti, N. Lapointe, L. Pojoga, T. Yao, L. Tran, G. H. Williams, G. K. Adler. (2011) Dietary sodium intake regulates angiotensin II type 1, mineralocorticoid receptor, and associated signaling proteins in heart. Journal of Endocrinology 211:1, 47-54
CrossRef60
Mustafa Dohadwala, N. A. Mark Estes, Mark S. Link. (2011) New Paradigms in the Prevention of Sudden Cardiac Arrest and Heart Failure Treatment. Current Cardiology Reports 13:5, 377-386
CrossRef61
, Simone Birocchi, Giulia Carla Luisa Cernuschi. (2011) Eplerenone, an aldosterone antagonist, reduces hospitalization and death in heart failure patients with nyha class II and an ejection fraction of less than 30%. Internal and Emergency Medicine 6:5, 453-454
CrossRef62
Gregory Egnaczyk, Carmelo A. Milano, Joseph G. Rogers. (2011) Clinical Trials in Mechanical Circulatory Support. Heart Failure Clinics 7:4, 457-466
CrossRef63
Agata Bielecka-Dabrowa, Jacek Rysz, Dimitri P Mikhailidis, Maciej Banach. (2011) What is the risk of hyperkalaemia in heart failure?. Expert Opinion on Pharmacotherapy 12:15, 2329-2338
CrossRef64
José Luis Górriz Teruel, Sandra Beltrán Catalán. (2011) Assessment of Renal Function, Iatrogenic Hyperkalemia and Acute Renal Dysfunction in Cardiology. Contrast-Induced Nephropathy. Revista Española de Cardiología (English Edition)
CrossRef65
José Luis Górriz Teruel, Sandra Beltrán Catalán. (2011) Valoración de afección renal, disfunción renal aguda e hiperpotasemia por fármacos usados en cardiología y nefrotoxicidad por contrastes. Revista Española de Cardiología
CrossRef66
Brian C Hiestan. (2011) Research in acute decompensated heart failure: challenges and opportunities. Clinical Investigation 1:10, 1361-1373
CrossRef67
Finn Gustafsson, Michel Azizi, Johann Bauersachs, Frederic Jaisser, Patrick Rossignol. (2011) Targeting the aldosterone pathway in cardiovascular disease. Fundamental & Clinical Pharmacologyno-no
CrossRef68
Yonghong Huan, Stephanie DeLoach, Scott W. Keith, Theodore L. Goodfriend, Bonita Falkner. (2011) Aldosterone and aldosterone: renin ratio associations with insulin resistance and blood pressure in African Americans. Journal of the American Society of Hypertension
CrossRef69
Xiaoyan Zhou, Martin F. Crook, Wanda Sharif-Rodriguez, Yonghua Zhu, Zadok Ruben, Yi Pan, Olga Urosevic-Price, Li Wang, Amy M. Flattery, Gail Forrest, Daphne Szeto, Huawei Zhao, Sophie Roy, Michael J. Forrest. (2011) Chronic Antagonism of the Mineralocorticoid Receptor Ameliorates Hypertension and End Organ Damage in a Rodent Model of Salt-Sensitive Hypertension. Clinical and Experimental Hypertension1-10
CrossRef70
R. A. P. Weir, I. K. Tsorlalis, T. Steedman, H. J. Dargie, R. Fraser, J. J. V. McMurray, J. M. C. Connell. (2011) Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction. European Journal of Heart Failure
CrossRef71
Richard L. Verrier, Thomas Klingenheben, Marek Malik, Nabil El-Sherif, Derek V. Exner, Stefan H. Hohnloser, Takanori Ikeda, Juan Pablo Martínez, Sanjiv M. Narayan, Tuomo Nieminen, David S. Rosenbaum. (2011) Microvolt T-Wave Alternans. Journal of the American College of Cardiology 58:13, 1309-1324
CrossRef72
Kevin Damman, Adriaan A. Voors, Gerjan Navis, Dirk J. van Veldhuisen, Hans L. Hillege. (2011) The Cardiorenal Syndrome in Heart Failure. Progress in Cardiovascular Diseases 54:2, 144-153
CrossRef73
Andrés A. Herrada, Carmen Campino, Cristián A. Amador, Luis F. Michea, Carlos E. Fardella, Alexis M. Kalergis. (2011) Aldosterone as a modulator of immunity. Journal of Hypertension 29:9, 1684-1692
CrossRef74
Robert Gros, Qingming Ding, Mark Davis, Rasha Shaikh, Bonan Liu, Jozef Chorazyczewski, J. Geoffrey Pickering, Ross D. Feldman. (2011) Delineating the receptor mechanisms underlying the rapid vascular contractile effects of aldosterone and estradiol. Canadian Journal of Physiology and Pharmacology 89:9, 655-663
CrossRef75
Michel E. Safar, Sandrine Millasseau, Azra Mahmud, Jacques Blacher. (2011) Relations between large artery structure and function and aldosterone. Journal of Hypertension 29:9, 1676-1683
CrossRef76
Nadia Aspromonte, Dinna N Cruz, Roberto Valle, Monica Bonello, Marco Tubaro, Giovanni Gambaro, Giuseppe Marchese, Massimo Santini, Claudio Ronco. (2011) Metabolic and toxicological considerations for diuretic therapy in patients with acute heart failure. Expert Opinion on Drug Metabolism & Toxicology 7:9, 1049-1063
CrossRef77
Nanette K. Wenger. (2011) What Do the 2011 American Heart Association Guidelines Tell Us About Prevention of Cardiovascular Disease in Women?. Clinical Cardiology 34:9, 520-523
CrossRef78
Murray Epstein, David A. Calhoun. (2011) Aldosterone Blockers (Mineralocorticoid Receptor Antagonism) and Potassium-Sparing Diuretics. The Journal of Clinical Hypertension 13:9, 644-648
CrossRef79
Morag J. Young, Amanda J. Rickard. (2011) Mechanisms of mineralocorticoid salt-induced hypertension and cardiac fibrosis. Molecular and Cellular Endocrinology
CrossRef80
, C. W. Hamm, J.-P. Bassand, S. Agewall, J. Bax, E. Boersma, H. Bueno, P. Caso, D. Dudek, S. Gielen, K. Huber, M. Ohman, M. C. Petrie, F. Sonntag, M. S. Uva, R. F. Storey, W. Wijns, D. Zahger, , J. J. Bax, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, C. Funck-Brentano, D. Hasdai, A. Hoes, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, A. Torbicki, A. Vahanian, S. Windecker, , S. Windecker, S. Achenbach, L. Badimon, M. Bertrand, H. E. Botker, J.-P. Collet, F. Crea, N. Danchin, E. Falk, J. Goudevenos, D. Gulba, R. Hambrecht, J. Herrmann, A. Kastrati, K. Kjeldsen, S. D. Kristensen, P. Lancellotti, J. Mehilli, B. Merkely, G. Montalescot, F.-J. Neumann, L. Neyses, J. Perk, M. Roffi, F. Romeo, M. Ruda, E. Swahn, M. Valgimigli, C. J. Vrints, P. Widimsky. (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal
CrossRef81
F. Edelmann, A. Tomaschitz, R. Wachter, G. Gelbrich, M. Knoke, H.-D. Dungen, S. Pilz, L. Binder, R. Stahrenberg, A. Schmidt, W. Marz, B. Pieske. (2011) Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. European Heart Journal
CrossRef82
Anita Deswal, Peter Richardson, Biykem Bozkurt, Douglas L. Mann. (2011) Results of the Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction Trial (RAAM-PEF). Journal of Cardiac Failure 17:8, 634-642
CrossRef83
Henry Krum, John R Teerlink. (2011) Medical therapy for chronic heart failure. The Lancet 378:9792, 713-721
CrossRef84
Martin Stockburger, Alice Krebs, Oezlem Celebi, Aischa Nitardy, Dirk Habedank, Thomas Knaus, Mathias Rauchhaus, Rainer Dietz. (2011) Long-Term Survival of Routine Implantable Cardioverter/Defibrillator Recipients Appears to be Significantly Impaired with Concomitant Diuretics and Improved with Aldosterone Antagonists. Cardiovascular Therapeutics 29:4, 243-250
CrossRef85
Charles F. Jackson, Nanette K. Wenger. (2011) Cardiovascular Disease in the Elderly. Revista Española de Cardiología (English Edition) 64:8, 697-712
CrossRef86
Charles F. Jackson, Nanette K. Wenger. (2011) Enfermedad cardiovascular en el anciano. Revista Española de Cardiología 64:8, 697-712
CrossRef87
Matthew J. Volk, Andrew S. Bomback, Philip J. Klemmer. (2011) Mineralocorticoid Receptor Blockade in Chronic Kidney Disease. Current Hypertension Reports 13:4, 282-288
CrossRef88
Wilbert S. Aronow, Jerome L. Fleg, Carl J. Pepine, Nancy T. Artinian, George Bakris, Alan S. Brown, Keith C. Ferdinand, Mary Ann Forciea, William H. Frishman, Cheryl Jaigobin, John B. Kostis, Giuseppi Mancia, Suzanne Oparil, Eduardo Ortiz, Efrain Reisin, Michael W. Rich, Douglas D. Schocken, Michael A. Weber, Deborah J. Wesley, Robert A. Harrington, Eric R. Bates, Deepak L. Bhatt, Charles R. Bridges, Mark J. Eisenberg, Victor A. Ferrari, John D. Fisher, Timothy J. Gardner, Federico Gentile, Michael F. Gilson, Mark A. Hlatky, Alice K. Jacobs, Sanjay Kaul, David J. Moliterno, Debabrata Mukherjee, Robert S. Rosenson, James H. Stein, Howard H. Weitz, Deborah J. Wesley. (2011) ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. Journal of the American Society of Hypertension 5:4, 259-352
CrossRef89
F. Zannad, J.-M. Ketelslegers, P. Bramlage. (2011) Role of biomarkers in guiding treatment with aldosterone-blocking agents. European Heart Journal Supplements 13:Suppl B, B31-B35
CrossRef90
P. Bramlage, E. Turgonyi, G. Montalescot. (2011) Aldosterone blockade: current research and future trends. European Heart Journal Supplements 13:Suppl B, B46-B50
CrossRef91
M. Bohm, J. C. Reil, P. Bramlage, B. Pitt, F. Zannad. (2011) Clinical efficacy of aldosterone-blocking agents. European Heart Journal Supplements 13:Suppl B, B36-B39
CrossRef92
B. Pitt, R. Latini, A. P. Maggioni, S. D. Solomon, B. A. Smith, M. Wright, M. F. Prescott, J. J. V. McMurray. (2011) Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. European Journal of Heart Failure 13:7, 755-764
CrossRef93
D. J. van Veldhuisen, K. Swedberg. (2011) Treatment of chronic heart failure with aldosterone-blocking agents. European Heart Journal Supplements 13:Suppl B, B43-B45
CrossRef94
Qian Li, Robert J. Glynn, Nancy A. Dreyer, Jun Liu, Helen Mogun, Soko Setoguchi. (2011) Validity of claims-based definitions of left ventricular systolic dysfunction in Medicare patients. Pharmacoepidemiology and Drug Safety 20:7, 700-708
CrossRef95
Ross D. Feldman, Robert Gros. (2011) Unraveling the mechanisms underlying the rapid vascular effects of steroids: sorting out the receptors and the pathways. British Journal of Pharmacology 163:6, 1163-1169
CrossRef96
Marcos F. Minicucci, Paula S. Azevedo, Bertha F. Polegato, Sergio A.R. Paiva, Leonardo A. M. Zornoff. (2011) Heart Failure After Myocardial Infarction: Clinical Implications and Treatment. Clinical Cardiology 34:7, 410-414
CrossRef97
Zachary C. Berwick, Gregory M. Dick, Johnathan D. Tune. (2011) Heart of the matter: Coronary dysfunction in metabolic syndrome. Journal of Molecular and Cellular Cardiology
CrossRef98
Agata Bielecka-Dabrowa, Dimitri P. Mikhailidis, Linda Jones, Jacek Rysz, Wilbert S. Aronow, Maciej Banach. (2011) The meaning of hypokalemia in heart failure. International Journal of Cardiology
CrossRef99
A. D. Struthers, T. Unger. (2011) Physiology of aldosterone and pharmacology of aldosterone blockers. European Heart Journal Supplements 13:Suppl B, B27-B30
CrossRef100
L. M. Ruilope. (2011) Safety aspects of aldosterone-blocking drugs. European Heart Journal Supplements 13:Suppl B, B40-B42
CrossRef101
B. Pitt. (2011) Introduction. European Heart Journal Supplements 13:Suppl B, B1-B3
CrossRef102
Salvatore Paterna, Sergio Fasullo, Gaspare Parrinello, Sergio Cannizzaro, Ivana Basile, Gabriella Vitrano, Gabriella Terrazzino, Giorgio Maringhini, Filippo Ganci, Sebastiano Scalzo, Filippo M. Sarullo, Gennaro Cice, Pietro Di Pasquale. (2011) Short-Term Effects of Hypertonic Saline Solution in Acute Heart Failure and Long-Term Effects of a Moderate Sodium Restriction in Patients With Compensated Heart Failure With New York Heart Association Class III (Class C) (SMAC-HF Study). The American Journal of the Medical Sciences 342:1, 27-37
CrossRef103
Shahriar Iravanian, Ali A. Sovari, Harvey A. Lardin, Hong Liu, Hong D. Xiao, Elena Dolmatova, Zhe Jiao, Brett S. Harris, Emily A. Witham, Robert G. Gourdie, Heather S. Duffy, Kenneth E. Bernstein, Samuel C. Dudley. (2011) Inhibition of renin-angiotensin system (RAS) reduces ventricular tachycardia risk by altering connexin43. Journal of Molecular Medicine 89:7, 677-687
CrossRef104
S. Messaoudi, F. Jaisser. (2011) Aldosterone and the mineralocorticoid receptor. European Heart Journal Supplements 13:Suppl B, B4-B9
CrossRef105
S. Yagi, M. Sata. (2011) Pre-clinical data on the role of mineralocorticoid receptor antagonists in reversing vascular inflammation. European Heart Journal Supplements 13:Suppl B, B15-B20
CrossRef106
Kanae Togo, Manabu Iwasaki. (2011) Sample size re-estimation for survival data in clinical trials with an adaptive design. Pharmaceutical Statistics 10:4, 325-331
CrossRef107
Theresa Dartsch, Robert Fischer, Andrej Gapelyuk, Marco Weiergraeber, Dennis Ladage, Toni Schneider, Alexander Schirdewan, Hannes Reuter, Jochen Mueller-Ehmsen, Carsten Zobel. (2011) Aldosterone induces electrical remodeling independent of hypertension. International Journal of Cardiology
CrossRef108
Taishi Nakamura, Masaya Fukuda, Keiichiro Kataoka, Hisato Nako, Yoshiko Tokutomi, Yi-Fei Dong, Eiichiro Yamamoto, Osamu Yasuda, Hisao Ogawa, Shokei Kim-Mitsuyama. (2011) Eplerenone potentiates protective effects of amlodipine against cardiovascular injury in salt-sensitive hypertensive rats. Hypertension Research 34:7, 817-824
CrossRef109
Peter Kolkhof, Steffen A. Borden. (2011) Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics. Molecular and Cellular Endocrinology
CrossRef110
Alex Odermatt, Denise V. Kratschmar. (2011) Tissue-specific modulation of mineralocorticoid receptor function by 11β-hydroxysteroid dehydrogenases: An overview. Molecular and Cellular Endocrinology
CrossRef111
Smail Messaoudi, Feriel Azibani, Claude Delcayre, Frederic Jaisser. (2011) Aldosterone, mineralocorticoid receptor, and heart failure. Molecular and Cellular Endocrinology
CrossRef112
Jessica Huyet, Grégory Maurice Pinon, Michel Raymond Fay, Marie-Edith Rafestin-Oblin, Jérôme Fagart. (2011) Structural determinants of ligand binding to the mineralocorticoid receptor. Molecular and Cellular Endocrinology
CrossRef113
Shigeru Shibata, Toshiro Fujita. (2011) Mineralocorticoid receptors in the pathophysiology of chronic kidney diseases and the metabolic syndrome. Molecular and Cellular Endocrinology
CrossRef114
Jun Yang, Peter J. Fuller. (2011) Interactions of the mineralocorticoid receptor – Within and without. Molecular and Cellular Endocrinology
CrossRef115
Damien Le Menuet, Mathilde Munier, Giulia Campostrini, Marc Lombès. (2011) Mineralocorticoid receptor and embryonic stem cell models: Molecular insights and pathophysiological relevance. Molecular and Cellular Endocrinology
CrossRef116
Claudia Grossmann, Michael Gekle. (2011) Interaction between mineralocorticoid receptor and epidermal growth factor receptor signaling. Molecular and Cellular Endocrinology
CrossRef117
F. Ivanes, S. Susen, F. Mouquet, P. Pigny, F. Cuilleret, K. Sautiere, J.-P. Collet, F. Beygui, B. Hennache, P. V. Ennezat, F. Juthier, F. Richard, J. Dallongeville, M. A. Hillaert, P. A. Doevendans, B. Jude, M. Bertrand, G. Montalescot, E. Van Belle. (2011) Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. European Heart Journal
CrossRef118
Jean-Philippe Bertocchio, Frédéric Jaisser. (2011) Aldostérone et pathologies rénales : une notion émergente avec des implications thérapeutiques importantes. Néphrologie & Thérapeutique 7:3, 139-147
CrossRef119
Raúl Quirós López, Javier García Alegría, María Dolores Martín Escalante, Javier Trujillo Santos, María Ángeles Villena Ruiz, Emilio Perea Milla. (2011) Factores pronósticos y supervivencia a largo plazo tras el diagnóstico inicial de insuficiencia cardiaca. Medicina Clínica
CrossRef120
Gregg C. Fonarow, Clyde W. Yancy, Adrian F. Hernandez, Eric D. Peterson, John A. Spertus, Paul A. Heidenreich. (2011) Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. American Heart Journal 161:6, 1024-1030.e3
CrossRef121
Ryan P. Morrissey, Lawrence Czer, Prediman K. Shah. (2011) Chronic Heart Failure. American Journal Cardiovascular Drugs 11:3, 153-171
CrossRef122
R. Pfister, C.A. Schneider. (2011) Diabetes mellitus und Herzinsuffizienz. Der Diabetologe 7:4, 247-253
CrossRef123
P. Friocourt. (2011) Traitement de l’insuffisance cardiaque du sujet âgé. NPG Neurologie - Psychiatrie - Gériatrie 11:63, 114-123
CrossRef124
Dennis Ladage, Nora Schützeberg, Theresa Dartsch, Benjamin Krausgrill, Marcel Halbach, Carsten Zobel, Jochen Müller-Ehmsen. (2011) Hyperaldosteronism is associated with a decrease in number and altered growth factor expression of endothelial progenitor cells in rats. International Journal of Cardiology 149:2, 152-156
CrossRef125
Alex Reyentovich, Stuart D. Katz. (2011) Mineralocorticoid-receptor Antagonists in Heart Failure: A Tale of Serendipity and Success. Current Heart Failure Reports 8:2, 87-90
CrossRef126
Luis M Ruilope, Julian Segura, Jose L Zamorano. (2011) New clinical concepts after the ONTARGET trial. Expert Review of Cardiovascular Therapy 9:6, 685-689
CrossRef127
Gert Klug, Agnes Mayr, Johannes Mair, Michael Schocke, Michael Nocker, Thomas Trieb, Werner Jaschke, Otmar Pachinger, Bernhard Metzler. (2011) Role of biomarkers in assessment of early infarct size after successful p-PCI for STEMI. Clinical Research in Cardiology 100:6, 501-510
CrossRef128
JoAnn Lindenfeld. (2011) Impressive Results for Aldosterone Antagonists in Mild Heart Failure. Current Cardiology Reports 13:3, 167-169
CrossRef129
Somya A. Chandrasekaran, Hector O. Ventura, Carl J. Lavie, Ileana Pina. (2011) Disparities in Women with Heart Failure. Current Cardiovascular Risk Reports 5:3, 261-265
CrossRef130
, Friedrich M. Fruhwald, Hanno Ulmer, Richard Pacher, Gerhard Pölzl, Claudia Dornaus, Manfred Wieser, Christian Ebner, Susanne Reiter, Lalit Kaltenbach, Johann Altenberger. (2011) Ruhepuls und funktionelle Einschränkungen als prognostische Parameter bei herzinsuffizienten Patienten im tatsächlichen Leben. Daten aus dem Herzinsuffizienz-Register der ÖKG. Wiener klinische Wochenschrift 123:11-12, 378-383
CrossRef131
Amy McCurley, Iris Z. Jaffe. (2011) Mineralocorticoid receptors in vascular function and disease. Molecular and Cellular Endocrinology
CrossRef132
T. Thum, K. Schmitter, F. Fleissner, V. Wiebking, B. Dietrich, J. D. Widder, V. Jazbutyte, S. Hahner, G. Ertl, J. Bauersachs. (2011) Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. European Heart Journal 32:10, 1275-1286
CrossRef133
S. D. Solomon, S. Hee Shin, A. Shah, H. Skali, A. Desai, L. Kober, A. P. Maggioni, J. L. Rouleau, R. Y. Kelly, A. Hester, J. J. V. McMurray, M. A. Pfeffer, . (2011) Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. European Heart Journal 32:10, 1227-1234
CrossRef134
Margaret A. Fitzgerald. (2011) Hypertension treatment update: Focus on direct renin inhibition. Journal of the American Academy of Nurse Practitioners 23:5, 239-248
CrossRef135
P. C. Deedwania, M. I. Ahmed, M. A. Feller, I. B. Aban, T. E. Love, B. Pitt, A. Ahmed. (2011) Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure. European Journal of Heart Failure 13:5, 551-559
CrossRef136
Hakan Coksuer, Mustafa Koplay, Fatih Oghan, Cengiz Coksuer, Nadi Keskin, Olcay Ozveren. (2011) Effects of estradiol–drospirenone hormone treatment on carotid artery intima-media thickness and vertigo/dizziness in postmenopausal women. Archives of Gynecology and Obstetrics 283:5, 1045-1051
CrossRef137
R. Scott Wright, Jeffrey L. Anderson, Cynthia D. Adams, Charles R. Bridges, Donald E. Casey, Steven M. Ettinger, Francis M. Fesmire, Theodore G. Ganiats, Hani Jneid, A. Michael Lincoff, Eric D. Peterson, George J. Philippides, Pierre Theroux, Nanette K. Wenger, James Patrick Zidar. (2011) 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 57:19, e215-e367
CrossRef138
Nicholas B Norgard, Gina M Prescott. (2011) Future of personalized pharmacotherapy in chronic heart failure patients. Future Cardiology 7:3, 357-379
CrossRef139
Hari K Parthasarathy, Joel Ménard, William B White, William F Young, Gordon H Williams, Bryan Williams, Luis Miguel Ruilope, Gordon T McInnes, John M Connell, Thomas M MacDonald. (2011) A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. Journal of Hypertension 29:5, 980-990
CrossRef140
Jean-Philippe Bertocchio, David G Warnock, Frederic Jaisser. (2011) Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney International 79:10, 1051-1060
CrossRef141
Shinpei Kimura, Masahiro Ito, Makoto Tomita, Makoto Hoyano, Hiroaki Obata, Limin Ding, Masaomi Chinushi, Haruo Hanawa, Makoto Kodama, Yoshifusa Aizawa. (2011) Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats. Hypertension Research 34:5, 584-591
CrossRef142
Barbara Schreier, Sindy Rabe, Bettina Schneider, Stefanie Ruhs, Claudia Grossmann, Steffen Hauptmann, Manfred Blessing, Joachim Neumann, Michael Gekle. (2011) Aldosterone/NaCl-induced renal and cardiac fibrosis is modulated by TGF-β responsiveness of T cells. Hypertension Research 34:5, 623-629
CrossRef143
Ali Ahmed. (2011) Chronic Heart Failure in Older Adults. Medical Clinics of North America 95:3, 439-461
CrossRef144
Wilbert S. Aronow, Jerome L. Fleg, Carl J. Pepine, Nancy T. Artinian, George Bakris, Alan S. Brown, Keith C. Ferdinand, Mary Ann Forciea, William H. Frishman, Cheryl Jaigobin, John B. Kostis, Giuseppi Mancia, Suzanne Oparil, Eduardo Ortiz, Efrain Reisin, Michael W. Rich, Douglas D. Schocken, Michael A. Weber, Deborah J. Wesley. (2011) ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. Journal of the American College of Cardiology 57:20, 2037-2114
CrossRef145
Fadi G Hage, Sulaf J Mansur, Suzanne Oparil. (2011) Rationale for the use of multiple blockers of the renin–angiotensin–aldosterone system in specific patient populations. Therapy 8:3, 227-236
CrossRef146
Angela Yee-Moon Wang, John E. Sanderson. (2011) Treatment of Heart Failure in Long-term Dialysis Patients: A Reappraisal. American Journal of Kidney Diseases 57:5, 760-772
CrossRef147
G. Michael Felker. (2011) Loop diuretics in heart failure. Heart Failure Reviews
CrossRef148
Simon Lucas, Matthias Negri, Ralf Heim, Christina Zimmer, Rolf W. Hartmann. (2011) Fine-Tuning the Selectivity of Aldosterone Synthase Inhibitors: Structure−Activity and Structure−Selectivity Insights from Studies of Heteroaryl Substituted 1,2,5,6-Tetrahydropyrrolo[3,2,1- ij ]quinolin-4-one Derivatives. Journal of Medicinal Chemistry 54:7, 2307-2319
CrossRef149
Henry Krum, Dirk J. van Veldhuisen, Christian Funck-Brentano, Emilio Vanoli, Bernard Silke, Erland Erdmann, Ferenc Follath, Piotr Ponikowski, Michael Goulder, Wilfried Meyer, Philippe Lechat, Ronnie Willenheimer, . (2011) Effect on Mode of Death of Heart Failure Treatment Started with Bisoprolol Followed by Enalapril, Compared to the Opposite Order: Results of the Randomized CIBIS III Trial. Cardiovascular Therapeutics 29:2, 89-98
CrossRef150
Mohammed El-Deeb, Ayman El-Menyar, Abdulrazzak Gehani, Kadhim Sulaiman. (2011) Acute coronary syndrome in pregnant women. Expert Review of Cardiovascular Therapy 9:4, 505-515
CrossRef151
Shigeru Shibata, Toshiro Fujita. (2011) The Kidneys and Aldosterone/Mineralocorticoid Receptor System in Salt-Sensitive Hypertension. Current Hypertension Reports 13:2, 109-115
CrossRef152
P. van der Meer, D. J. van Veldhuisen. (2011) To bind or not to bind: potassium-lowering drugs in heart failure. European Heart Journal 32:7, 791-792
CrossRef153
Marie Briet, Ernesto L. Schiffrin. (2011) The Role of Aldosterone in the Metabolic Syndrome. Current Hypertension Reports 13:2, 163-172
CrossRef154
Firas J. Al Badarin, Mohammad A. Abuannadi, Carl J. Lavie, James H. O'Keefe. (2011) Evidence-Based Diuretic Therapy for Improving Cardiovascular Prognosis in Systemic Hypertension. The American Journal of Cardiology 107:8, 1178-1184
CrossRef155
K. Damman, A. H. Maass, P. van der Meer. (2011) Heart failure highlights in 2010. European Journal of Heart Failure 13:4, 358-363
CrossRef156
J. G. F. Cleland, A. P. Coletta, L. Buga, R. Antony, P. Pellicori, N. Freemantle, A. L. Clark. (2011) Clinical trials update from the American Heart Association Meeting 2010: EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT. European Journal of Heart Failure 13:4, 460-465
CrossRef157
Kosaku Nitta. (2011) Pathogenesis and therapeutic implications of cardiorenal syndrome. Clinical and Experimental Nephrology 15:2, 187-194
CrossRef158
Soo S. Rhee, Elizabeth N. Pearce. (2011) Sistema endocrino y corazón: una revisión. Revista Española de Cardiología 64:3, 220-231
CrossRef159
Markus Haass. (2011) Highlights of the latest clinical trials from the 2010 Scientific Sessions of the American Heart Association. Future Cardiology 7:2, 163-167
CrossRef160
Miriam S. Jacob, W. H. Wilson Tang. (2011) Aldosterone-Receptor Antagonists in Heart Failure: Insights After EMPHASIS-HF. Current Heart Failure Reports 8:1, 7-13
CrossRef161
J. M. Ritter. (2011) Dual blockade of the renin-angiotensin system with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). British Journal of Clinical Pharmacology 71:3, 313-315
CrossRef162
Nirla Gomes Guedes, Marcos Venícios de Oliveira Lopes, Thelma Leite de Araujo, Rafaella Pessoa Moreira, Larissa Castelo Guedes Martins. (2011) Predictive Factors of the Nursing Diagnosis Sedentary Lifestyle in People with High Blood Pressure. Public Health Nursing 28:2, 193-200
CrossRef163
Saurabh Malhotra, Mithilesh K Das. (2011) Delayed and indirect effects of antiarrhythmic drugs in reducing sudden cardiac death. Future Cardiology 7:2, 203-217
CrossRef164
Andreas Tomaschitz, Stefan Pilz, Eberhard Ritz, Tanja Grammer, Christiane Drechsler, Bernhard O. Boehm, Winfried März. (2011) Association of Plasma Aldosterone With Cardiovascular Mortality in Patients With Low Estimated GFR: The Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. American Journal of Kidney Diseases 57:3, 403-414
CrossRef165
Yohann Rautureau, Pierre Paradis, Ernesto L. Schiffrin. (2011) Cross-talk between aldosterone and angiotensin signaling in vascular smooth muscle cells. Steroids
CrossRef166
John D. Horowitz, Robert S. Rosenson, John J. V. McMurray, Nikolaus Marx, Willem J. Remme. (2011) Clinical Trials Update AHA Congress 2010. Cardiovascular Drugs and Therapy 25:1, 69-76
CrossRef167
K. Graf. (2011) Aldosteronblockade bei gering symptomatischer Herzinsuffizienz. Der Kardiologe 5:1, 43-44
CrossRef168
Luis M. Ruilope. (2011) On the Need to Reissue Renin-Angiotensin-Aldosterone System Suppression in Chronic Kidney Disease. Current Cardiovascular Risk Reports 5:1, 5-6
CrossRef169
Cheng-Shi Jiang, Rong Zhou, Jing-Xu Gong, Li-Li Chen, Tibor Kurtán, Xu Shen, Yue-Wei Guo. (2011) Synthesis, modification, and evaluation of (R)-de-O-methyllasiodiplodin and analogs as nonsteroidal antagonists of mineralocorticoid receptor. Bioorganic & Medicinal Chemistry Letters 21:4, 1171-1175
CrossRef170
Masanori Abe, Kazuyoshi Okada, Noriaki Maruyama, Shiro Matsumoto, Takashi Maruyama, Takayuki Fujita, Koichi Matsumoto, Masayoshi Soma. (2011) Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. Hypertension Research 34:2, 268-273
CrossRef171
Mihai Gheorghiade, Andrew Ambrosy. (2011) Heart failure in 2010: One step forward, two steps back. Nature Reviews Cardiology 8:2, 72-73
CrossRef172
Chiara Nediani, Laura Raimondi, Elisabetta Borchi, Elisabetta Cerbai. (2011) Nitric Oxide/Reactive Oxygen Species Generation and Nitroso/Redox Imbalance in Heart Failure: From Molecular Mechanisms to Therapeutic Implications. Antioxidants & Redox Signaling 14:2, 289-331
CrossRef173
Armstrong, Paul W., . (2011) Aldosterone Antagonists — Last Man Standing?. New England Journal of Medicine 364:1, 79-80
Full Text174
Zannad, Faiez, McMurray, John J.V., Krum, Henry, van Veldhuisen, Dirk J., Swedberg, Karl, Shi, Harry, Vincent, John, Pocock, Stuart J., Pitt, Bertram, . (2011) Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine 364:1, 11-21
Full Text175
Lutz Frankenstein, Andrew L. Clark, Jorge P. Ribeiro. (2011) Influence of Sex on Treatment and Outcome in Chronic Heart Failure. Cardiovascular Therapeuticsno-no
CrossRef176
Andrew A. House, Mikko Haapio, Johan Lassus, Rinaldo Bellomo, Claudio Ronco. (2011) Pharmacological Management of Cardiorenal Syndromes. International Journal of Nephrology 2011, 1-8
CrossRef177
Keisuke ISHIZAWA. (2011) Drug Discovery for Improvement of Chronic Kidney Disease and Cardiovascular Disease. YAKUGAKU ZASSHI 131:9, 1347-1352
CrossRef178
LEONARDO CALÒ, ANNAMARIA MARTINO, LUIGI SCIARRA, ANTONIO CICCAGLIONI, ERMENEGILDO DE RUVO, LUCIA DE LUCA, ANTONELLA SETTE, GIUSEPPE GIUNTA, ERNESTO LIOY, FRANCESCO FEDELE. (2011) Upstream Effect for Atrial Fibrillation: Still a Dilemma?. Pacing and Clinical Electrophysiology 34:1, 111-128
CrossRef179
Marsha A. Raebel. (2011) Hyperkalemia Associated with Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. Cardiovascular Therapeuticsno-no
CrossRef180
Anastasios Lymperopoulos, Giuseppe Rengo, Carmela Zincarelli, Jihee Kim, Walter J. Koch. (2011) Adrenal Beta-Arrestin 1 Inhibition In Vivo Attenuates Post-Myocardial Infarction Progression to Heart Failure and Adverse Remodeling Via Reduction of Circulating Aldosterone Levels. Journal of the American College of Cardiology 57:3, 356-365
CrossRef181
Tetsuro Nariai, Katsuya Fujita, Masaya Mori, Seiji Katayama, Seiji Hori, Kazuki Matsui. (2011) SM-368229, a Novel Selective and Potent Non-steroidal Mineralocorticoid Receptor Antagonist With Strong Urinary Na+ Excretion Activity. Journal of Pharmacological Sciences 115:3, 346-353
CrossRef182
Eric E. Essick, Flora Sam. (2011) Cardiac Hypertrophy and Fibrosis in the Metabolic Syndrome: A Role for Aldosterone and the Mineralocorticoid Receptor. International Journal of Hypertension 2011, 1-12
CrossRef183
M. Gheorghiade, M. Albaghdadi, F. Zannad, G. C. Fonarow, M. Bohm, C. Gimpelewicz, J. Botha, S. Moores, E. F. Lewis, H. Rattunde, A. Maggioni, , M. Gheorghiade, A. Maggioni, G. C. Fonarow, M. Bohm, F. Zannad, S. Solomon, E. Lewis, P. Finn, H. Hartley, L. Weinrach, E. Barkoudah, C. Duong, A. Rogers, K. Swedberg, S. Pocock, B. Pitt, J. S. Borer, J. Rouleau, M. Wibberg. (2011) Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). European Journal of Heart Failure 13:1, 100-106
CrossRef184
Domenic A. Sica, John M. Flack. (2011) Treatment Considerations With Aldosterone Receptor Antagonists. The Journal of Clinical Hypertension 13:1, 65-69
CrossRef185
(2011) Erratum. Journal of Cardiac Failure 17:1, 90-90.e4
CrossRef186
C. Soeby-Land, U. Dixen, S.K. Therkelsen, A. Kjaer. (2011) Increased Plasma Aldosterone during Atrial Fibrillation Declines following Cardioversion. Cardiology 118:4, 239-244
CrossRef187
Jerome L. Fleg, Wilbert S. Aronow, William H. Frishman. (2011) Cardiovascular drug therapy in the elderly: benefits and challenges. Nature Reviews Cardiology 8:1, 13-28
CrossRef188
M. Demede, A. Pandey, L. Innasimuthu, G. Jean-Louis, S. I. McFarlane, G. Ogedegbe. (2011) Management of Hypertension in High-Risk Ethnic Minority with Heart Failure. International Journal of Hypertension 2011, 1-8
CrossRef189
Tsuyoshi Shiga. (2011) Japanese Journal of Electrocardiology 31:4, 365-375
CrossRef190
Shinsuke Harasawa, Yuji Otsuka, Katsuaki Okubo, Miyuki Koike, Hirotaka Fujita, Toshio Kushiro, Ken Nagao, Atsushi Hirayama. (2010) Amlodipine suppressed cardiac gene expression of brain natriuretic peptide, transforming growth factor-β1 and fibronectin mediated by aldosterone in male stroke-prone spontaneously hypertensive rats. Journal of Pharmacy and Pharmacology 62:12, 1740-1745
CrossRef191
Sanae Hamaguchi, Shintaro Kinugawa, Miyuki Tsuchihashi-Makaya, Kazutomo Goto, Daisuke Goto, Takashi Yokota, Satoshi Yamada, Hisashi Yokoshiki, Akira Takeshita, Hiroyuki Tsutsui. (2010) Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure. American Heart Journal 160:6, 1156-1162
CrossRef192
Jalal K. Ghali, Barry M. Massie, Douglas L. Mann, Michael W. Rich. (2010) Heart Failure Guidelines, Performance Measures, and the Practice of Medicine. Journal of the American College of Cardiology 56:25, 2077-2080
CrossRef193
Mehmet Kayrak, Ahmet Bacaksiz, Mehmet A. Vatankulu, Selim S. Ayhan, Hatem Ari, Zeynettin Kaya, Kurtulus Ozdemir. (2010) The effects of spironolactone on atrial remodeling in patients with preserved left ventricular function after an acute myocardial infarction. Coronary Artery Disease 21:8, 477-485
CrossRef194
Marcus Quinkler, Paul M. Stewart. (2010) Treatment of primary aldosteronism. Best Practice & Research Clinical Endocrinology & Metabolism 24:6, 923-932
CrossRef195
John W. Funder, Martin Reincke. (2010) Aldosterone: A cardiovascular risk factor?. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1802:12, 1188-1192
CrossRef196
Kimiaki Komukai, Seibu Mochizuki, Michihiro Yoshimura. (2010) Gender and the renin-angiotensin-aldosterone system. Fundamental & Clinical Pharmacology 24:6, 687-698
CrossRef197
U.C. Hoppe, E. Erdmann. (2010) Herzinsuffizienz Update 2010 und aktuelle ESC-Leitlinien. Herz 35:8, 535-541
CrossRef198
Leonardo A. Sechi, GianLuca Colussi, Alessandro Di Fabio, Cristiana Catena. (2010) Cardiovascular and Renal Damage in Primary Aldosteronism: Outcomes After Treatment. American Journal of Hypertension 23:12, 1253-1260
CrossRef199
Victoria Cachofeiro, Natalia López-Andrés, Maria Miana, Beatriz Martín-Fernández, Natalia de las Heras, Ernesto Martínez, Vicente Lahera, María Antonia Fortuño. (2010) Aldosterone and the cardiovascular system: a dangerous association. Hormone Molecular Biology and Clinical Investigation 4:2, 539-548
CrossRef200
F. Braunschweig, G. Boriani, A. Bauer, R. Hatala, C. Herrmann-Lingen, J. Kautzner, S. S. Pedersen, S. Pehrson, R. Ricci, M. J. Schalij. (2010) Management of patients receiving implantable cardiac defibrillator shocks: Recommendations for acute and long-term patient management. Europace 12:12, 1673-1690
CrossRef201
Keith A Thompson, Parag Bharadwaj, Kiran J Philip, Ernst R Schwarz. (2010) Heart failure therapy: beyond the guidelines. Journal of Cardiovascular Medicine 11:12, 919-927
CrossRef202
Rongqin Ren, John A. Cidlowski. (2010) Glucocorticoid signaling in cardiac disease. Hormone Molecular Biology and Clinical Investigation 4:2, 559-564
CrossRef203
Sulaf J. Mansur, Fadi G. Hage, Suzanne Oparil. (2010) Have the Renin-Angiotensin-Aldosterone System Perturbations in Cardiovascular Disease Been Exhausted?. Current Cardiology Reports 12:6, 450-463
CrossRef204
M. O. Gore, F. A. Masoudi, D. K. McGuire. (2010) Diabetes mellitus in patients with myocardial infarction complicated by heart failure: a 'low ejection fraction' equivalent?. European Journal of Heart Failure 12:11, 1156-1158
CrossRef205
Masayuki Yamaji, Takayoshi Tsutamoto, Chiho Kawahara, Keizo Nishiyama, Takashi Yamamoto, Masanori Fujii, Minoru Horie. (2010) Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure. American Heart Journal 160:5, 915-921
CrossRef206
Enrico Vizzardi, Antonio D'Aloia, Raffaele Giubbini, Tania Bordonali, Silvia Bugatti, Natalia Pezzali, Alessia Romeo, Alessandra Dei Cas, Marco Metra, Livio Dei Cas. (2010) Effect of Spironolactone on Left Ventricular Ejection Fraction and Volumes in Patients With Class I or II Heart Failure. The American Journal of Cardiology 106:9, 1292-1296
CrossRef207
Fabian Hammer, Nicola C. Edwards, Beverly A. Hughes, Richard P. Steeds, Charles J. Ferro, Jonathan N. Townend, Paul M. Stewart. (2010) The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. Clinical Endocrinology 73:5, 566-572
CrossRef208
G. K. Adler, I. Bonyhay, V. Curren, E. Waring, R. Freeman. (2010) Hypoglycaemia increases aldosterone in a dose-dependent fashion. Diabetic Medicine 27:11, 1250-1255
CrossRef209
Iris Z. Jaffe, Brenna G. Newfell, Mark Aronovitz, Najwa N. Mohammad, Adam P. McGraw, Roger E. Perreault, Peter Carmeliet, Afshin Ehsan, Michael E. Mendelsohn. (2010) Placental growth factor mediates aldosterone-dependent vascular injury in mice. Journal of Clinical Investigation 120:11, 3891-3900
CrossRef210
Ruchika Dutta, Barry H. Greenberg. 2010. Neurohormonal Blocking Agents in the Treatment of Patients with Left Ventricular Dysfunction and Heart Failure. , 83-116.
CrossRef211
Vijay U. Rao, John R. Teerlink. 2010. Treating Systolic Heart Failure. , 287-326.
CrossRef212
Farzin Beygui, Eric Vicaut, Patrick Ecollan, Jacques Machecourt, Eric Van Belle, Faiez Zannad, Gilles Montalescot. (2010) Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial. American Heart Journal 160:4, 642-648.e1
CrossRef213
Brenda K. Huntley, Tomoko Ichiki, S. Jeson Sangaralingham, Horng H. Chen, John C. Burnett. (2010) B-type natriuretic peptide and extracellular matrix protein interactions in human cardiac fibroblasts. Journal of Cellular Physiology 225:1, 251-255
CrossRef214
Matthew J. O'Connor, David N. Rosenthal, Robert E. Shaddy. (2010) Outpatient Management of Pediatric Heart Failure. Heart Failure Clinics 6:4, 515-529
CrossRef215
Amil M. Shah, Marc A. Pfeffer, L. Howard Hartley, Lemuel A. Moyé, Bernard J. Gersh, John D. Rutherford, Gervasio A. Lamas, Jean L. Rouleau, Eugene Braunwald, Scott D. Solomon. (2010) Risk of All-Cause Mortality, Recurrent Myocardial Infarction, and Heart Failure Hospitalization Associated With Smoking Status Following Myocardial Infarction With Left Ventricular Dysfunction. The American Journal of Cardiology 106:7, 911-916
CrossRef216
Doson Chua, Anita Lo, Chris Lo. (2010) Spironolactone Use in Heart Failure Patients With End-Stage Renal Disease on Hemodialysis: Is It Safe?. Clinical Cardiology 33:10, 604-608
CrossRef217
Andrew A. House, Mikko Haapio, Johan Lassus, Rinaldo Bellomo, Claudio Ronco. (2010) Therapeutic Strategies for Heart Failure in Cardiorenal Syndromes. American Journal of Kidney Diseases 56:4, 759-773
CrossRef218
Giuseppe Boriani, Igor Diemberger, Cinzia Valzania, Mauro Biffi, Cristian Martignani, Emanuel Raschi, Valentina Mantovani, Matteo Ziacchi, Matteo Bertini, Fabrizio De Ponti, Angelo Branzi. (2010) Role of drugs and devices in patients at risk of sudden cardiac death. Fundamental & Clinical Pharmacology 24:5, 575-594
CrossRef219
Melissa H. Kong, Eric D. Peterson, Gregg C. Fonarow, Gillian D. Sanders, Clyde W. Yancy, Andrea M. Russo, Anne B. Curtis, Samuel F. Sears, Kevin L. Thomas, Susan Campbell, Mark D. Carlson, Chris Chiames, Nakela L. Cook, David L. Hayes, Michelle LaRue, Adrian F. Hernandez, Edward L. Lyons, Sana M. Al-Khatib. (2010) Addressing disparities in sudden cardiac arrest care and the underutilization of effective therapies. American Heart Journal 160:4, 605-618.e1
CrossRef220
Guido Lastra, Sonal Dhuper, Megan S. Johnson, James R. Sowers. (2010) Salt, aldosterone, and insulin resistance: impact on the cardiovascular system. Nature Reviews Cardiology 7:10, 577-584
CrossRef221
F. H. Messerli, J. A. Staessen, F. Zannad. (2010) Of fads, fashion, surrogate endpoints and dual RAS blockade. European Heart Journal 31:18, 2205-2208
CrossRef222
Bertram Pitt, Faiez Zannad, Mihai Gheorghiade, Felipe Martínez, Thomas E. Love, Casey Daniel, Ali Ahmed. (2010) Transatlantic similarities and differences in major natural history endpoints of heart failure after acute myocardial infarction: A propensity-matched study of the EPHESUS trial. International Journal of Cardiology 143:3, 309-316
CrossRef223
John W Funder. (2010) Aldosterone, hypertension and heart failure: insights from clinical trials. Hypertension Research 33:9, 872-875
CrossRef224
Jay Margolis, Robert A Gerber, Craig Roberts, Mihai Gheorghiade. (2010) Adherence to Aldosterone-Blocking Agents in Patients with Heart Failure. American Journal of Therapeutics 17:5, 446-454
CrossRef225
Farzin Beygui, Johanne Silvain, Ana Pena, Anne Bellemain-Appaix, Jean-Philippe Collet, Helmut Drexler, Deepak Bhatt, Eric Vicaut, Gilles Montalescot. (2010) Usefulness of Biomarker Strategy to Improve GRACE Score's Prediction Performance in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome and Low Event Rates. The American Journal of Cardiology 106:5, 650-658
CrossRef226
Javed Butler, Inder S. Anand, Michael A. Kuskowski, Thomas Rector, Peter Carson, Jay N. Cohn, . (2010) Digoxin Use and Heart Failure Outcomes: Results from the Valsartan Heart Failure Trial (Val-HeFT). Congestive Heart Failure 16:5, 191-195
CrossRef227
Jiafu Wei, Juan Ni, Dejia Huang, Mao Chen, Shaodi Yan, Yong Peng. (2010) The Effect of Aldosterone Antagonists for Ventricular Arrhythmia: A Meta-Analysis. Clinical Cardiology 33:9, 572-577
CrossRef228
Justin A. Ezekowitz, Padma Kaul. (2010) The epidemiology and management of elderly patients with myocardial infarction or heart failure. Heart Failure Reviews 15:5, 407-413
CrossRef229
Naohiko Kobayashi, Hiromichi Fukushima, Hiroshi Takeshima, Wataru Koguchi, Yasuko Mamada, Hisato Hirata, Yoshifumi Machida, Noriko Suzuki, Fumie Yokotsuka, Kyoko Tabei, Eri Kobayashi, Noboru Fukuda, Toshihiko Ishimitsu. (2010) Effect of Eplerenone on Endothelial Progenitor Cells and Oxidative Stress in Ischemic Hindlimb. American Journal of Hypertension 23:9, 1007-1013
CrossRef230
Michael R Lattanzio, Matthew R Weir. (2010) Have we fallen off target with concerns surrounding dual RAAS blockade?. Kidney International 78:6, 539-545
CrossRef231
Robert D Toto. (2010) Aldosterone blockade in chronic kidney disease: can it improve outcome?. Current Opinion in Nephrology and Hypertension 19:5, 444-449
CrossRef232
Aviva Gamliel-Lazarovich, Anna Gantman, Raymond Coleman, Arco Y Jeng, Marielle Kaplan, Shlomo Keidar. (2010) FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice. Journal of Hypertension 28:9, 1900-1907
CrossRef233
Shin-ichiro Miura, Keijiro Saku. (2010) Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors?. Journal of Hypertension 28:8, 1614-1616
CrossRef234
Teemu L. Ahola, Ilkka M. Kantola, Pauli Puukka, Anna Kattainen, Timo Klaukka, Antti Reunanen, Antti M. Jula. (2010) Positive change in the utilization of antihypertensive and lipid-lowering drugs among adult CHD patients in Finland: results from a large national database between 2000 and 2006. European Journal of Cardiovascular Prevention & Rehabilitation 17:4, 477-485
CrossRef235
Finn Gustafsson, Julian Segura, Luis M Ruilope. (2010) How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?. Journal of Hypertension 28:8, 1595-1598
CrossRef236
Amir Tirosh, Rajesh Garg, Gail K. Adler. (2010) Mineralocorticoid Receptor Antagonists and the Metabolic Syndrome. Current Hypertension Reports 12:4, 252-257
CrossRef237
Akira Sezai, Kazutomo Minami, Mitsumasa Hata, Isamu Yoshitake, Shinji Wakui, Ayako Takasaka, Tomohiko Murakami, Motomi Shiono, Tadateru Takayama, Atsushi Hirayama. (2010) Long-Term Results (Three-Year) of Emergency Coronary Artery Bypass Grafting for Patients With Unstable Angina Pectoris. The American Journal of Cardiology 106:4, 511-516
CrossRef238
F. Edelmann, A. G. Schmidt, G. Gelbrich, L. Binder, C. Herrmann-Lingen, M. Halle, G. Hasenfuss, R. Wachter, B. Pieske. (2010) Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure 12:8, 874-882
CrossRef239
Christopher M. Adams, Chii-Whei Hu, Arco Y. Jeng, Rajeshri Karki, Gary Ksander, Dan LaSala, Jennifer Leung-Chu, Guiqing Liang, Qian Liu, Erik Meredith, Chang Rao, Dean F. Rigel, Jie Shi, Sherri Smith, Clayton Springer, Chun Zhang. (2010) The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-β-hydroxylase. Bioorganic & Medicinal Chemistry Letters 20:15, 4324-4327
CrossRef240
Filippo Brandimarte, Gian Francesco Mureddu, Alessandro Boccanelli, Giuseppe Cacciatore, Camillo Brandimarte, Francesco Fedele, Mihai Gheorghiade. (2010) Diuretic therapy in heart failure: current controversies and new approaches for fluid removal. Journal of Cardiovascular Medicine 11:8, 563-570
CrossRef241
D. Le Menuet, M. Munier, G. Meduri, S. Viengchareun, M. Lombes. (2010) Mineralocorticoid receptor overexpression in embryonic stem cell-derived cardiomyocytes increases their beating frequency. Cardiovascular Research 87:3, 467-475
CrossRef242
Justin A. Ezekowitz, Paul W. Armstrong, Christopher B. Granger, Pierre Theroux, Amanda Stebbins, Raymond J. Kim, Manesh R. Patel. (2010) Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. American Heart Journal 160:2, 272-278
CrossRef243
Thomas J Povsic, Christopher M O’Connor. (2010) Cell therapy for heart failure: the need for a new therapeutic strategy. Expert Review of Cardiovascular Therapy 8:8, 1107-1126
CrossRef244
Claudia Grossmann, Stefanie Ruhs, Anja Seiferth, Michael Gekle. (2010) Interaction between mineralocorticoid receptor and cAMP/CREB signaling. Steroids 75:8-9, 539-543
CrossRef245
Miki Nagase. (2010) Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome. Clinical and Experimental Nephrology 14:4, 303-314
CrossRef246
Felipe A. Martinez. (2010) Aldosterone Inhibition and Cardiovascular Protection: More Important Than it Once Appeared. Cardiovascular Drugs and Therapy 24:4, 345-350
CrossRef247
Jaroslav Kalvoda, Marc de Gasparo. 2010. Eplerenone: Selective Aldosterone Antagonist. , 359-381.
CrossRef248
Guliz Erdem, Tobias Geisler, Marcus D. Flather. (2010) What Goes Into a Major Acute Coronary Syndrome Trial and What Will Future Trials Look Like?. Current Cardiology Reports 12:4, 348-355
CrossRef249
Barry Greenberg. (2010) Managing hyponatremia in patients with heart failure. Journal of Hospital Medicine 5:S3, S33-S39
CrossRef250
Daniel Sürder, Jürg Schwitter, Tiziano Moccetti, Giuseppe Astori, Kaspar Rufibach, Sven Plein, Viviana Lo Cicero, Sabrina Soncin, Stephan Windecker, Aris Moschovitis, Andreas Wahl, Paul Erne, Peiman Jamshidi, Christoph Auf der Maur, Robert Manka, Gianni Soldati, Ines Bühler, Christophe Wyss, Ulf Landmesser, Thomas F. Lüscher, Roberto Corti. (2010) Cell-based therapy for myocardial repair in patients with acute myocardial infarction: Rationale and study design of the SWiss multicenter Intracoronary Stem cells Study in Acute Myocardial Infarction (SWISS-AMI). American Heart Journal 160:1, 58-64
CrossRef251
Christian Werner, Janine Pöss, Michael Böhm. (2010) Optimal Antagonism of the Renin-Angiotensin-Aldosterone System. Drugs 70:10, 1215-1230
CrossRef252
Philip A. Kithas, Mark A. Supiano. (2010) Spironolactone and Hydrochlorothiazide Decrease Vascular Stiffness and Blood Pressure in Geriatric Hypertension. Journal of the American Geriatrics Society 58:7, 1327-1332
CrossRef253
Hiromichi Kosaka, Kazunori Hirayama, Nobuyuki Yoda, Katsutoshi Sasaki, Tetsuya Kitayama, Hideaki Kusaka, Masahiro Matsubara. (2010) The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family. European Journal of Pharmacology 635:1-3, 49-55
CrossRef254
Ellen W Seely. (2010) Editorial overview. Current Opinion in Endocrinology, Diabetes and Obesity 17:3, 187
CrossRef255
(2010) Section 13: Evaluation and Therapy for Heart Failure in the Setting of Ischemic Heart Disease. Journal of Cardiac Failure 16:6, e157-e165
CrossRef256
F. Zannad, J. J. V. McMurray, H. Drexler, H. Krum, D. J. van Veldhuisen, K. Swedberg, H. Shi, J. Vincent, B. Pitt. (2010) Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). European Journal of Heart Failure 12:6, 617-622
CrossRef257
Emmanuel M. Kanoupakis, Emmanuel G. Manios, Eleftherios M. Kallergis, Hercules E. Mavrakis, Christos A. Goudis, Ilias G. Saloustros, Maria E. Milathianaki, Gregory I. Chlouverakis, Panos E. Vardas. (2010) Serum Markers of Collagen Turnover Predict Future Shocks in Implantable Cardioverter-Defibrillator Recipients With Dilated Cardiomyopathy on Optimal Treatment. Journal of the American College of Cardiology 55:24, 2753-2759
CrossRef258
A. H. Wu, B. Pitt, S. D. Anker, J. Vincent, M. Mujib, A. Ahmed. (2010) Association of obesity and survival in systolic heart failure after acute myocardial infarction: potential confounding by age. European Journal of Heart Failure 12:6, 566-573
CrossRef259
Masanori Asakura, Masafumi Kitakaze. (2010) Cardioprotection in the Clinical Setting-Lessons from J-WIND Studies. Cardiovascular Drugs and Therapy 24:3, 289-295
CrossRef260
(2010) Section 15: Management of Heart Failure in Special Populations. Journal of Cardiac Failure 16:6, e169-e175
CrossRef261
(2010) Section 7: Heart Failure in Patients With Reduced Ejection Fraction. Journal of Cardiac Failure 16:6, e73-e97
CrossRef262
Heart Failure Society of America. (2010) Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure 16:6, 475-539
CrossRef263
A Sato, S Fukuda. (2010) Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. Journal of Human Hypertension 24:6, 387-394
CrossRef264
Robert M Carey. (2010) Aldosterone and cardiovascular disease. Current Opinion in Endocrinology, Diabetes and Obesity 17:3, 194-198
CrossRef265
Yongji Yan, Jinzhi Ouyang, Chao Wang, Zhun Wu, Xin Ma, Hongzhao Li, Hua Xu, Zheng Hu, Jun Li, Baojun Wang, Taoping Shi, Daojing Gong, Dong Ni, Xu Zhang. (2010) Aortic cell apoptosis in rat primary aldosteronism model. Journal of Huazhong University of Science and Technology [Medical Sciences] 30:3, 385-390
CrossRef266
(2010) Section 9: Electrophysiology Testing and the Use of Devices in Heart Failure. Journal of Cardiac Failure 16:6, e115-e121
CrossRef267
Katsuyuki Ando, Hiroshi Ohtsu, Yoshihiro Arakawa, Kiyoshi Kubota, Takuhiro Yamaguchi, Miki Nagase, Akira Yamada, Toshiro Fujita. (2010) Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertension Research 33:6, 616-621
CrossRef268
A. Tomaschitz, S. Pilz, E. Ritz, A. Meinitzer, B. O. Boehm, W. Marz. (2010) Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. European Heart Journal 31:10, 1237-1247
CrossRef269
Marie Briet, Ernesto L. Schiffrin. (2010) Aldosterone: effects on the kidney and cardiovascular system. Nature Reviews Nephrology 6:5, 261-273
CrossRef270
O. James Ekundayo, Chris Adamopoulos, Mustafa I. Ahmed, Bertram Pitt, James B. Young, Jerome L. Fleg, Thomas E. Love, Xuemei Sui, Gilbert J. Perry, David S. Siscovick, George Bakris, Ali Ahmed. (2010) Oral potassium supplement use and outcomes in chronic heart failure: A propensity-matched study. International Journal of Cardiology 141:2, 167-174
CrossRef271
Bodh I Jugdutt. (2010) Heart failure in the elderly: advances and challenges. Expert Review of Cardiovascular Therapy 8:5, 695-715
CrossRef272
Christian A. Schneider, Roman Pfister, Erland Erdmann. (2010) Diabetes und Herzinsuffizienz. Herz 35:3, 140-146
CrossRef273
Andrea D Eckhart. (2010) Mineralocorticoid receptors, corticosteroids and the heart: where do we stand?. Journal of Hypertension 28:5, 889-891
CrossRef274
Kosuke Kaji, Hitoshi Yoshiji, Mitsuteru Kitade, Yasuhide Ikenaka, Ryuichi Noguchi, Yusaku Shirai, Junichi Yoshii, Koji Yanase, Tadashi Namisaki, Masaharu Yamazaki, Tatsuhiro Tsujimoto, Hideto Kawaratani, Hiroshi Fukui. (2010) Selective aldosterone blocker, eplerenone, attenuates hepatocellular carcinoma growth and angiogenesis in mice. Hepatology Research 40:5, 540-549
CrossRef275
Wenxia Chai, Johannes Hofland, Pieter M Jansen, Ingrid M Garrelds, René de Vries, Antoon J van den Bogaerdt, Richard A Feelders, Frank H de Jong, AH Jan Danser. (2010) Steroidogenesis vs. steroid uptake in the heart: do corticosteroids mediate effects via cardiac mineralocorticoid receptors?. Journal of Hypertension 28:5, 1044-1053
CrossRef276
Anju Bhardwaj, Shafiq U. Rehman, Asim Mohammed, Aaron L. Baggish, Stephanie A. Moore, James L. Januzzi. (2010) Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. American Heart Journal 159:4, 532-538.e1
CrossRef277
Alejandro Martinez-Aguayo, Cristian A. Carvajal, Carmen Campino, Marlene Aglony, Lillian Bolte, Hernán Garcia, Carlos E. Fardella. (2010) Primary Aldosteronism and its Impact on the Generation of Arterial Hypertension, Endothelial Injury and Oxidative Stress. Journal of Pediatric Endocrinology and Metabolism 23:4, 323-330
CrossRef278
J Zhao, J Li, W Li, Y Li, H Shan, Y Gong, B Yang. (2010) Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. British Journal of Pharmacology 159:8, 1584-1594
CrossRef279
Emile G Daoud, John D Hummel, Troy E Rhodes. (2010) Management of sudden cardiac death risk in the very early postmyocardial infarction period. Current Opinion in Cardiology1
CrossRef280
Kenji Oki, Kiminori Yamane, Kenichi Satoh, Shuhei Nakanishi, Hideya Yamamoto, Nobuoki Kohno. (2010) Aldosterone synthase (CYP11B2) C-344T polymorphism affects the association of age-related changes of the serum C-reactive protein. Hypertension Research 33:4, 326-330
CrossRef281
Brian L. Furman. 2010. Endocrine and Metabolic Agents. .
CrossRef282
Christopher M. O'Connor, Vic Hasselblad, Rajendra H. Mehta, Gudaye Tasissa, Robert M. Califf, Mona Fiuzat, Joseph G. Rogers, Carl V. Leier, Lynne W. Stevenson. (2010) Triage After Hospitalization With Advanced Heart Failure. Journal of the American College of Cardiology 55:9, 872-878
CrossRef283
Rona K. Reibis, Andras Treszl, Karl Wegscheider, Bettina Ehrlich, Rüdiger Dissmann, Heinz Völler. (2010) Exercise Capacity Is the Most Powerful Predictor of 2-Year Mortality in Patients with Left Ventricular Systolic Dysfunction. Herz 35:2, 104-110
CrossRef284
Jennifer NA Silva, Charles E Canter. (2010) Current management of pediatric dilated cardiomyopathy. Current Opinion in Cardiology 25:2, 80-87
CrossRef285
Pengxiang Huang, Vikas Chandra, Fraydoon Rastinejad. (2010) Structural Overview of the Nuclear Receptor Superfamily: Insights into Physiology and Therapeutics. Annual Review of Physiology 72:1, 247-272
CrossRef286
Maartje CJ Slagman, Gerjan Navis, Gozewijn D Laverman. (2010) Dual blockade of the renin–angiotensin–aldosterone system in cardiac and renal disease. Current Opinion in Nephrology and Hypertension 19:2, 140-152
CrossRef287
John W. Funder. (2010) Aldosterone and Mineralocorticoid Receptors in the Cardiovascular System. Progress in Cardiovascular Diseases 52:5, 393-400
CrossRef288
Birgit Assmus, Torsten Tonn, Florian H. Seeger, Chang-Hwan Yoon, David Leistner, Jens Klotsche, Volker Schächinger, Erhard Seifried, Andreas M. Zeiher, Stefanie Dimmeler. (2010) Red Blood Cell Contamination of the Final Cell Product Impairs the Efficacy of Autologous Bone Marrow Mononuclear Cell Therapy. Journal of the American College of Cardiology 55:13, 1385-1394
CrossRef289
Ross D. Feldman, Robert Gros. (2010) Rapid vascular effects of steroids – a question of balance?. Canadian Journal of Cardiology 26, 22A-26A
CrossRef290
Hiroaki Kawano, Koichi Node. (2010) Medical agents acting on the renin–angiotensin–aldosterone axis for the treatment of heart failure. Hypertension Research 33:3, 192-193
CrossRef291
Jason Pellman, Robert C. Lyon, Farah Sheikh. (2010) Extracellular matrix remodeling in atrial fibrosis: Mechanisms and implications in atrial fibrillation. Journal of Molecular and Cellular Cardiology 48:3, 461-467
CrossRef292
Hans Oberleithner, Kristina Kusche-Vihrog, Hermann Schillers. (2010) Endothelial cells as vascular salt sensors. Kidney International 77:6, 490-494
CrossRef293
Jane-Lise Samuel, Claude Delcayre. (2010) Heart failure: Aldosterone antagonists are underused by clinicians. Nature Reviews Cardiology 7:3, 125-127
CrossRef294
Mithilesh K Das, Douglas P Zipes. (2010) Antiarrhythmic and Nonantiarrhythmic Drugs for Sudden Cardiac Death Prevention. Journal of Cardiovascular Pharmacology1
CrossRef295
Michael Bader. (2010) Tissue Renin-Angiotensin-Aldosterone Systems: Targets for Pharmacological Therapy. Annual Review of Pharmacology and Toxicology 50:1, 439-465
CrossRef296
Shuntaro Kagiyama, Kiyoshi Matsumura, Kenichi Goto, Toshio Otsubo, Mitsuo Iida. (2010) Role of Rho kinase and oxidative stress in cardiac fibrosis induced by aldosterone and salt in angiotensin type 1a receptor knockout mice. Regulatory Peptides 160:1-3, 133-139
CrossRef297
Osman Najam, Nizar Yonan, Simon G. Williams, Steven M. Shaw. (2010) The Usefulness of Chronic Heart Failure Treatments in Chronic Cardiac Graft Failure. Cardiovascular Therapeutics 28:1, 48-58
CrossRef298
Charles R Salters, Alison L Bailey, Thomas F Whayne. (2010) Current treatment of heart failure in the USA. Expert Review of Cardiovascular Therapy 8:2, 279-290
CrossRef299
Oliver Vonend, Ivo Quack, Lars Christian Rump. (2010) Aldosteron und Hypertonie. Wiener klinische Wochenschrift 122:3-4, 65-74
CrossRef300
Zefeng Zhang, Elizabeth M. Mahoney, Paul Kolm, John Spertus, Jaime Caro, Richard Willke, William S. Weintraub. (2010) Cost Effectiveness of Eplerenone in Patients with Heart Failure after Acute Myocardial Infarction Who were Taking Both ACE Inhibitors and β-Blockers. American Journal Cardiovascular Drugs 10:1, 55-63
CrossRef301
Carlos M. Ferrario. (2010) Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin–angiotensin–aldosterone system: Antihypertensive effects and benefits beyond BP control. Life Sciences 86:9-10, 289-299
CrossRef302
McMurray, John J.V., . (2010) Systolic Heart Failure. New England Journal of Medicine 362:3, 228-238
Full Text303
Roger Hullin. 2010. Treatment of Left Ventricular Failure. , 152-160.
CrossRef304
Mari Hosoda, Toshiharu Fujita, Masayuki Hashiguchi, Yosuke Fujii, Mayumi Mochizuki. (2010) A Pharmacologic Study on Risk Factors of Hyperkalaemia or Increased Blood Potassium Associated with ACE-Inhibitor Therapy. Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku 15:2, 49-59
CrossRef305
Xiao-Jun Du, Ross A. D. Bathgate, Chrishan S. Samuel, Anthony M. Dart, Roger J. Summers. (2010) Cardiovascular effects of relaxin: from basic science to clinical therapy. Nature Reviews Cardiology 7:1, 48-58
CrossRef306
Shepard D. Weiner, LeRoy E. Rabbani. (2010) Secondary prevention strategies for coronary heart disease. Journal of Thrombosis and Thrombolysis 29:1, 8-24
CrossRef307
Pei De-An, Li Li, Xu Zhi-Yun, Huang Jin-Yu, Xu Zheng-Ming, Wang Min, Yao Qiang, Huang Shi-eng. (2010) Increased Expression of Mineralocorticoid Receptor and 11β-Hydroxysteroid Dehydrogenase Type 2 in Human Atria During Atrial Fibrillation. Clinical Cardiology 33:1, 23-29
CrossRef308
Yoshinori Yoshida, Tatsuya Morimoto, Tomohide Takaya, Teruhisa Kawamura, Yoichi Sunagawa, Hiromichi Wada, Masatoshi Fujita, Akira Shimatsu, Toru Kita, Koji Hasegawa. (2010) Aldosterone Signaling Associates With p300/GATA4 Transcriptional Pathway During the Hypertrophic Response of Cardiomyocytes. Circulation Journal 74:1, 156-162
CrossRef309
Hirofumi Ueno, Michihiro Yoshimura, Masafumi Nakayama, Megumi Yamamuro, Tsunenori Nishijima, Kenichi Kusuhara, Yasuhiro Nagayoshi, Sunao Kojima, Koichi Kaikita, Hitoshi Sumida, Seigo Sugiyama, Hisao Ogawa. (2010) Clinical factors affecting serum potassium concentration in cardio-renal decompensation syndrome. International Journal of Cardiology 138:2, 174-181
CrossRef310
Steven A Yarows. (2010) Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases. Expert Review of Cardiovascular Therapy 8:1, 19-33
CrossRef311
Robin A.P. Weir, Ashley M. Miller, Grace E.J. Murphy, Suzanne Clements, Tracey Steedman, John M.C. Connell, Iain B. McInnes, Henry J. Dargie, John J.V. McMurray. (2010) Serum Soluble ST2. Journal of the American College of Cardiology 55:3, 243-250
CrossRef312
Mario Bollati, Argyrios Gerasimou, Dario Sillano, Giuseppe Biondi-Zoccai, Paolo Garrone, Claudio Moretti, Filippo Sciuto, Pierluigi Omedé, Gian Paolo Trevi, Imad Sheiban. (2010) Results of percutaneous drug-eluting stent implantation for unprotected left main coronary disease according to left ventricular systolic function. Catheterization and Cardiovascular InterventionsNA-NA
CrossRef313
Anders Hovland, Anne Fagerheim, Randolf Hardersen, Erik Nielsen. (2010) Eldre mann med kjent hjertesvikt innlagt med kardiogent sjokk. Tidsskrift for Den norske legeforening 130:13, 1352-1354
CrossRef314
Laura D. Kubzansky, Gail K. Adler. (2010) Aldosterone: A forgotten mediator of the relationship between psychological stress and heart disease. Neuroscience & Biobehavioral Reviews 34:1, 80-86
CrossRef315
Akira Nishiyama, Shokei Kim-Mitsuyama. (2010) New Approaches to Blockade of the Renin–Angiotensin–Aldosterone System: Overview of Regulation of the Renin–Angiotensin–Aldosterone System. Journal of Pharmacological Sciences 113:4, 289-291
CrossRef316
Akira Nishiyama, Koichi Hasegawa, Suwarni Diah, Hirofumi Hitomi. (2010) New Approaches to Blockade of the Renin–Angiotensin–Aldosterone System: Mineralocorticoid-Receptor Blockers Exert Antihypertensive and Renoprotective Effects Independently of the Renin–Angiotensin System. Journal of Pharmacological Sciences 113:4, 310-314
CrossRef317
Pawan D Patel, Rohit R Arora. (2010) Practical Implications of ACC/AHA 2007 Guidelines for the Management of Unstable Angina/Non-ST Elevation Myocardial Infarction. American Journal of Therapeutics 17:1, e24-e40
CrossRef318
Shinichiro Ueda. (2010) New Approaches to Blockade of the Renin–Angiotensin–Aldosterone System: Evidence From Randomized Controlled Trials (RCTs) of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II–Receptor Blockers — Questions Remain Unsolved. Journal of Pharmacological Sciences 113:4, 292-295
CrossRef319
Young Seok Kim. (2010) Ascites, Hepatorenal Syndrome and Spontaneous Bacterial Peritonitis in Patients with Portal Hypertension. The Korean Journal of Gastroenterology 56:3, 168
CrossRef320
Clive Rosendorff. (2010) Spironolactone for all hypertensive patients?. Journal of Hypertension 28:1, 13-14
CrossRef321
Kazuro Sugishita, Hironori Muraoka, Akiko Kawana, Masako Asakawa, Shin-ichi Usui, Toshiyuki Takahashi. (2010) Primary Aldosteronism With Right-Dominant Heart Failure. International Heart Journal 51:4, 293-297
CrossRef322
Jane A Leopold. (2009) Rapid Aldosterone Signaling and Vascular Reactivity: Relax or Donʼt Do It. Journal of Cardiovascular Pharmacology 54:6, 465-467
CrossRef323
Rona Limor, Marielle Kaplan, Orly Sharon, Esther Knoll, Michal Naidich, Gary Weisinger, Shlomo Keidar, Naftali Stern. (2009) Aldosterone up-regulates 12- and 15-lipoxygenase expression and LDL oxidation in human vascular smooth muscle cells. Journal of Cellular Biochemistry 108:5, 1203-1210
CrossRef324
Robert H. Neumayr, Paul J. Hauptman. (2009) β-Adrenergic receptor blockers and heart failure risk after myocardial infarction: A critical review. Current Heart Failure Reports 6:4, 220-228
CrossRef325
Anita D. Szady, James A. Hill. (2009) Diuretics in Heart Failure. Drugs 69:17, 2451-2461
CrossRef326
Elizabeth M. Volz, G. Michael Felker. (2009) How to use diuretics in heart failure. Current Treatment Options in Cardiovascular Medicine 11:6, 426-432
CrossRef327
Farouk Mookadam, Sherif E. Moustafa. (2009) Prevention of late postmyocardial infarction left ventricular remodeling: An update. Current Heart Failure Reports 6:4, 245-253
CrossRef328
Akshay S. Desai. (2009) Hyperkalemia in patients with heart failure: Incidence, prevalence, and management. Current Heart Failure Reports 6:4, 272-280
CrossRef329
Bruno Vogt, Michel Burnier. (2009) Aldosterone and cardiovascular risk. Current Hypertension Reports 11:6, 450-455
CrossRef330
S. Brenner, S. Störk, C.E. Angermann. (2009) Behandlung der chronischen Linksherzinsuffizienz. Der Internist 50:12, 1325-1336
CrossRef331
Young-Sin Kim, Barry Greenberg. (2009) Update on renin-angiotensin-aldosterone blockade in heart failure. Current Treatment Options in Cardiovascular Medicine 11:6, 455-466
CrossRef332
Young Sun Kang, Dae Ryong Cha. (2009) Aldosterone and diabetic kidney disease. Current Diabetes Reports 9:6, 453-459
CrossRef333
Bertram Pitt. (2009) Pharmacotherapy: Cardiovascular effects of aldosterone blockade in CKD. Nature Reviews Cardiology 6:11, 679-680
CrossRef334
Jeffrey J. Goldberger, Rod Passman. (2009) Implantable Cardioverter-Defibrillator Therapy After Acute Myocardial Infarction. Journal of the American College of Cardiology 54:22, 2001-2005
CrossRef335
F. Zannad, N. Agrinier, F. Alla. (2009) Heart failure burden and therapy. Europace 11:Supplement 5, v1-v9
CrossRef336
C. Adamopoulos, A. Ahmed, R. Fay, M. Angioi, G. Filippatos, J. Vincent, B. Pitt, F. Zannad, . (2009) Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. European Journal of Heart Failure 11:11, 1099-1105
CrossRef337
Madhan Shanmugasundaram, Joseph S. Alpert. (2009) Acute Coronary Syndrome in the Elderly. Clinical Cardiology 32:11, 608-613
CrossRef338
Filippos Triposkiadis, George Karayannis, Grigorios Giamouzis, John Skoularigis, George Louridas, Javed Butler. (2009) The Sympathetic Nervous System in Heart Failure. Journal of the American College of Cardiology 54:19, 1747-1762
CrossRef339
Daniel LaSala, Yasuhiko Shibanaka, Arco Y. Jeng. (2009) Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors. Analytical Biochemistry 394:1, 56-61
CrossRef340
Takemi Handa, Rajesh G. Katare, Yoshihiko Kakinuma, Mikihiko Arikawa, Motonori Ando, Shiro Sasaguri, Fumiyasu Yamasaki, Takayuki Sato. (2009) Anti-Alzheimer's Drug, Donepezil, Markedly Improves Long-Term Survival After Chronic Heart Failure in Mice. Journal of Cardiac Failure 15:9, 805-811
CrossRef341
Vin-Cent Wu, Shih-Chieh Chueh, Hung-Wei Chang, Lian-Yu Lin, Kao-Lang Liu, Yen-Hung Lin, Yi-Luwn Ho, Wei-Chou Lin, Shuo-Meng Wang, Kuo-How Huang, Kuan-Yu Hung, Tze-Wah Kao, Shuei-Liong Lin, Ruoh-Fang Yen, Yung-Ming Chen, Bor-Sen Hsieh, Kwan-Dun Wu. (2009) Association of Kidney Function With Residual Hypertension After Treatment of Aldosterone-Producing Adenoma. American Journal of Kidney Diseases 54:4, 665-673
CrossRef342
A. Hirata, N. Maeda, A. Hiuge, T. Hibuse, K. Fujita, T. Okada, S. Kihara, T. Funahashi, I. Shimomura. (2009) Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovascular Research 84:1, 164-172
CrossRef343
Stefan Farese, Anja Kruse, Andreas Pasch, Bernhard Dick, Brigitte M Frey, Dominik E Uehlinger, Felix J Frey. (2009) Glycyrrhetinic acid food supplementation lowers serum potassium concentration in chronic hemodialysis patients. Kidney International 76:8, 877-884
CrossRef344
Andrew S. Bomback, Robert Toto. (2009) Dual Blockade of the Renin–Angiotensin–Aldosterone System: Beyond the ACE Inhibitor and Angiotensin-II Receptor Blocker Combination. American Journal of Hypertension 22:10, 1032-1040
CrossRef345
A. Kumar, C. P. Cannon. (2009) Acute Coronary Syndromes: Diagnosis and Management, Part I. Mayo Clinic Proceedings 84:10, 917-938
CrossRef346
Fedja A. Rochling, Rowen K. Zetterman. (2009) Management of Ascites. Drugs 69:13, 1739-1760
CrossRef347
P.A. Mehta, S. McDonagh, J. Phillips, R. Grocott-Mason, S.W. Dubrey. (2009) Angiotensin Receptor Blocker Therapy for Heart Failure Patients: Is Combination Treatment a Feasible Prospect?. Clinical Cardiology 32:9, 513-518
CrossRef348
C. Grossmann, M. Gekle. (2009) New aspects of rapid aldosterone signaling. Molecular and Cellular Endocrinology 308:1-2, 53-62
CrossRef349
A. Brent Alper, Ruth C. Campbell, Stefan D. Anker, George Bakris, Christy Wahle, Thomas E. Love, L. Lee Hamm, Marjan Mujib, Ali Ahmed. (2009) A propensity-matched study of low serum potassium and mortality in older adults with chronic heart failure. International Journal of Cardiology 137:1, 1-8
CrossRef350
Christina Ries, Simon Lucas, Ralf Heim, Barbara Birk, Rolf W. Hartmann. (2009) Selective aldosterone synthase inhibitors reduce aldosterone formation in vitro and in vivo. The Journal of Steroid Biochemistry and Molecular Biology 116:3-5, 121-126
CrossRef351
E. Visús, E. Gargallo, P. Conthe. (2009) Novedades terapéuticas: estudio I-PRESERVE. Revista Clínica Española 209, 36-40
CrossRef352
Alan H. Gradman. (2009) Role of Angiotensin II Type 1 Receptor Antagonists in the Treatment of Hypertension in Patients Aged ≥65 Years. Drugs & Aging 26:9, 751-767
CrossRef353
Michael A. Chen. (2009) Heart Failure with Preserved Ejection Fraction in Older Adults. The American Journal of Medicine 122:8, 713-723
CrossRef354
Eileen M. Hsich, Ileana L. Piña. (2009) Heart Failure in Women. Journal of the American College of Cardiology 54:6, 491-498
CrossRef355
Takayoshi Tsutamoto, Toshinari Tanaka, Keizo Nishiyama, Masayuki Yamaji, Chiho Kawahara, Masanori Fujii, Takashi Yamamoto, Minoru Horie. (2009) Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension. Hypertension Research 32:8, 670-674
CrossRef356
William C. Little, Paul M. Kirkman. (2009) Moving Beyond Angiotensin II to Also Target Aldosterone?. Journal of the American College of Cardiology 54:6, 513-514
CrossRef357
Michal Kardasinski, Thomas Thum. (2009) Cardiac fibroblasts on the fast track –. Journal of Molecular and Cellular Cardiology 47:2, 174-176
CrossRef358
Miki Nagase, Toshiro Fujita. (2009) Mineralocorticoid receptor activation in obesity hypertension. Hypertension Research 32:8, 649-657
CrossRef359
Junko Kurokawa, Hugues Abriel. (2009) Neurohormonal Regulation of Cardiac Ion Channels in Chronic Heart Failure. Journal of Cardiovascular Pharmacology 54:2, 98-105
CrossRef360
E. Ritz, A. Tomaschitz. (2009) Aldosterone, a vasculotoxic agent--novel functions for an old hormone. Nephrology Dialysis Transplantation 24:8, 2302-2305
CrossRef361
Nicola C. Edwards, Richard P. Steeds, Paul M. Stewart, Charles J. Ferro, Jonathan N. Townend. (2009) Effect of Spironolactone on Left Ventricular Mass and Aortic Stiffness in Early-Stage Chronic Kidney Disease. Journal of the American College of Cardiology 54:6, 505-512
CrossRef362
B. A. Haynes, F. Mookadam. (2009) Male Gynecomastia. Mayo Clinic Proceedings 84:8, 672-672
CrossRef363
J. H. O'Keefe, M. D. Carter, C. J. Lavie. (2009) Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach. Mayo Clinic Proceedings 84:8, 741-757
CrossRef364
Sankar D Navaneethan, Sagar U Nigwekar, Ashwini R Sehgal, Giovanni FM Strippoli, Sankar D Navaneethan. 2009. Aldosterone antagonists for preventing the progression of chronic kidney disease. .
CrossRef365
Fernando Otero-Raviña, Lilian Grigorian-Shamagian, Luis Fransi-Galiana, Carlos Názara-Otero, José Ma Fernández-Villaverde, Alberto del Álamo-Alonso, Enrique Nieto-Pol, Miguel de Santiago-Boullón, Isidro López-Rodríguez, José Ma Cardona-Vidal, Alfonso Varela-Román, José R. González-Juanatey. (2009) Morbidity and mortality among heart failure patients in Galicia, N.W. Spain: the GALICAP study. International Journal of Cardiology 136:1, 56-63
CrossRef366
Philip JW Koh, Audrey Koitka, Mark E Cooper, Terri J Allen. (2009) Eplerenone does not attenuate diabetes-associated atherosclerosis. Journal of Hypertension 27:7, 1431-1438
CrossRef367
Ralph AH Stewart. (2009) Clinical trials in heart valve disease. Current Opinion in Cardiology 24:4, 279-287
CrossRef368
Guido Lastra-Lastra, James R. Sowers, Katherine Restrepo-Erazo, Camila Manrique-Acevedo, Guido Lastra-González. (2009) Role of aldosterone and angiotensin II in insulin resistance: an update. Clinical Endocrinology 71:1, 1-6
CrossRef369
Dmitriy Kireyev, Edward C. Yun, Brian J. Page, William E. Boden. (2009) Medical therapy in acute coronary syndromes: Which medicines and at what doses?. Current Cardiology Reports 11:4, 267-275
CrossRef370
Michael Gekle, Claudia Grossmann. (2009) Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?. Pflügers Archiv - European Journal of Physiology 458:2, 231-246
CrossRef371
Bertram Pitt, John Nicklas. (2009) Loop Diuretics in Patients With Heart Failure: Time to Change to Torsemide?. Journal of Cardiovascular Pharmacology 53:6, 435-437
CrossRef372
Bertram Pitt. (2009) Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: How much is too much?. Current Heart Failure Reports 6:2, 112-116
CrossRef373
R. A.P. Weir, K. S. Chong, J. R. Dalzell, C. J. Petrie, C. A. Murphy, T. Steedman, P. B. Mark, T. A. McDonagh, H. J. Dargie, J. J.V. McMurray. (2009) Plasma apelin concentration is depressed following acute myocardial infarction in man. European Journal of Heart Failure 11:6, 551-558
CrossRef374
Veselin Mitrovic, Karl-Friedrich Appel, Nicolaos Proskynitopoulos, Seyfettin Dereli, Christian Wilhelm Hamm. (2009) Effects of candesartan cilexetil “add-on” treatment in congestive heart failure outpatients in daily practice. Clinical Research in Cardiology 98:6, 379-389
CrossRef375
Robin A.P. Weir, Patrick B. Mark, Colin J. Petrie, Suzanne Clements, Tracey Steedman, Ian Ford, Leong L. Ng, Iain B. Squire, Galen S. Wagner, John J.V. McMurray, Henry J. Dargie. (2009) Left ventricular remodeling after acute myocardial infarction: Does eplerenone have an effect?. American Heart Journal 157:6, 1088-1096
CrossRef376
Marcelle D. Smit, Isabelle C. Gelder, Michael Böhm, Hans-Ruprecht Neuberger, Dirk J. Veldhuisen. (2009) Should aldosterone blockade be used beyond current indications in heart failure?. Current Heart Failure Reports 6:2, 117-125
CrossRef377
H. R. Zandbergen, M. W. M. Schellings. (2009) Molecular imaging of ventricular remodeling. Journal of Nuclear Cardiology 16:3, 456-465
CrossRef378
Bruce A. Runyon. (2009) Management of adult patients with ascites due to cirrhosis: An update. Hepatology 49:6, 2087-2107
CrossRef379
J. Fernández de Bobadilla, J. López-Sendón. (2009) Enfermedad renal: implicaciones terapéuticas en insuficiencia cardíaca y cardiopatía isquémica. Medicina Clínica 132, 48-54
CrossRef380
Camila Manrique, Guido Lastra, Michael Gardner, James R. Sowers. (2009) The Renin Angiotensin Aldosterone System in Hypertension: Roles of Insulin Resistance and Oxidative Stress. Medical Clinics of North America 93:3, 569-582
CrossRef381
Krishna K. Gaddam, Anil Verma, Mark Thompson, Rohit Amin, Hector Ventura. (2009) Hypertension and Cardiac Failure in its Various Forms. Medical Clinics of North America 93:3, 665-680
CrossRef382
Tomohito Ohtani, Toshiaki Mano, Shungo Hikoso, Yasushi Sakata, Mayu Nishio, Yasuharu Takeda, Kinya Otsu, Takeshi Miwa, Tohru Masuyama, Masatsugu Hori, Kazuhiro Yamamoto. (2009) Cardiac steroidogenesis and glucocorticoid in the development of cardiac hypertrophy during the progression to heart failure. Journal of Hypertension 27:5, 1074-1083
CrossRef383
José Antonio Costa, Enrique Rodilla, Francisco Pérez-Lahiguera, José María Pascual. (2009) Eplerenona en hipertensión arterial resistente con intolerancia previa a espironolactona. Medicina Clínica 132:19, 756-757
CrossRef384
Zubin Eapen, Joseph G Rogers. (2009) Strategies to attenuate pathological remodeling in heart failure. Current Opinion in Cardiology 24:3, 223-229
CrossRef385
Sankar D Navaneethan, Francesca Pansini, Vlado Perkovic, Carlo Manno, Fabio Pellegrini, David W Johnson, Jonathan C Craig, Giovanni FM Strippoli, Sankar D Navaneethan. 2009. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. .
CrossRef386
Quynh A. Truong, Christopher P. Cannon, Neil A. Zakai, Ian S. Rogers, Robert P. Giugliano, Stephen D. Wiviott, Carolyn H. McCabe, David A. Morrow, Eugene Braunwald. (2009) Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial. American Heart Journal 157:4, 673-679.e1
CrossRef387
M. Lai, S.-E. Bae, J. E. Bell, J. R. Seckl, M. R. Macleod. (2009) Mineralocorticoid receptor mRNA expression is increased in human hippocampus following brief cerebral ischaemia. Neuropathology and Applied Neurobiology 35:2, 156-164
CrossRef388
Sharon Ann Hunt, William T. Abraham, Marshall H. Chin, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Mariell Jessup, Marvin A. Konstam, Donna M. Mancini, Keith Michl, John A. Oates, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson, Clyde W. Yancy. (2009) 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Journal of the American College of Cardiology 53:15, e1-e90
CrossRef389
Rosemeire M. Kanashiro-Takeuchi, Bettina Heidecker, Guillaume Lamirault, Jennifer W. Dharamsi, Joshua M. Hare. (2009) Sex-Specific Impact of Aldosterone Receptor Antagonism on Ventricular Remodeling and Gene Expression after Myocardial Infarction. Clinical and Translational Science 2:2, 134-142
CrossRef390
Jalal K Ghali. (2009) Sex, race and ethnicity: providing quality care for elderly patients hospitalized with heart failure. Aging Health 5:2, 171-176
CrossRef391
Pieter M Jansen, AH Jan Danser, Ben P Imholz, Anton H van den Meiracker. (2009) Aldosterone-receptor antagonism in hypertension. Journal of Hypertension 27:4, 680-691
CrossRef392
Gerald W. Dorn. (2009) Novel pharmacotherapies to abrogate postinfarction ventricular remodeling. Nature Reviews Cardiology 6:4, 283-291
CrossRef393
Colin D. Clyne, Ching-Yi Chang, Rachid Safi, Peter J. Fuller, Donald P. McDonnell, Morag J. Young. (2009) Purification and characterization of recombinant human mineralocorticoid receptor. Molecular and Cellular Endocrinology 302:1, 81-85
CrossRef394
Xiao-Jun Du, Qi Xu, Edna Lekgabe, Xiao-Ming Gao, Helen Kiriazis, Xiao-Lei Moore, Anthony M. Dart, Geoffrey W. Tregear, Ross A. D. Bathgate, Chrishan S. Samuel. (2009) Reversal of Cardiac Fibrosis and Related Dysfunction by Relaxin. Annals of the New York Academy of Sciences 1160:1, 278-284
CrossRef395
M. Komajda. (2009) Heart failure guidelines in North America and Europe: agreement or disagreement?. European Journal of Heart Failure Supplements 8:Supplement 1, i11-i14
CrossRef396
Farzin Beygui, Gilles Montalescot, Eric Vicaut, Stephanie Rouanet, Eric Van Belle, Cathrine Baulac, Alexia Degrandsart, Jean Dallongeville. (2009) Aldosterone and long-term outcome after myocardial infarction: A substudy of the french nationwide Observatoire sur la Prise en charge hospitalière, l'Evolution à un an et les caRactéristiques de patients présentant un infArctus du myocarde avec ou sans onde Q (OPERA) study. American Heart Journal 157:4, 680-687
CrossRef397
Jun Iwanami, Masaki Mogi, Masaru Iwai, Masatsugu Horiuchi. (2009) Inhibition of the renin–angiotensin system and target organ protection. Hypertension Research 32:4, 229-237
CrossRef398
Saraswathy Manickavasagam, Ramanna Merla, Michael M Koerner, Ken Fujise, Sanjay Kunapuli, Salvatore Rosanio, Alejandro Barbagelata. (2009) Management of hypertension in chronic heart failure. Expert Review of Cardiovascular Therapy 7:4, 423-433
CrossRef399
Andreas Rolf, Thorsten Dill. (2009) Magnetic resonance assessment of stem cells. Current Cardiovascular Imaging Reports 2:2, 138-144
CrossRef400
H.J. Dargie. (2009) Current controversies in drug use. European Journal of Heart Failure Supplements 8:Supplement 1, i15-i20
CrossRef401
R. Kreutz. (2009) Besonderheiten der Pharmakotherapie beim älteren Hypertoniker. Der Internist 50:4, 442-454
CrossRef402
Radhakrishnan Ramaraj. (2009) Role of aldosterone receptor antagonist eplerenone in aortic stenosis. American Heart Journal 157:3, e13
CrossRef403
John W. Funder, Anastasia S. Mihailidou. (2009) Aldosterone and mineralocorticoid receptors: Clinical studies and basic biology. Molecular and Cellular Endocrinology 301:1-2, 2-6
CrossRef404
Patrick W.F. Hadoke, Javaid Iqbal, Brian R. Walker. (2009) Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease. British Journal of Pharmacology 156:5, 689-712
CrossRef405
Ralph A.H. Stewart, Harvey D. White. (2009) Reply to: Role of aldosterone receptor antagonist eplerenone in aortic steroids. American Heart Journal 157:3, e17
CrossRef406
C. D. Holloway, S. M. MacKenzie, R. Fraser, S. Miller, M. Barr, D. Wilkinson, G. H. Forbes, E. Friel, J. M. C. Connell, E. Davies. (2009) Effects of genetic variation in the aldosterone synthase ( CYP11B2 ) gene on enzyme function. Clinical Endocrinology 70:3, 363-371
CrossRef407
Kurt R. Daniel, Gretchen Wells, Kathryn Stewart, Brian Moore, Dalane W. Kitzman. (2009) Effect of Aldosterone Antagonism on Exercise Tolerance, Doppler Diastolic Function, and Quality of Life in Older Women With Diastolic Heart Failure. Congestive Heart Failure 15:2, 68-74
CrossRef408
Henry Krum, William T Abraham. (2009) Heart failure. The Lancet 373:9667, 941-955
CrossRef409
Eugene S. Chung, Wojciech Mazur, Santosh G. Menon, Edward J. Schloss, Theodore Chow, Dean J. Kereiakes. (2009) Peri-infarct Pacing with CRT in the Early Postinfarct Phase to Attenuate Long-term Remodeling. Journal of Cardiovascular Translational Research 2:1, 126-129
CrossRef410
Theodore A. Kotchen, Jane M. Kotchen, Clarence E. Grim, Shanthi Krishnaswami, Srividya Kidambi. (2009) Aldosterone and Alterations of Hypertension-Related Vascular Function in African Americans. American Journal of Hypertension 22:3, 319-324
CrossRef411
(2009) Guías de Práctica Clínica de la Sociedad Europea de Cardiología (ESC). Manejo del infarto agudo de miocardio en pacientes con elevación persistente del segmento ST. Revista Española de Cardiología 62:3, 293.e1-293.e47
CrossRef412
Eleanor Davies, Scott M. MacKenzie, E. Marie Freel, Samantha Alvarez-Madrazo, Robert Fraser, John M.C. Connell. (2009) Altered corticosteroid biosynthesis in essential hypertension: A digenic phenomenon. Molecular and Cellular Endocrinology 300:1-2, 185-191
CrossRef413
P.A. Mehta, S.W. Dubrey. (2009) High output heart failure. QJM 102:4, 235-241
CrossRef414
Cynthia A Sanoski. (2009) Aliskiren: An Oral Direct Renin Inhibitor for the Treatment of Hypertension. Pharmacotherapy 29:2, 193-212
CrossRef415
Krishna K. Gaddam, Eduardo Pimenta, Saima Husain, David A. Calhoun. (2009) Aldosterone and Cardiovascular Disease. Current Problems in Cardiology 34:2, 51-84
CrossRef416
Helmut Gohlke, Christian Albus, Detlef Bernd Gysan, Harry W. Hahmann, Peter Mathes. (2009) Cardiovascular Prevention in Clinical Practice (ESC and German Guidelines 2007). Herz 34:1, 4-14
CrossRef417
Alex Odermatt, Atanas G. Atanasov. (2009) Mineralocorticoid receptors: Emerging complexity and functional diversity. Steroids 74:2, 163-171
CrossRef418
Cara A. Wasywich, Gillian A. Whalley, Helen A. Walsh, Greg D. Gamble, Robert N. Doughty. (2009) Changes in Tissue-Doppler Echocardiographic Assessment of Left Ventricular Filling During NT-proBNP Guided Heart Failure Treatment Titration: A Pilot Study. Heart, Lung and Circulation 18:1, 38-44
CrossRef419
Susanne W.M. van den Borne, Satoshi Isobe, H. Reinier Zandbergen, Peng Li, Artiom Petrov, Nathan D. Wong, Shinichiro Fujimoto, Ai Fujimoto, Dagfinn Lovhaug, Jos F.M. Smits, Mat J.A.P. Daemen, W. Matthijs Blankesteijn, Chris Reutelingsperger, Faiez Zannad, Navneet Narula, Mani A. Vannan, Bertram Pitt, Leonard Hofstra, Jagat Narula. (2009) Molecular Imaging for Efficacy of Pharmacologic Intervention in Myocardial Remodeling. JACC: Cardiovascular Imaging 2:2, 187-198
CrossRef420
Murray Epstein. (2009) Hyperkalemia as a Constraint to Therapy With Combination Renin-Angiotensin System Blockade: The Elephant in the Room. The Journal of Clinical Hypertension 11:2, 55-60
CrossRef421
Riccardo Lacchini, Maricene Sabha, Fernanda B Coeli, Fabrício F Favero, Juan Yugar-Toledo, Tatiane C Izidoro-Toledo, Valéria C Sandrim, José E Tanus-Santos, Maricilda P de Mello, Heitor Moreno. (2009) T allele of −344C/T polymorphism in aldosterone synthase gene is not associated with resistant hypertension. Hypertension Research 32:2, 159-162
CrossRef422
Anil Kumar, Wilbert S Aronow, Aniket Vadnerkar, Kasturi Sivan, Sanjay Mittal. (2009) Effects of Increased Dose of Diuretics on Symptoms, Weight, 6-Minute Walk Distance, and Echocardiographic Measurements of Left Ventricular Systolic and Diastolic Function in 51 Patients With Symptomatic Heart Failure Caused by Reduced Left Ventricular Ejection Fraction Treated With Beta Blockers and Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers. American Journal of Therapeutics 16:1, 5-7
CrossRef423
Kathy M Makkar, Cynthia A Sanoski, Sarah A Spinler. (2009) Role of Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Aldosterone Antagonists in the Prevention of Atrial and Ventricular Arrhythmias. Pharmacotherapy 29:1, 31-48
CrossRef424
Miyashita Yutaka, Mizuo Mifune, Eiji Kubota, Hiroshi Itoh, Ikuo Saito. (2009) Comparison of Effects of Low Dose of Spironolactone and a Thiazide Diuretic in Patients with Hypertension Treated with an Angiotensin-Converting Enzyme Inhibitor or an Angiotensin Type 1 Receptor Blocker. Clinical and Experimental Hypertension 31:8, 648-656
CrossRef425
Atsuhisa SATO. (2009) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 40:2, 51S-52S
CrossRef426
James D. Flaherty, Jeroen J. Bax, Leonardo De Luca, Joseph S. Rossi, Charles J. Davidson, Gerasimos Filippatos, Peter P. Liu, Marvin A. Konstam, Barry Greenberg, Mandeep R. Mehra, Günter Breithardt, Peter S. Pang, James B. Young, Gregg C. Fonarow, Robert O. Bonow, Mihai Gheorghiade. (2009) Acute Heart Failure Syndromes in Patients With Coronary Artery Disease. Journal of the American College of Cardiology 53:3, 254-263
CrossRef427
E. Born-Frontsberg, M. Quinkler. (2009) Conn-Syndrom. Der Internist 50:1, 17-26
CrossRef428
Nicola Acquarone, Cristoforo Castello, Giancarlo Antonucci, Sergio Lione, Paolo Bellotti. (2009) Pharmacologic therapy in patients with chronic heart failure and chronic kidney disease: a complex issue. Journal of Cardiovascular Medicine 10:1, 13-21
CrossRef429
Shinsuke Suzuki, Tomoko Ohkusa, Takashi Sato, Masaaki Yoshida, Kenji Yasui, Keiko Miwa, Jong-Kook Lee, Masafumi Yano, Itsuo Kodama, Masunori Matsuzaki. (2009) Effects of Aldosterone on Cx43 Gap Junction Expression in Neonatal Rat Cultured Cardiomyocytes. Circulation Journal 73:8, 1504-1512
CrossRef430
Wilbert S. Aronow. (2009) Treating Hypertension in Older Adults. Drug Safety 32:2, 111-118
CrossRef431
Pramod Reddy, Arshag D Mooradian. (2009) Diuretics: An Update on the Pharmacology and Clinical Uses. American Journal of Therapeutics 16:1, 74-85
CrossRef432
Erkan Sengul, Tayfun Sahin, Erce Sevin, Ahmet Yilmaz. (2009) Effect of Spironolactone on Urinary Protein Excretion in Patients with Chronic Kidney Disease. Renal Failure 31:10, 928-932
CrossRef433
A. Boccanelli, G. F. Mureddu, G. Cacciatore, F. Clemenza, A. Di Lenarda, A. Gavazzi, M. Porcu, R. Latini, D. Lucci, A. P. Maggioni, S. Masson, M. Vanasia, G. de Simone, . (2009) Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. European Journal of Heart Failure 11:1, 68-76
CrossRef434
Hiromi RAKUGI. (2009) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 40:2, 49S-50S
CrossRef435
Akira Nishiyama, Hirofumi Hitomi, Asadur Rahman, Hideyasu Kiyomoto. (2009) Drug Discovery for Overcoming Chronic Kidney Disease (CKD): Pharmacological Effects of Mineralocorticoid-Receptor Blockers. Journal of Pharmacological Sciences 109:1, 1-6
CrossRef436
Alexander Göhler, Benjamin P. Geisler, Jennifer M. Manne, Mikhail Kosiborod, Zefeng Zhang, William S. Weintraub, John A. Spertus, G. Scott Gazelle, Uwe Siebert, David J. Cohen. (2009) Utility Estimates for Decision–Analytic Modeling in Chronic Heart Failure—Health States Based on New York Heart Association Classes and Number of Rehospitalizations. Value in Health 12:1, 185-187
CrossRef437
Rajesh Garg, Gail K. Adler. 2009. Aldosterone and its Cardiovascular Effects. , 349-359.
CrossRef438
John Coghlan, James F. Tait. 2009. Aldosterone: History and Introduction. , 309-327.
CrossRef439
William E. Rainey, Wendy B. Bollag, Carlos M. Isales. 2009. Regulation of Aldosterone Production. , 361-381.
CrossRef440
John C. Alexander, Daniel E. Salazar. 2009. Modern Drug Discovery and Development. , 361-380.
CrossRef441
Jason G. Umans, Edgardo J. Abalos, Marshall D. Lindheimer. 2009. Antihypertensive Treatment. , 369-387.
CrossRef442
Michael D. Faulx, Gary S. Francis. (2008) Adverse Drug Reactions in Patients with Cardiovascular Disease. Current Problems in Cardiology 33:12, 703-768
CrossRef443
María Miana, David Sanz-Rosa, Natalia de las Heras, Beatriz Martín, Victoria Cachofeiro, Vicente Lahera. (2008) Participación de los mineralocorticoides en la respuesta inflamatoria vascular asociada a la hipertensión. Clínica e Investigación en Arteriosclerosis 20:6, 233-238
CrossRef444
Benjamin W Van Tassell, Przemyslaw Radwanski, Matthew Movsesian, Mark A Munger. (2008) Combination Therapy with β-Adrenergic Receptor Antagonists and Phosphodiesterase Inhibitors for Chronic Heart Failure. Pharmacotherapy 28:12, 1523-1530
CrossRef445
J. Paul Rocchiccioli, John J.V. McMurray. (2008) Medical management of advanced heart failure. Progress in Palliative Care 16:5, 229-240
CrossRef446
Domenico Corradi, Sergio Callegari, Roberta Maestri, Stefano Benussi, Ottavio Alfieri. (2008) Structural remodeling in atrial fibrillation. Nature Clinical Practice Cardiovascular Medicine 5:12, 782-796
CrossRef447
(2008) Guía de práctica clínica de la Sociedad Europea de Cardiología (ESC) para el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica (2008). Revista Española de Cardiología 61:12, 1329.e1-1329.e70
CrossRef448
Beth D. Kaufman, Robert E. Shaddy, Girish S. Shirali, Ronn Tanel, Jeffrey A. Towbin. (2008) Assessment and management of the failing heart in children. Cardiology in the Young 18:S3, 63
CrossRef449
Bodh I. Jugdutt. (2008) Pleiotropic effects of cardiac drugs on healing post-MI. The good, bad, and ugly. Heart Failure Reviews 13:4, 439-452
CrossRef450
Lilian Grigorian-Shamagian, Fernando Otero Raviña, Emad Abu Assi, Rafael Vidal Perez, Elvis Teijeira-Fernandez, Alfonso Varela Roman, Laura Moreira Sayagues, Jose Ramon Gonzalez-Juanatey. (2008) Why and when do patients with heart failure and normal left ventricular ejection fraction die? Analysis of >600 deaths in a community long-term study. American Heart Journal 156:6, 1184-1190
CrossRef451
George V. Moukarbel, Scott D. Solomon. (2008) Treatment of asymptomatic left ventricular dysfunction. Current Treatment Options in Cardiovascular Medicine 10:6, 476-485
CrossRef452
Harlan M. Krumholz, Jeffrey L. Anderson, Brian L. Bachelder, Francis M. Fesmire, Stephan D. Fihn, JoAnne M. Foody, P. Michael Ho, Mikhail N. Kosiborod, Frederick A. Masoudi, Brahmajee K. Nallamothu. (2008) ACC/AHA 2008 Performance Measures for Adults With ST-Elevation and Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 52:24, 2046-2099
CrossRef453
GUOSHUANG XU, AN LIU, XIAOWEI LIU. (2008) Aldosterone induces collagen synthesis via activation of extracellular signal-regulated kinase 1 and 2 in renal proximal tubules. Nephrology 13:8, 694-701
CrossRef454
G Marshall, G McKay, M Fisher. (2008) Eplerenone. Practical Diabetes International 25:9, 377-378
CrossRef455
Ricardo J. Lopes, Ana Patricia Lourenço, Joana Mascarenhas, Ana Azevedo, Paulo Bettencourt. (2008) Safety of Spironolactone Use in Ambulatory Heart Failure Patients. Clinical Cardiology 31:11, 509-513
CrossRef456
Jalal K. Ghali, S. William Tam, Michael L. Sabolinski, Anne L. Taylor, Joann Lindenfeld, Jay N. Cohn, Manuel Worcel. (2008) Exploring the Potential Synergistic Action of Spironolactone on Nitric Oxide–Enhancing Therapy: Insights From the African-American Heart Failure Trial. Journal of Cardiac Failure 14:9, 718-723
CrossRef457
Tariq Khan, J. Thomas Heywood. (2008) Inpatient management of patients with volume overload and high filling pressures. Journal of Hospital Medicine 3:S6, S25-S32
CrossRef458
D. Tobing, J. French, J. Varigos, A. Meehan, B. Billah, H. Krum, . (2008) Do patients with heart failure appropriately undergo invasive procedures post-myocardial infarction? Results from a prospective multicentre study. Internal Medicine Journal 38:11, 845-851
CrossRef459
Victoria Delgado, Sjoerd A. Mollema, Claudia Ypenburg, Laurens F. Tops, Ernst E. van der Wall, Martin J. Schalij, Jeroen J. Bax. (2008) Relation Between Global Left Ventricular Longitudinal Strain Assessed with Novel Automated Function Imaging and Biplane Left Ventricular Ejection Fraction in Patients with Coronary Artery Disease. Journal of the American Society of Echocardiography 21:11, 1244-1250
CrossRef460
V. Regitz-Zagrosek, C. Schubert. (2008) Geschlechterunterschiede in der kardiovaskulären Pharmakotherapie. Der Internist 49:11, 1383-1390
CrossRef461
Dominic Kelly, Iain B. Squire, Sohail Q. Khan, Paulene Quinn, Joachim Struck, Nils G. Morgenthaler, Joan E. Davies, Leong L. NG. (2008) C-Terminal Provasopressin (Copeptin) is Associated With Left Ventricular Dysfunction, Remodeling, and Clinical Heart Failure in Survivors of Myocardial Infarction. Journal of Cardiac Failure 14:9, 739-745
CrossRef462
David A. Calhoun, William B. White. (2008) Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. Journal of the American Society of Hypertension 2:6, 462-468
CrossRef463
Francisco M. Gomez-Soto, José L. Puerto, José L. Andrey, Francisco J. Fernandez, Miguel A. Escobar, Antonio A. Garcia-Egido, Sotero P. Romero, José A. Bernal, F. Gomez. (2008) Consultation between specialists in Internal Medicine and Family Medicine improves management and prognosis of heart failure. European Journal of Internal Medicine 19:7, 548-554
CrossRef464
Jeanne Loughlin, John D. Seeger, P. Mona Eng, Marie Foegh, C. Robin Clifford, Jennifer Cutone, Alexander M. Walker. (2008) Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives. Contraception 78:5, 377-383
CrossRef465
, F. Van de Werf, J. Bax, A. Betriu, C. Blomstrom-Lundqvist, F. Crea, V. Falk, G. Filippatos, K. Fox, K. Huber, A. Kastrati, A. Rosengren, P. G. Steg, M. Tubaro, F. Verheugt, F. Weidinger, M. Weis, , A. Vahanian, J. Camm, R. De Caterina, V. Dean, K. Dickstein, G. Filippatos, C. Funck-Brentano, I. Hellemans, S. D. Kristensen, K. McGregor, U. Sechtem, S. Silber, M. Tendera, P. Widimsky, J. L. Zamorano, , S. Silber, F. V. Aguirre, N. Al-Attar, E. Alegria, F. Andreotti, W. Benzer, O. Breithardt, N. Danchin, C. D. Mario, D. Dudek, D. Gulba, S. Halvorsen, P. Kaufmann, R. Kornowski, G. Y. H. Lip, F. Rutten. (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:. European Heart Journal 29:23, 2909-2945
CrossRef466
Domenic A. Sica. (2008) Edema Mechanisms in the Patient with Heart Failure and Treatment Options. Heart Failure Clinics 4:4, 511-518
CrossRef467
Julian Segura, Luis M. Ruilope. (2008) Hyperkalemia Risk and Treatment of Heart Failure. Heart Failure Clinics 4:4, 455-464
CrossRef468
Ali Ahmed, Ruth C. Campbell. (2008) Epidemiology of Chronic Kidney Disease in Heart Failure. Heart Failure Clinics 4:4, 387-399
CrossRef469
, K. Dickstein, A. Cohen-Solal, G. Filippatos, J. J.V. McMurray, P. Ponikowski, P. A. Poole-Wilson, A. Stromberg, D. J. van Veldhuisen, D. Atar, A. W. Hoes, A. Keren, A. Mebazaa, M. Nieminen, S. G. Priori, K. Swedberg, , A. Vahanian, J. Camm, R. De Caterina, V. Dean, K. Dickstein, G. Filippatos, C. Funck-Brentano, I. Hellemans, S. D. Kristensen, K. McGregor, U. Sechtem, S. Silber, M. Tendera, P. Widimsky, J. L. Zamorano, , M. Tendera, A. Auricchio, J. Bax, M. Bohm, U. Corra, P. della Bella, P. M. Elliott, F. Follath, M. Gheorghiade, Y. Hasin, A. Hernborg, T. Jaarsma, M. Komajda, R. Kornowski, M. Piepoli, B. Prendergast, L. Tavazzi, J.-L. Vachiery, F. W. A. Verheugt, J. L. Zamorano, F. Zannad. (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal 29:19, 2388-2442
CrossRef470
Wanpen Vongpatanasin. (2008) Management of hypertension in patients with coronary artery disease. Current Hypertension Reports 10:5, 349-354
CrossRef471
Axel Bauer, Marek Malik, Georg Schmidt, Petra Barthel, Hendrik Bonnemeier, Iwona Cygankiewicz, Przemyslaw Guzik, Federico Lombardi, Alexander Müller, Ali Oto, Raphael Schneider, Mari Watanabe, Dan Wichterle, Wojciech Zareba. (2008) Heart Rate Turbulence: Standards of Measurement, Physiological Interpretation, and Clinical Use. Journal of the American College of Cardiology 52:17, 1353-1365
CrossRef472
Sana M. Al-Khatib, Gillian D. Sanders, Mark Carlson, Aida Cicic, Anne Curtis, Gregg C. Fonarow, Peter W. Groeneveld, David Hayes, Paul Heidenreich, Daniel Mark, Eric Peterson, Eric N. Prystowsky, Philip Sager, Marcel E. Salive, Kevin Thomas, Clyde W. Yancy, Wojciech Zareba, Douglas Zipes. (2008) Preventing tomorrow's sudden cardiac death today. American Heart Journal 156:4, 613-622
CrossRef473
PHYLLIS K STEIN, DEVANG SANGHAVI, PETER P. DOMITROVICH, ROBERT A. MACKEY, PRAKASH DEEDWANIA. (2008) Ambulatory ECG-Based T-Wave Alternans Predicts Sudden Cardiac Death in High-Risk Post-MI Patients with Left Ventricular Dysfunction in the EPHESUS Study. Journal of Cardiovascular Electrophysiology 19:10, 1037-1042
CrossRef474
J. A. Ezekowitz, F. A. McAlister. (2008) Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. European Heart Journal 30:4, 469-477
CrossRef475
Helmy Siragy, Jiqian Huang, David C Lieb. (2008) The development of the direct renin inhibitor aliskiren: treating hypertension and beyond. Expert Opinion on Emerging Drugs 13:3, 417-430
CrossRef476
Alain Cohen-Solal, Florence Beauvais, Damien Logeart. (2008) Heart Failure and Diabetes Mellitus: Epidemiology and Management of an Alarming Association. Journal of Cardiac Failure 14:7, 615-625
CrossRef477
Lilian Grigorian-Shamagian, Jose Ramon Gonzalez-JuAnatey, Rafael Vazquez, Juan Cinca, Antoni Bayes-Genis, Domingo Pascual, Carlos Fernandez-Palomeque, Alfredo Bardaji, Jesus Almendral, Vicente Nieto, Carlos Macaya, Ricardo Pavon Jimenez, Antoni Bayes de Luna. (2008) Association of Blood Pressure and Its Evolving Changes With the Survival of Patients With Heart Failure. Journal of Cardiac Failure 14:7, 561-568
CrossRef478
Vasilios G. Athyros, Anna I. Kakafika, Asterios Karagiannis, Dimitri P. Mikhailidis. (2008) Do we need to consider inflammatory markers when we treat atherosclerotic disease?. Atherosclerosis 200:1, 1-12
CrossRef479
Oliviero Olivieri, Francesca Pizzolo, Alberto Ciacciarelli, Roberto Corrocher, Denise Signorelli, Salvatore Falcone, Gian S. Blengio. (2008) Menopause Not Aldosterone-to-Renin Ratio Predicts Blood Pressure Response to a Mineralocorticoid Receptor Antagonist in Primary Care Hypertensive Patients. American Journal of Hypertension 21:9, 976-982
CrossRef480
Mª.T. Mories Álvarez. (2008) Protocolo de utilización de fármacos antialdosterónicos. Medicine - Programa de Formación Médica Continuada Acreditado 10:15, 1021-1023
CrossRef481
Michael Kindermann, M. Bohm. (2008) Aktuelle konservative Therapie der chronischen Herzinsuffizienz. Zeitschrift für Herz-,Thorax- und Gefäßchirurgie 22:4, 184-196
CrossRef482
Sonya Addison, Sameer Stas, Melvin R. Hayden, James R. Sowers. (2008) Insulin resistance and blood pressure. Current Hypertension Reports 10:4, 319-325
CrossRef483
R. Mariotti, G. Borelli, M. Coceani, S. Zingaro, A. Barison, I. Morelli, L. Rondinini. (2008) Aldosterone receptor antagonism and heart failure: insights from an outpatient clinic. Journal of Clinical Pharmacy and Therapeutics 33:4, 349-356
CrossRef484
Marc A. Simon, John Watson, J. Timothy Baldwin, William R. Wagner, Harvey S. Borovetz. (2008) Current and Future Considerations in the Use of Mechanical Circulatory Support Devices*. Annual Review of Biomedical Engineering 10:1, 59-84
CrossRef485
M J Forrest, D Bloomfield, R J Briscoe, P N Brown, A-M Cumiskey, J Ehrhart, J C Hershey, W J Keller, X Ma, H E McPherson, E Messina, L B Peterson, W Sharif-Rodriguez, P K S Siegl, P J Sinclair, C P Sparrow, A S Stevenson, S-Y Sun, C Tsai, H Vargas, M Walker, S H West, V White, R F Woltmann. (2008) Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. British Journal of Pharmacology 154:7, 1465-1473
CrossRef486
Miki Nagase, Toshiro Fujita. (2008) Aldosterone and glomerular podocyte injury. Clinical and Experimental Nephrology 12:4, 233-242
CrossRef487
Anton H van den Meiracker, Wendy W Batenburg. (2008) Corticosteroid-dependent, aldosterone-independent mineralocorticoid-receptor activation in the heart. Journal of Hypertension 26:7, 1307-1309
CrossRef488
Rik Hermanides, Jan Paul Ottervanger. (2008) Treatment of ST-elevation myocardial infarction. Future Cardiology 4:4, 391-397
CrossRef489
Laura D. Carbone, Jessica D. Cross, Syed H. Raza, Andrew J. Bush, Robert J. Sepanski, Saurabh Dhawan, Bilal Q. Khan, Malini Gupta, Khurram Ahmad, Rami N. Khouzam, Dwight A. Dishmon, Joseph P. Nesheiwat, Mohammad A. Hajjar, Waqas A. Chishti, Wael Nasser, Mehwish Khan, Catherine R. Womack, Tara Cho, Ashley R. Haskin, Karl T. Weber. (2008) Fracture Risk in Men With Congestive Heart Failure. Journal of the American College of Cardiology 52:2, 135-138
CrossRef490
Nicholas B Norgard, Jennifer E Stark. (2008) Pharmacotherapy for Heart Failure with Left Ventricular Dysfunction: Beyond Angiotensin-Converting Enzyme Inhibitors and β-Blockers. Pharmacotherapy 28:7, 920-931
CrossRef491
ChunYuan Fan, Yasuyuki Kawai, Satoru Inaba, Kenichiro Arakawa, Masato Katsuyama, Kouji Kajinami, Toshihiro Yasuda, Chihiro Yabe-Nishimura, Tadashi Konoshita, Isamu Miyamori. (2008) Synergy of aldosterone and high salt induces vascular smooth muscle hypertrophy through up-regulation of NOX1. The Journal of Steroid Biochemistry and Molecular Biology 111:1-2, 29-36
CrossRef492
K Haynes, DF Heitjan, PA Kanetsky, S Hennessy. (2008) Declining Public Health Burden of Digoxin Toxicity From 1991 to 2004. Clinical Pharmacology & Therapeutics 84:1, 90-94
CrossRef493
Hong Wang, Tatsuo Shimosawa, Hiromitsu Matsui, Tomoyo Kaneko, Sayoko Ogura, Yuzaburo Uetake, Katsu Takenaka, Yutaka Yatomi, Toshiro Fujita. (2008) Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions. Journal of Hypertension 26:7, 1453-1462
CrossRef494
Melvin R. Hayden, James R. Sowers. (2008) Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome. Journal of the American Society of Hypertension 2:4, 239-266
CrossRef495
Paulus Kirchhof, Lisa Fortmüller, Christoph Waldeyer, Günter Breithardt, Larissa Fabritz. (2008) Drugs that interact with cardiac electro-mechanics: Old and new targets for treatment. Progress in Biophysics and Molecular Biology 97:2-3, 497-512
CrossRef496
Guido Lastra-Gonzalez, Camila Manrique-Acevedo, James R. Sowers. (2008) The role of aldosterone in cardiovascular disease in people with diabetes and hypertension: An update. Current Diabetes Reports 8:3, 203-207
CrossRef497
Y Shimoni, K Chen, T Emmett, G Kargacin. (2008) Aldosterone and the autocrine modulation of potassium currents and oxidative stress in the diabetic rat heart. British Journal of Pharmacology 154:3, 675-687
CrossRef498
Stephen G Oxberry, Miriam J Johnson. (2008) Review of the evidence for the management of dyspnoea in people with chronic heart failure. Current Opinion in Supportive and Palliative Care 2:2, 84-88
CrossRef499
J. H. O’Keefe, H. Abuissa, B. Pitt. (2008) Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. Diabetes, Obesity and Metabolism 10:6, 492-497
CrossRef500
Shahriar Iravanian, Samuel C. Dudley. (2008) The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias. Heart Rhythm 5:6, S12-S17
CrossRef501
Hussam Abuissa, James O’Keefe. (2008) The role of renin–angiotensin–aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection. Diabetes, Obesity and Metabolism 0:0, 080520205432340-???
CrossRef502
B. R. Palmer, A. P. Pilbrow, C. M. Frampton, T. G. Yandle, L. Skelton, M. G. Nicholls, A. M. Richards. (2008) Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. European Heart Journal 29:20, 2489-2496
CrossRef503
B. Pitt. (2008) The measurement of plasma aldosterone in patients post-myocardial infarction. European Heart Journal 29:20, 2451-2452
CrossRef504
Andreas Brieke, Joseph Cleveland, JoAnn Lindenfeld. (2008) Mechanical support in acute and chronic heart failure. Current Cardiology Reports 10:3, 168-175
CrossRef505
A. Morton. (2008) Eplerenone in the treatment of Gitelman’s syndrome. Internal Medicine Journal 38:5, 377-377
CrossRef506
K. Swaminathan, J. Davies, J. George, N. S. Rajendra, A. D. Morris, A. D. Struthers. (2008) Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia 51:5, 762-768
CrossRef507
Wayne C. Levy, David T. Linker. (2008) Prediction of mortality in patients with heart failure and systolic dysfunction. Current Cardiology Reports 10:3, 198-205
CrossRef508
Marmar Vaseghi, Kalyanam Shivkumar. (2008) The Role of the Autonomic Nervous System in Sudden Cardiac Death. Progress in Cardiovascular Diseases 50:6, 404-419
CrossRef509
Aysha Arshad, Anisha Mandava, Ganesh Kamath, Dan Musat. (2008) Sudden Cardiac Death and the Role of Medical Therapy. Progress in Cardiovascular Diseases 50:6, 420-438
CrossRef510
E. M. Freel, M. Ingram, A. M. Wallace, A. White, R. Fraser, E. Davies, J. M. C. Connell. (2008) Effect of variation in CYP11B1 and CYP11B2 on corticosteroid phenotype and hypothalamic–pituitary–adrenal axis activity in hypertensive and normotensive subjects. Clinical Endocrinology 68:5, 700-706
CrossRef511
Elke Wühl, Franz Schaefer. (2008) Therapeutic strategies to slow chronic kidney disease progression. Pediatric Nephrology 23:5, 705-716
CrossRef512
Alan R. Tall, Laurent Yvan-Charvet, Naoki Terasaka, Tamara Pagler, Nan Wang. (2008) HDL, ABC Transporters, and Cholesterol Efflux: Implications for the Treatment of Atherosclerosis. Cell Metabolism 7:5, 365-375
CrossRef513
Osamu Akizuki, Atsushi Inayoshi, Tetsuya Kitayama, Kozo Yao, Shiro Shirakura, Katsutoshi Sasaki, Hideaki Kusaka, Masahiro Matsubara. (2008) Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. European Journal of Pharmacology 584:2-3, 424-434
CrossRef514
T. Thum, G. Ertl, J. Bauersachs. (2008) Prävention des linksventrikulären Remodelings. Der Kardiologe 2:2, 100-107
CrossRef515
Allan Struthers, Henry Krum, Gordon H. Williams. (2008) A Comparison of the Aldosterone-blocking Agents Eplerenone and Spironolactone. Clinical Cardiology 31:4, 153-158
CrossRef516
Thomas Dieterle, Matthias Pfisterer, Hanspeter Brunner-La Rocca. (2008) Heart failure in the elderly. Aging Health 4:2, 137-155
CrossRef517
Gian Paolo Rossi, Achille Cesare Pessina, Anthony M Heagerty. (2008) Primary aldosteronism: an update on screening, diagnosis and treatment. Journal of Hypertension 26:4, 613-621
CrossRef518
John W Funder. (2008) TRANSLATIONAL RESEARCH GOES BOTH WAYS: LESSONS FROM CLINICAL STUDIES. Clinical and Experimental Pharmacology and Physiology 35:4, 526-529
CrossRef519
Steven G. Chrysant, Alexander V. Murray, Uta C. Hoppe, Dan Dattani, Samir Patel, Huang Hsu, Jack Zhang. (2008) Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Current Medical Research and Opinion 24:4, 1039-1047
CrossRef520
M. Yamada, M. Kushibiki, T. Osanai, H. Tomita, K. Okumura. (2008) Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization. Cardiovascular Research 79:1, 169-178
CrossRef521
Matthew T. Wheeler, Michael Ho, Joshua W. Knowles, Aleks Pavlovic, Euan A. Ashley. (2008) Pharmacogenetics of Heart Failure: Evidence, Opportunities, and Challenges for Cardiovascular Pharmacogenomics. Journal of Cardiovascular Translational Research 1:1, 25-36
CrossRef522
Yoshiaki Kawase, Hung Q. Ly, Fabrice Prunier, Djamel Lebeche, Yanfen Shi, Hongwei Jin, Lahouaria Hadri, Ryuichi Yoneyama, Kozo Hoshino, Yoshiaki Takewa, Susumu Sakata, Richard Peluso, Krisztina Zsebo, Judith K. Gwathmey, Jean-Claude Tardif, Jean-François Tanguay, Roger J. Hajjar. (2008) Reversal of Cardiac Dysfunction After Long-Term Expression of SERCA2a by Gene Transfer in a Pre-Clinical Model of Heart Failure. Journal of the American College of Cardiology 51:11, 1112-1119
CrossRef523
Jay N. Cohn, Jesse M. Goldman. (2008) Establishing A New Option for Target-organ Protection: Rationale for ARB Plus ACE Inhibitor Combination Therapy. American Journal of Hypertension 21:3, 248-256
CrossRef524
Asterios Karagiannis, Konstantinos Tziomalos, Athanasios Papageorgiou, Anna I Kakafika, Efstathios D Pagourelias, Panagiotis Anagnostis, Vasilios G Athyros, Dimitri P Mikhailidis. (2008) Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opinion on Pharmacotherapy 9:4, 509-515
CrossRef525
Hans-Ulrich Stempfle, Andrea Alt, Jutta Stief, Uwe Siebert. (2008) The Munich Score: A Clinical Index to Predict Survival in Ambulatory Patients With Chronic Heart Failure in the Era of New Medical Therapies. The Journal of Heart and Lung Transplantation 27:2, 222-228
CrossRef526
Wilbert S. Aronow. 2008. Management of the Older Patient After Myocardial Infarction. , 327-350.
CrossRef527
Dalane W. Kitzman, Jerome L. Fleg. 2008. Heart Failure. , 542-576.
CrossRef528
Christine K Choy, Jo E Rodgers, Jean M Nappi, Stuart T Haines. (2008) Type 2 Diabetes Mellitus and Heart Failure. Pharmacotherapy 28:2, 170-192
CrossRef529
Paul J. Hauptman. (2008) Medication adherence in heart failure. Heart Failure Reviews 13:1, 99-106
CrossRef530
Kapil Kumar, Kevin F. Kwaku, Richard L. Verrier. (2008) Treatment options for patients with coronary artery disease identified as high risk by T-wave alternans testing. Current Treatment Options in Cardiovascular Medicine 10:1, 39-48
CrossRef531
Renee Margossian. (2008) Contemporary management of pediatric heart failure. Expert Review of Cardiovascular Therapy 6:2, 187-197
CrossRef532
William H. Frishman. 2008. Systemic Hypertension in the Elderly. , 137-158.
CrossRef533
Giovanni Pedrazzini, Eugenio Santoro, Roberto Latini, Laurie Fromm, Maria Grazia Franzosi, Tiziano Mocetti, Lidia Staszewsky, Simona Barlera, Gianni Tognoni, Aldo P. Maggioni. (2008) Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: Findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)–3 trial. American Heart Journal 155:2, 388-394
CrossRef534
Michael W. Rich. 2008. Therapy of Acute Myocardial Infarction. , 293-326.
CrossRef535
Robert E Shaddy, Gary Webb. (2008) Applying heart failure guidelines to adult congenital heart disease patients. Expert Review of Cardiovascular Therapy 6:2, 165-174
CrossRef536
Melanie D Everitt, Anji T Yetman. (2008) Congestive heart failure in the pediatric patient with congenital heart disease. Pediatric Health 2:1, 33-45
CrossRef537
Andrew S. Bomback, Abhijit V. Kshirsagar, M. Ahinee Amamoo, Philip J. Klemmer. (2008) Change in Proteinuria After Adding Aldosterone Blockers to ACE Inhibitors or Angiotensin Receptor Blockers in CKD: A Systematic Review. American Journal of Kidney Diseases 51:2, 199-211
CrossRef538
Sankar D Navaneethan, Sagar U Nigwekar, Giovanni FM Strippoli, Sankar D Navaneethan. 2008. Aldosterone antagonists for preventing the progression of chronic kidney disease. .
CrossRef539
Hironori HAYASHI, Miyuki KOBARA, Masaki ABE, Nana TANAKA, Eri GOUDA, Hiroe TOBA, Hiroyuki YAMADA, Tetsuya TATSUMI, Tetsuo NAKATA, Hiroaki MATSUBARA. (2008) Aldosterone Nongenomically Produces NADPH Oxidase−Dependent Reactive Oxygen Species and Induces Myocyte Apoptosis. Hypertension Research 31:2, 363-375
CrossRef540
Young Mee Park, Bong Hee Lim, Rhian M. Touyz, Jeong Bae Park. (2008) Expression of NAD(P)H Oxidase Subunits and Their Contribution to Cardiovascular Damage in Aldosterone/Salt-Induced Hypertensive Rat. Journal of Korean Medical Science 23:6, 1039
CrossRef541
Emmanuel L. Bravo. 2008. Adrenal Disorders. , 691-695.
CrossRef542
Frances McManus, Gordon T McInnes, John MC Connell. (2008) Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist. Nature Clinical Practice Endocrinology & Metabolism 4:1, 44-52
CrossRef543
Akiko MUTOH, Masashi ISSHIKI, Toshiro FUJITA. (2008) Aldosterone Enhances Ligand-Stimulated Nitric Oxide Production in Endothelial Cells. Hypertension Research 31:9, 1811-1820
CrossRef544
Kayoko MIYATA, Hirofumi HITOMI, Peng GUO, Guo-Xing ZHANG, Shoji KIMURA, Hideyasu KIYOMOTO, Naohisa HOSOMI, Shoji KAGAMI, Masakazu KOHNO, Akira NISHIYAMA. (2008) Possible Involvement of Rho-Kinase in Aldosterone-Induced Vascular Smooth Muscle Cell Remodeling. Hypertension Research 31:7, 1407-1413
CrossRef545
Grace Casaclang-Verzosa, Bernard J. Gersh, Teresa S.M. Tsang. (2008) Structural and Functional Remodeling of the Left Atrium. Journal of the American College of Cardiology 51:1, 1-11
CrossRef546
LIVIU KLEIN, ROBERT O. BONOW. 2008. Diabetes Mellitus. , 333-342.
CrossRef547
Macaulay A.C. Onuigbo, Nnonyelum T.C. Onuigbo. (2008) Late Onset Azotemia from RAAS Blockade in CKD Patients with Normal Renal Arteries and No Precipitating Risk Factors. Renal Failure 30:1, 73-80
CrossRef548
Sang Youl Rhee, Young Seol Kim. (2008) Evidence Based Medicine in Endocrinology. Journal of Korean Endocrine Society 23:6, 379
CrossRef549
William B. White, Vladimir Hanes, Madhavi Mallareddy, Vijay Chauhan. (2008) Effects of the hormone therapy, drospirenone and 17-beta estradiol, on early morning blood pressure in postmenopausal women with hypertension. Journal of the American Society of Hypertension 2:1, 20-27
CrossRef550
ANNE S. KANDERIAN, AJAY BHARGAVA, GARY S. FRANCIS. 2008. General Treatment of Diastolic Heart Failure. , 415-427.
CrossRef551
Qingfen ZHANG, Yoshihiko SAITO, Noriyuki NAYA, Keiichi IMAGAWA, Satoshi SOMEKAWA, Hiroyuki KAWATA, Yukiji TAKEDA, Shiro UEMURA, Ichiro KISHIMOTO, Kazuwa NAKAO. (2008) The Specific Mineralocorticoid Receptor Blocker Eplerenone Attenuates Left Ventricular Remodeling in Mice Lacking the Gene Encoding Guanylyl Cyclase-A. Hypertension Research 31:6, 1251-1256
CrossRef552
Megumi Yamamuro, Michihiro Yoshimura, Masafumi Nakayama, Koji Abe, Hitoshi Sumida, Seigo Sugiyama, Yoshihiko Saito, Kazuwa Nakao, Hirofumi Yasue, Hisao Ogawa. (2008) Aldosterone, but Not Angiotensin II, Reduces Angiotensin Converting Enzyme 2 Gene Expression Levels in Cultured Neonatal Rat Cardiomyocytes. Circulation Journal 72:8, 1346-1350
CrossRef553
Macaulay A. C. Onuigbo, Nnonyelum T. C. Onuigbo. (2008) Renal Failure and Concurrent RAAS Blockade in Older CKD Patients with Renal Artery Stenosis: An Extended Mayo Clinic Prospective 63-Month Experience. Renal Failure 30:4, 363-371
CrossRef554
Hideyasu Kiyomoto, Kazi Rafiq, Mahbub Mostofa, Akira Nishiyama. (2008) Possible Underlying Mechanisms Responsible for Aldosterone and Mineralocorticoid Receptor–Dependent Renal Injury. Journal of Pharmacological Sciences 108:4, 399-405
CrossRef555
Yasutomi HIGASHIKUNI, Nobukazu ISHIZAKA, Yuko ISHIZAKA, Ei-ichi TODA, Ryozo NAGAI, Minoru YAMAKADO. (2008) Relationship between Blood Pressure and Chronic Kidney Disease in the Japanese Population: The Lower the Better Even in Individuals without Hypertension?. Hypertension Research 31:2, 213-219
CrossRef556
Kamel S. Kamel, Man S. Oh, Shih-Hua Lin, Mitchell L. Halperin. 2008. Treatment of Hypokalemia and Hyperkalemia. , 353-367.
CrossRef557
Enrique Galve. (2008) Fármacos antialdosterónicos: su papel en la insuficiencia cardíaca. Medicina Clínica 130:1, 30-34
CrossRef558
Arthur L. Riba. (2008) Evidence-Based Performance and Quality Improvement in the Acute Cardiac Care Setting. Critical Care Clinics 24:1, 201-229
CrossRef559
Benoît Allenet, Étienne Brudieu, Jean-Philippe Baguet, François Gimenez†, Claude Cassat. 2008. Traitement de l'insuffisance cardiaque. , 101-125.
CrossRef560
Sharad Rastogi, Sudhish Mishra, Valerio Zacà, Issa Alesh, Ramesh C. Gupta, Sidney Goldstein, Hani N. Sabbah. (2007) Effect of Long-term Monotherapy with the Aldosterone Receptor Blocker Eplerenone on Cytoskeletal Proteins and Matrix Metalloproteinases in Dogs with Heart Failure. Cardiovascular Drugs and Therapy 21:6, 415-422
CrossRef561
Anil Verma, Scott D. Solomon. (2007) Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist. Current Heart Failure Reports 4:4, 183-189
CrossRef562
Maryse Palardy, Anique Ducharme, Eileen O’Meara. (2007) Inhibiting the renin-angiotensin system with ACE inhibitors or ARBs after MI. Current Heart Failure Reports 4:4, 190-197
CrossRef563
E. M. Freel, M. Ingram, E. C. Friel, R. Fraser, M. Brown, N. J. Samani, M. Caulfield, P. Munroe, M. Farrall, J. Webster, D. Clayton, A. F. Dominiczak, E. Davies, J. M. C. Connell. (2007) Phenotypic consequences of variation across the aldosterone synthase and 11-beta hydroxylase locus in a hypertensive cohort: data from the MRC BRIGHT Study. Clinical Endocrinology 67:6, 832-838
CrossRef564
Jacob George, Allan D Struthers. (2007) Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure. Expert Opinion on Pharmacotherapy 8:17, 3053-3059
CrossRef565
Masoor Kamalesh. (2007) Heart Failure in Diabetes and Related Conditions. Journal of Cardiac Failure 13:10, 861-873
CrossRef566
Alipio Mangas Rojas, Francisco Gómez Rodríguez. (2007) Tratamiento multifactorial de la arteriosclerosis. Medicina Clínica 129:20, 785-796
CrossRef567
R.-P. Martins, A.-E. Baruteau, E. Donal, C. de Place, J.-C. Daubert, P. Mabo. (2007) Insuffisance mitrale ischémique: apport de l'échocardiographie d'effort et nouvelles perspectives thérapeutiques. Annales de Cardiologie et d'Angéiologie 56:6, 289-296
CrossRef568
B. R. Walker. (2007) Glucocorticoids and Cardiovascular Disease. European Journal of Endocrinology 157:5, 545-559
CrossRef569
A. Fiebeler. (2007) Neues zu Aldosteron und dem Mineralokortikoidrezeptor. Der Nephrologe 2:6, 423-431
CrossRef570
Lawrence R Krakoff. (2007) Is aldosterone a pro-arrhythmic hormone?. Journal of Hypertension 25:11, 2207-2208
CrossRef571
Nimit C Shah, Stuart D Pringle, Peter T Donnan, Allan D Struthers. (2007) Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. Journal of Hypertension 25:11, 2345-2351
CrossRef572
Richard J. Auchus, Fiemu E. Nwariaku. (2007) Primary aldosteronism. Current Cardiology Reports 9:6, 447-452
CrossRef573
Lars Gullestad, Erik Øie, Thor Ueland, Arne Yndestad, Pål Aukrust. (2007) The role of statins in heart failure. Fundamental & Clinical Pharmacology 21:s2, 35-40
CrossRef574
Victoria McEneaney, Brian J. Harvey, Warren Thomas. (2007) Aldosterone rapidly activates protein kinase D via a mineralocorticoid receptor/EGFR trans-activation pathway in the M1 kidney CCD cell line. The Journal of Steroid Biochemistry and Molecular Biology 107:3-5, 180-190
CrossRef575
Olga Delgado Sánchez, Francesc Puigventós Latorre, Manel Pinteño Blanco, Pere Ventayol Bosch. (2007) Equivalencia terapéutica: concepto y niveles de evidencia. Medicina Clínica 129:19, 736-745
CrossRef576
Motoi Kushibiki, Masahiro Yamada, Koichi Oikawa, Hirofumi Tomita, Tomohiro Osanai, Ken Okumura. (2007) Aldosterone causes vasoconstriction in coronary arterioles of rats via angiotensin II type-1 receptor: Influence of hypertension. European Journal of Pharmacology 572:2-3, 182-188
CrossRef577
Barbara J Zarowitz. (2007) Limits of evidence-based medicine in older adults. Aging Health 3:5, 601-610
CrossRef578
Claudia Grossmann, Michael Gekle. (2007) Non-classical actions of the mineralocorticoid receptor: Misuse of EGF receptors?. Molecular and Cellular Endocrinology 277:1-2, 6-12
CrossRef579
Domenic A. Sica, Todd W.B. Gehr, William H. Frishman. (2007) Use of Diuretics in the Treatment of Heart Failure in the Elderly. Heart Failure Clinics 3:4, 455-464
CrossRef580
Wilbert S. Aronow. (2007) Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in the Elderly. Heart Failure Clinics 3:4, 423-436
CrossRef581
A W Krug, K Vleugels, S Schinner, V Lamounier-Zepter, C G Ziegler, S R Bornstein, M Ehrhart-Bornstein. (2007) Human adipocytes induce an ERK1/2 MAP kinases-mediated upregulation of steroidogenic acute regulatory protein (StAR) and an angiotensin II — sensitization in human adrenocortical cells. International Journal of Obesity 31:10, 1605-1616
CrossRef582
(2007) Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. Revista Española de Cardiología 60:10, 1070.e1-1070.e80
CrossRef583
Wilbert S. Aronow. (2007) Heart Failure–Complicating Acute Myocardial Infarction. Heart Failure Clinics 3:4, 465-475
CrossRef584
James F. Neuenschwander, Ragavendra R. Baliga. (2007) Acute Decompensated Heart Failure. Critical Care Clinics 23:4, 737-758
CrossRef585
Wilbert S. Aronow. (2007) Treatment After Myocardial Infarction. Comprehensive Therapy 33:1, 39-47
CrossRef586
U.C. Hoppe. (2007) Leitliniengerechte Therapie der chronischen Herzinsuffizienz. Der Internist 48:9, 929-937
CrossRef587
Alessandro Boccanelli, Giuseppe Cacciatore, Gian Francesco Mureddu, Giovanni de Simone, Francesco Clemenza, Renata De Maria, Andrea Di Lenarda, Antonello Gavazzi, Roberto Latini, Serge Masson, Maurizio Porcu, Massimo Vanasia, Lucio Gonzini, Aldo Pietro Maggioni. (2007) Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of Cardiovascular Medicine 8:9, 683-691
CrossRef588
Andrew S Bomback, Philip J Klemmer. (2007) The incidence and implications of aldosterone breakthrough. Nature Clinical Practice Nephrology 3:9, 486-492
CrossRef589
Larisa H. Cavallari, Vicki L. Groo, Kathryn M. Momary, Thomas D. Stamos, Paul T. Vaitkus. (2007) Markers of Cardiac Collagen Turnover Are Similar in Patients With Mild and More Severe Symptoms of Heart Failure. Congestive Heart Failure 13:5, 275-279
CrossRef590
Severa Bunda, Peter Liu, Yanting Wang, Kela Liu, Aleksander Hinek. (2007) Aldosterone Induces Elastin Production in Cardiac Fibroblasts through Activation of Insulin-Like Growth Factor-I Receptors in a Mineralocorticoid Receptor-Independent Manner. The American Journal of Pathology 171:3, 809-819
CrossRef591
Luc Roumen, Marijn P. A. Sanders, Koen Pieterse, Peter A. J. Hilbers, Ralf Plate, Erica Custers, Marcel Gooyer, Jos F. M. Smits, Ilona Beugels, Judith Emmen, Harry C. J. Ottenheijm, Dirk Leysen, J. J. R. Hermans. (2007) Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics. Journal of Computer-Aided Molecular Design 21:8, 455-471
CrossRef592
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette Kass Wenger, R. Scott Wright, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliott M. Antman, Jonathan L. Halperin, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 50:7, e1-e157
CrossRef593
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette Kass Wenger, R. Scott Wright, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliot M. Antman, Jonathan L. Halperin, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction—Executive Summary. Journal of the American College of Cardiology 50:7, 652-726
CrossRef594
E. Murat Tuzcu, Randall C. Starling, James D. Thomas. (2007) ACC.07 and i2 Summit Highlights: A Conversation With the Experts. Journal of the American College of Cardiology 50:8, C2-C31
CrossRef595
Jigar Patel, Michael Smith, J. Thomas Heywood. (2007) Optimal use of diuretics in patients with heart failure. Current Treatment Options in Cardiovascular Medicine 9:4, 332-342
CrossRef596
J. Eduardo Rame, Daniel L. Dries. (2007) Heart failure and cardiac hypertrophy. Current Treatment Options in Cardiovascular Medicine 9:4, 289-301
CrossRef597
James N. Kirkpatrick, Mani A. Vannan, Jagat Narula, Roberto M. Lang. (2007) Echocardiography in Heart Failure. Journal of the American College of Cardiology 50:5, 381-396
CrossRef598
Martin Cadeiras, Manuel Prinz von Bayern, Mario C. Deng. (2007) Cardiac Transplantation: Any Role Left?. Heart Failure Clinics 3:3, 321-347
CrossRef599
Srinivasa R Kalidindi, WH Wilson Tang, Gary S Francis. (2007) Drug Insight: aldosterone-receptor antagonists in heart failure—the journey continues. Nature Clinical Practice Cardiovascular Medicine 4:7, 368-378
CrossRef600
E. V. Gelfand, C. P. Cannon. (2007) Myocardial infarction: contemporary management strategies. Journal of Internal Medicine 262:1, 59-77
CrossRef601
Gregg C. Fonarow, Clyde W. Yancy, Nancy M. Albert, Anne B. Curtis, Wendy Gattis Stough, Mihai Gheorghiade, J. Thomas Heywood, Mandeep Mehra, Christopher M. O'Connor, Dwight Reynolds, Mary Norine Walsh. (2007) Improving the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting: The IMPROVE HF performance improvement registry. American Heart Journal 154:1, 12-38
CrossRef602
Andreia Biolo, Tania Chao, Toni-Ann S. Duhaney, Eugene Kotlyar, Donald Allensworth-Davies, Joseph Loscalzo, Flora Sam. (2007) Usefulness of the Aldosterone Synthase Gene Polymorphism C-344-T to Predict Cardiac Remodeling in African-Americans Versus Non–African-Americans With Chronic Systolic Heart Failure. The American Journal of Cardiology 100:2, 285-290
CrossRef603
Raymond Lee, Yiong-Huak Chan, Jennifer Wong, Diana Lau, Kenneth Ng. (2007) The 6-minute walk test predicts clinical outcome in Asian patients with chronic congestive heart failure on contemporary medical therapy: A study of the multiracial population in Singapore. International Journal of Cardiology 119:2, 168-175
CrossRef604
Kartikya Ahuja, Gregory A. Crooke, Eugene A. Grossi, Aubrey C. Galloway, Ulrich P. Jorde. (2007) Reversing Left Ventricular Remodeling in Chronic Heart Failure. Cardiology in Review 15:4, 184-190
CrossRef605
Jun Iwanami, Masaki Mogi, Shoko Okamoto, Xin-Yu Gao, Jian-Mei Li, Li-Juan Min, Ayumi Ide, Kana Tsukuda, Masaru Iwai, Masatsugu Horiuchi. (2007) Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model. European Journal of Pharmacology 566:1-3, 153-159
CrossRef606
Paul J. Mather, Marvin A. Konstam. (2007) Newer mechanical devices in the management of acute heart failure. Heart Failure Reviews 12:2, 167-172
CrossRef607
Jithendra B. Somaratne, Gillian A. Whalley, Greg D. Gamble, Robert N. Doughty. (2007) Restrictive Filling Pattern is a Powerful Predictor of Heart Failure Events Postacute Myocardial Infarction and in Established Heart Failure: A Literature-Based Meta-Analysis. Journal of Cardiac Failure 13:5, 346-352
CrossRef608
&NA;. (2007) Appropriate pharmacology should be initiated before, during and following percutaneous coronary intervention in patients with left ventricular dysfunction or heart failure. Drugs & Therapy Perspectives 23:6, 16-20
CrossRef609
Larisa H Cavallari, Kathryn M Momary, Vicki L Groo, Marlos A. G Viana, Joseph R Camp, Thomas D Stamos. (2007) Association of β-Blocker Dose with Serum Procollagen Concentrations and Cardiac Response to Spironolactone in Patients with Heart Failure. Pharmacotherapy 27:6, 801-812
CrossRef610
Hadi N. Skouri, W. H. Wilson Tang. (2007) The impact of diabetes on heart failure: Opportunities for intervention. Current Heart Failure Reports 4:2, 70-77
CrossRef611
Jean-Pierre Monassier, Laurent Monassier. (2007) Prise en charge du post-infarctus. La Presse Médicale 36:6, 999-1006
CrossRef612
Brian Olshansky, Freda Wood, Anne S. Hellkamp, Jeanne E. Poole, Jill Anderson, George W. Johnson, Robin Boineau, Michael J. Domanski, Daniel B. Mark, Kerry L. Lee, Gust H. Bardy. (2007) Where patients with mild to moderate heart failure die: Results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). American Heart Journal 153:6, 1089-1094
CrossRef613
Anette Fiebeler, Dominik N Muller, Erdenechimeg Shagdarsuren, Friedrich C Luft. (2007) Aldosterone, mineralocorticoid receptors, and vascular inflammation. Current Opinion in Internal Medicine 6:3, 295-303
CrossRef614
Michael Gekle, Sigrid Mildenberger, Ruth Freudinger, Claudia Grossmann. (2007) Altered collagen homeostasis in human aortic smooth muscle cells (HAoSMCs) induced by aldosterone. Pflügers Archiv - European Journal of Physiology 454:3, 403-413
CrossRef615
Murray Epstein, David A. Calhoun. (2007) The role of aldosterone in resistant hypertension: Implications for pathogenesis and therapy. Current Hypertension Reports 9:2, 98-105
CrossRef616
E. M. Freel, M. Bernhardt, R. Ingram, A. M. Wallace, R. Fraser, E. Davies, J. M. C. Connell. (2007) Endogenous corticosteroid biosynthesis in subjects after bilateral adrenalectomy. Clinical Endocrinology 66:5, 659-665
CrossRef617
Robert G. Dluhy. (2007) In the Literature: Prevalence and Conn-sequences of Primary Aldosteronism. American Journal of Kidney Diseases 49:5, 566-568
CrossRef618
Chang Bai, Osvaldo Flores, Azriel Schmidt. (2007) Opportunities for development of novel therapies targeting steroid hormone receptors. Expert Opinion on Drug Discovery 2:5, 725-737
CrossRef619
Christine' S. Rigsby, David M. Pollock, Anne M. Dorrance. (2007) Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone rats. Microvascular Research 73:3, 198-205
CrossRef620
James O Mudd, David A Kass. (2007) Reversing chronic remodeling in heart failure. Expert Review of Cardiovascular Therapy 5:3, 585-598
CrossRef621
Giuseppe Boriani, Cinzia Valzania, Igor Diemberger, Mauro Biffi, Cristian Martignani, Matteo Bertini, Matteo Ziacchi, Giulia Domenichini, Davide Saporito, Claudio Rapezzi, Angelo Branzi. (2007) Potential of non-antiarrhythmic drugs to provide an innovative upstream approach to the pharmacological prevention of sudden cardiac death. Expert Opinion on Investigational Drugs 16:5, 605-623
CrossRef622
Richard A. Preston, Paul M. Norris, Alberto B. Alonso, Pingping Ni, Vladimir Hanes, Adel H. Karara. (2007) Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. Menopause 14:3, 408-414
CrossRef623
I Hamming, ME Cooper, BL Haagmans, NM Hooper, R Korstanje, ADME Osterhaus, W Timens, AJ Turner, G Navis, H van Goor. (2007) The emerging role of ACE2 in physiology and disease. The Journal of Pathology 212:1, 1-11
CrossRef624
Ana Martín, Alberto Cordero, Moisés Rodríguez. (2007) Importancia del estudio de la función renal en cardiología. Medicina Clínica 128:18, 705-710
CrossRef625
Heath E. Saltzman, Kumar Sharma, Paul J. Mather, Sharon Rubin, Suzanne Adams, David Joshua Whellan. (2007) Renal dysfunction in heart failure patients: what is the evidence?. Heart Failure Reviews 12:1, 37-47
CrossRef626
John G. F. Cleland, Periaswamy Velavan, Mansour Nasir. (2007) Fighting against sudden death: A single or multidisciplinary approach. Journal of Interventional Cardiac Electrophysiology 17:3, 205-210
CrossRef627
(2007) Primary Percutaneous Coronary Intervention. New England Journal of Medicine 356:15, 1588-1590
Full Text628
Nabil Uddin, J. Herbert Patterson. (2007) Current Guidelines for Treatment of Heart Failure: 2006 Update. Pharmacotherapy 27:4 Part 2, 12S-17S
CrossRef629
Mark E Dunlap. (2007) New Studies Influencing Treatment of Heart Failure: 2006 Update. Pharmacotherapy 27:4 Part 2, 3S-11S
CrossRef630
Pim van der Harst, Gerrit van der Steege, Rudolf A. de Boer, Adriaan A. Voors, Alistair S. Hall, Marcel J. Mulder, Wiek H. van Gilst, Dirk J. van Veldhuisen. (2007) Telomere Length of Circulating Leukocytes Is Decreased in Patients With Chronic Heart Failure. Journal of the American College of Cardiology 49:13, 1459-1464
CrossRef631
Xiuren Gao, Longyun Peng, Chandra M. Adhikari, Jun Lin, Zhiyi Zuo. (2007) Spironolactone Reduced Arrhythmia and Maintained Magnesium Homeostasis in Patients With Congestive Heart Failure. Journal of Cardiac Failure 13:3, 170-177
CrossRef632
Camille G. Frazier, Karen P. Alexander, L. Kristin Newby, Susan Anderson, Erik Iverson, Milton Packer, Jay Cohn, Sidney Goldstein, Pamela S. Douglas. (2007) Associations of Gender and Etiology With Outcomes in Heart Failure With Systolic Dysfunction. Journal of the American College of Cardiology 49:13, 1450-1458
CrossRef633
Mark E Anderson, Peter J Mohler. (2007) MicroRNA may have macro effect on sudden death. Nature Medicine 13:4, 410-411
CrossRef634
Vasilios G Athyros, Dimitri P Mikhailidis, Anna I Kakafika, Konstantinos Tziomalos, Asterios Karagiannis. (2007) Angiotensin II reactivation and aldosterone escape phenomena in renin–angiotensin–aldosterone system blockade: is oral renin inhibition the solution?. Expert Opinion on Pharmacotherapy 8:5, 529-535
CrossRef635
Iwan C. C. Horst, Adriaan A. Voors, Dirk J. Veldhuisen. (2007) Treatment of heart failure with ACE inhibitors and beta-blockers. Clinical Research in Cardiology 96:4, 193-195
CrossRef636
Deirdre A Lane, Sarah Shah, D Gareth Beevers. (2007) Low-dose spironolactone in the management of resistant hypertension: a surveillance study. Journal of Hypertension 25:4, 891-894
CrossRef637
JoAnn Lindenfeld, Frederick A. Masoudi. (2007) Fluid Retention With Thiazolidinediones. Journal of the American College of Cardiology 49:16, 1705-1707
CrossRef638
H. S. Hwang, G. Cirrincione, D. P. Thomas, R. J. McCormick, M. O. Boluyt. (2007) Aldosterone Antagonism Fails to Attenuate Age-Associated Left Ventricular Fibrosis. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 62:4, 382-388
CrossRef639
Paul J. Mather, Marvin A. Konstam. (2007) Percutaneous mechanical devices in the management of decompensated heart failure. Current Heart Failure Reports 4:1, 43-47
CrossRef640
Mohsin Farooq, Amer S Qureshi, Iain B Squire. (2007) Early management of ST elevation myocardial infarction: a review of practice. Expert Opinion on Pharmacotherapy 8:4, 401-413
CrossRef641
Yohannes Gebreegziabher, Amgad N Makaryus, John N Makaryus, Samy I McFarlane. (2007) Heart failure: metabolic derangements and therapeutic rationale. Expert Review of Cardiovascular Therapy 5:2, 331-343
CrossRef642
Katherine T. Murray, Lisa C. Mace, Zhenjiang Yang. (2007) Nonantiarrhythmic drug therapy for atrial fibrillation. Heart Rhythm 4:3, S88-S90
CrossRef643
Olivier Muller, Sylvain Pradervand, Stefan Berger, Gabriel Centeno, Aude Milet, Pascal Nicod, Thierry Pedrazzini, François Tronche, Günter Schütz, Kenneth Chien, Bernard C. Rossier, Dmitri Firsov. (2007) Identification of corticosteroid-regulated genes in cardiomyocytes by serial analysis of gene expression. Genomics 89:3, 370-377
CrossRef644
Pietro Di Pasquale, Filippo M. Sarullo, Salvatorew Paterna. (2007) Novel Strategies: Challenge Loop Diuretics and Sodium Management in Heart Failure?Part I. Congestive Heart Failure 13:2, 93-98
CrossRef645
Caroline Schirpenbach, Martin Reincke. (2007) Primary aldosteronism: current knowledge and controversies in Conn's syndrome. Nature Clinical Practice Endocrinology & Metabolism 3:3, 220-227
CrossRef646
Hari Krishnan Parthasarathy, Thomas M. MacDonald. (2007) Mineralocorticoid receptor antagonists. Current Hypertension Reports 9:1, 45-52
CrossRef647
Uta Hillebrand, Hermann Schillers, Christoph Riethmüller, Christian Stock, Marianne Wilhelmi, Hans Oberleithner, Martin Hausberg. (2007) Dose-dependent endothelial cell growth and stiffening by aldosterone: endothelial protection by eplerenone. Journal of Hypertension 25:3, 639-647
CrossRef648
Wilbert S. Aronow. (2007) Heart-Failure–Complicating Acute Myocardial Infarction. Clinics in Geriatric Medicine 23:1, 123-139
CrossRef649
Wilbert S. Aronow. (2007) Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in the Elderly. Clinics in Geriatric Medicine 23:1, 61-81
CrossRef650
Frederick A. Masoudi, Silvio E. Inzucchi. (2007) Diabetes Mellitus and Heart Failure: Epidemiology, Mechanisms, and Pharmacotherapy. The American Journal of Cardiology 99:4, 113-132
CrossRef651
Mihai Gheorghiade, Gregg C. Fonarow. (2007) Management of Post-Myocardial Infarction Patients with Left Ventricular Systolic Dysfunction. The American Journal of Medicine 120:2, 109-120
CrossRef652
Domenic A. Sica, Todd W.B. Gehr, William H. Frishman. (2007) Use of Diuretics in the Treatment of Heart Failure in the Elderly. Clinics in Geriatric Medicine 23:1, 107-121
CrossRef653
Vijay S Ramanath, Kim A Eagle. (2007) Evidence-Based Medical Therapy of Patients with Acute Coronary Syndromes. American Journal of Cardiovascular Drugs 7:2, 95-116
CrossRef654
Eman Hamad, Paul J Mather, Siva Srinivasan, Sharon Rubin, David J Whellan, Arthur M Feldman. (2007) Pharmacologic Therapy of Chronic Heart Failure. American Journal of Cardiovascular Drugs 7:4, 235-248
CrossRef655
Tsuyoshi Shiga, Hiroshi Kasanuki. (2007) Drug Therapy for Ventricular Tachyarrhythmia in Heart Failure. Circulation Journal 71:SupplementA, A90-A96
CrossRef656
Mitsuo TAKEDA, Tetsuya TATSUMI, Shinsaku MATSUNAGA, Hironori HAYASHI, Masaki KIMATA, Shoken HONSHO, Susumu NISHIKAWA, Akiko MANO, Jun SHIRAISHI, Hiroyuki YAMADA, Tomosaburo TAKAHASHI, Satoaki MATOBA, Miyuki KOBARA, Hiroaki MATSUBARA. (2007) Spironolactone Modulates Expressions of Cardiac Mineralocorticoid Receptor and 11.BETA.-Hydroxysteroid Dehydrogenase 2 and Prevents Ventricular Remodeling in Post-Infarct Rat Hearts. Hypertension Research 30:5, 427-437
CrossRef657
Eugene S. Chung, Santosh G. Menon, Raul Weiss, Edward J. Schloss, Theodore Chow, Dean J. Kereiakes, Wojciech Mazur, Rodney W. Salo, Elizabeth Galle, Joseph M. Pastore. (2007) Feasibility of Biventricular Pacing in Patients With Recent Myocardial Infarction: Impact on Ventricular Remodeling. Congestive Heart Failure 13:1, 9-15
CrossRef658
T. Rau, T. Eschenhagen. (2007) Aldosteron und Aldosteronrezeptorantagonisten in der Herzinsuffizienztherapie. Clinical Research in Cardiology Supplements 2:1, 55-64
CrossRef659
Apurva Motivala, Bertram Pitt. (2007) Drospirenone for Oral Contraception and Hormone Replacement Therapy. Drugs 67:5, 647-655
CrossRef660
Shuntaro KAGIYAMA, Kiyoshi MATSUMURA, Masayo FUKUHARA, Kanae SAKAGAMI, Koji FUJII, Mitsuo IIDA. (2007) Aldosterone-and-Salt-Induced Cardiac Fibrosis Is Independent from Angiotensin II Type 1a Receptor Signaling in Mice. Hypertension Research 30:10, 979-989
CrossRef661
Lucia Del Vecchio, Mirella Procaccio, Sara Viganò, Daniele Cusi. (2007) Mechanisms of Disease: the role of aldosterone in kidney damage and clinical benefits of its blockade. Nature Clinical Practice Nephrology 3:1, 42-49
CrossRef662
Gregor Leibundgut, Matthias Pfisterer, Hans-Peter Brunner-La Rocca. (2007) Drug Treatment of Chronic Heart Failure in the Elderly. Drugs & Aging 24:12, 991-1006
CrossRef663
John D. Bisognano, Kevin A. Townsend, Amy J. Skyles, Kiela M. Samuels. (2007) Prevalence of Comorbidities and Their Influence on Blood Pressure Goal Attainment in Geriatric Patients. The American Journal of Geriatric Cardiology 16:1, 24-29
CrossRef664
John W Funder. (2007) The Role of Aldosterone and Mineralocorticoid Receptors in Cardiovascular Disease. American Journal of Cardiovascular Drugs 7:3, 151-157
CrossRef665
Adriana K. Burla, Mario Fritsch Neves, Wille Oigman, Carlos A. Mandarim-de-Lacerda. (2007) Eplerenone offsets cardiac and aortic adverse remodeling in spontaneously hypertensive rats. International Journal of Cardiology 114:1, 64-70
CrossRef666
David Sidebotham, Robert Doughty. 2007. Heart Failure. , 278-292.
CrossRef667
Roman M. Sniecinski, Susan Wright, Jerrold H. Levy. 2007. Cardiovascular Pharmacology. , 33-52.
CrossRef668
The J-MELODIC Program Committee. (2007) Rationale and Design of a Randomized Trial to Assess the Effects of Diuretics in Heart Failure. Circulation Journal 71:7, 1137-1140
CrossRef669
Alberto Villamil, Steven G Chrysant, David Calhoun, Bonnie Schober, Huang Hsu, Linda Matrisciano-Dimichino, Jack Zhang. (2007) Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of Hypertension 25:1, 217-226
CrossRef670
Takanobu YOSHIMOTO, Yukio HIRATA. (2007) Aldosterone as a Cardiovascular Risk Hormone. Endocrine Journal 54:3, 359-370
CrossRef671
Hani N. Sabbah, Makoto Imai, Doug Cowart, Antonino Amato, Paolo Carminati, Mihai Gheorghiade. (2007) Hemodynamic Properties of a New-Generation Positive Luso-Inotropic Agent for the Acute Treatment of Advanced Heart Failure. The American Journal of Cardiology 99:2, S41-S46
CrossRef672
J.-P. Cambou, E. Vicaut, A. Papadopoulos-Degrandsart, N. Danchin. (2007) Prise en charge thérapeutique de l'insuffisance cardiaque et de la dysfonction ventriculaire gauche post-infarctus du myocarde dans les unités de soins intensifs en cardiologie française. Annales de Cardiologie et d'Angéiologie 56:1, 36-41
CrossRef673
Daisuke NAGATA, Yasunobu HIRATA. (2007) Molecular Mechanism of Cardiovascular Damage Induced by Aldosterone. YAKUGAKU ZASSHI 127:9, 1339-1346
CrossRef674
Marvin J Meyers, Xiao Hu. (2007) Non-steroidal mineralocorticoid receptor antagonists. Expert Opinion on Therapeutic Patents 17:1, 17-23
CrossRef675
Stephen Scheidt, Nanette K. Wenger, Michael Weber. (2007) Denial of Standard Treatment to the Elderly: Why?. The American Journal of Geriatric Cardiology 16:1, 5-7
CrossRef676
Toshinari TANAKA, Takayoshi TSUTAMOTO, Hiroshi SAKAI, Masanori FUJII, Takashi YAMAMOTO, Minoru HORIE. (2007) Comparison of the Effects of Efonidipine and Amlodipine on Aldosterone in Patients with Hypertension. Hypertension Research 30:8, 691-697
CrossRef677
Jill M. Gelow, James C. Fang. (2006) Update in the Approach to and Management of Heart Failure. Southern Medical Journal 99:12, 1346-1355
CrossRef678
Simona Maule, Paolo Mulatero, Alberto Milan, Giannina Leotta, Mimma Caserta, Chiara Bertello, Franco Rabbia, Franco Veglio. (2006) QT interval in patients with primary aldosteronism and low-renin essential hypertension. Journal of Hypertension 24:12, 2459-2464
CrossRef679
, G. Breithardt. (2006) Empfehlungen zur Diagnostik und Behandlung von Patienten mit koronarer Herzkrankheit und Niereninsuffizienz. Clinical Research in Cardiology Supplements 1:2, 103-117
CrossRef680
Wilbert S. Aronow. (2006) Treatment of heart failure with decreased left ventricular ejection fraction. Comprehensive Therapy 32:4, 218-225
CrossRef681
R MA Van de Wal, A A Voors, R T Gansevoort. (2006) Urinary albumin excretion and the renin–angiotensin system in cardiovascular risk management. Expert Opinion on Pharmacotherapy 7:18, 2505-2520
CrossRef682
Adnan Siddiqui, Peter R Kowey. (2006) Sudden death secondary to cardiac arrhythmias: mechanisms and treatment strategies. Current Opinion in Internal Medicine 5:6, 544-552
CrossRef683
Toni L Ripley, Jennifer S Chonlahan, Robin E Germany. (2006) Candesartan in heart failure. Clinical Interventions in Aging 1:4, 357-366
CrossRef684
Xiao Hu, Charles W. Bolten. (2006) Adrenal corticosteroids, their receptors and hypertension. Drug Development Research 67:12, 871-883
CrossRef685
Micheline Monteiro de Resende, Alison Jessica Kriegel, Andrew Seth Greene. (2006) Combined Effects of Low-Dose Spironolactone and Captopril Therapy in a Rat Model of Genetic Hypertrophic Cardiomyopathy. Journal of Cardiovascular Pharmacology 48:6, 265-273
CrossRef686
Jens Jakob Thune, Scott D. Solomon. (2006) Left ventricular diastolic function following myocardial infarction. Current Heart Failure Reports 3:4, 170-174
CrossRef687
John D. Harding, Mariell Jessup. (2006) New Directions in the Medical Management of Heart Failure. Seminars in Thoracic and Cardiovascular Surgery 17:4, 334-342
CrossRef688
M H Weinberger, F C Luft. (2006) Comprehensive suppression of the renin–angiotensin–aldosterone system in chronic kidney disease: Covering all of the bases. Kidney International 70:12, 2051-2053
CrossRef689
Wenxia Chai, A. H. Jan Danser. (2006) Why are mineralocorticoid receptor antagonists cardioprotective?. Naunyn-Schmiedeberg's Archives of Pharmacology 374:3, 153-162
CrossRef690
K. A. Pöschel, G. Wolf. (2006) Das Renin-Angiotensin-Aldosteron-System als Zentraler Mediator der Progression der Niereninsuffizienz. Der Nephrologe 1:4, 233-240
CrossRef691
P Gosse, R J Macfadyen. (2006) Does eplerenone have a future in the management of hypertension in Europe?. Journal of Human Hypertension 20:11, 829-832
CrossRef692
Reem H. Elbekai, Ayman O.S. El-Kadi. (2006) Cytochrome P450 enzymes: Central players in cardiovascular health and disease. Pharmacology & Therapeutics 112:2, 564-587
CrossRef693
B. Assmus, V. Schächinger, A. M. Zeiher. (2006) Regenerative Therapien in der Kardiologie. Der Internist 47:11, 1177-1182
CrossRef694
2006. Chronic Heart Failure. .
CrossRef695
Brady S. Moffett, Anthony C. Chang. (2006) Future Pharmacologic Agents for Treatment of Heart Failure in Children. Pediatric Cardiology 27:5, 533-551
CrossRef696
Alpesh Amin. (2006) Improving the management of patients after myocardial infarction, from admission to discharge. Clinical Therapeutics 28:10, 1509-1539
CrossRef697
James T. Willerson, Paul W Armstrong. 2006. Acute Myocardial Infarction. , 611-646.
CrossRef698
Bertram Pitt, Roberto Ferrari, Mihai Gheorghiade, Dirk J. van Veldhuisen, Henry Krum, John McMurray, Jose Lopez-Sendon. (2006) Aldosterone blockade in post-acute myocardial infarction heart failure. Clinical Cardiology 29:10, 434-438
CrossRef699
Schächinger, Volker, Erbs, Sandra, Elsässer, Albrecht, Haberbosch, Werner, Hambrecht, Rainer, Hölschermann, Hans, Yu, Jiangtao, Corti, Roberto, Mathey, Detlef G., Hamm, Christian W., Süselbeck, Tim, Assmus, Birgit, Tonn, Torsten, Dimmeler, Stefanie, Zeiher, Andreas M., . (2006) Intracoronary Bone Marrow–Derived Progenitor Cells in Acute Myocardial Infarction. New England Journal of Medicine 355:12, 1210-1221
Full Text700
Gregg C. Fonarow, Preethi Srikanthan. (2006) Diabetic Cardiomyopathy. Endocrinology & Metabolism Clinics of North America 35:3, 575-599
CrossRef701
Ihsan Dursun, Mahmut Sahin. (2006) Difficulties in maintaining potassium homeostasis in patients with heart failure. Clinical Cardiology 29:9, 388-392
CrossRef702
Dennis M. McNamara, S. William Tam, Michael L. Sabolinski, Page Tobelmann, Karen Janosko, Anne L. Taylor, Jay N. Cohn, Arthur M. Feldman, Manuel Worcel. (2006) Aldosterone Synthase Promoter Polymorphism Predicts Outcome in African Americans With Heart Failure. Journal of the American College of Cardiology 48:6, 1277-1282
CrossRef703
Leanne Groban, John Butterworth. (2006) Perioperative Management of Chronic Heart Failure. Anesthesia & Analgesia 103:3, 557-575
CrossRef704
Kyung W Park. (2006) Angiotensin-Converting Enzyme Inhibitors, AG Receptor Blockers, and Aldosterone Receptor Antagonists. International Anesthesiology Clinics 43:2, 23-37
CrossRef705
Fabian Hammer, Paul M. Stewart. (2006) Cortisol metabolism in hypertension. Best Practice & Research Clinical Endocrinology & Metabolism 20:3, 337-353
CrossRef706
M. Quinkler, M. Reincke. (2006) Moderne pharmakologische Aspekte der Therapie des Aldosteronismus. Der Internist 47:9, 953-959
CrossRef707
Friedrich C. Luft. (2006) The serum- and glucocorticoid-induced kinase in DOCA–salt hypertension. Journal of Molecular Medicine 84:9, 709-711
CrossRef708
, G. Breithardt. (2006) Empfehlungen zur Diagnostik und Behandlung von Patienten mit koronarer Herzkrankheit und Niereninsuffizienz. Clinical Research in Cardiology Supplements 1:1, 8-30
CrossRef709
Douglas P. Zipes, A. John Camm, Martin Borggrefe, Alfred E. Buxton, Bernard Chaitman, Martin Fromer, Gabriel Gregoratos, George Klein, Arthur J. Moss, Robert J. Myerburg, Silvia G. Priori, Miguel A. Quinones, Dan M. Roden, Michael J. Silka, Cynthia Tracy, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Elliott M. Antman, Jeffrey L. Anderson, Sharon A. Hunt, Jonathan L. Halperin, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel, Silvia G. Priori, Jean-Jacques Blanc, Andrzej Budaj, A. John Camm, Veronica Dean, Jaap W. Deckers, Catherine Despres, Kenneth Dickstein, John Lekakis, Keith McGregor, Marco Metra, Joao Morais, Ady Osterspey, Juan Luis Tamargo, José Luis Zamorano. (2006) ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology 48:5, e247-e346
CrossRef710
John W Funder. (2006) Eplerenone: hypertension, heart failure and the importance of mineralocorticoid receptor blockade. Future Cardiology 2:5, 535-541
CrossRef711
Caroline Schirpenbach, Martin Reincke. (2006) Screening for primary aldosteronism. Best Practice & Research Clinical Endocrinology & Metabolism 20:3, 369-384
CrossRef712
Michael W. Rich. (2006) Heart Failure in Older Adults. Medical Clinics of North America 90:5, 863-885
CrossRef713
Veronica Franco, Yiu-Fai Chen, Ji A Feng, Peng Li, Dajun Wang, Erum Hasan, Suzanne Oparil, Gilbert J Perry. (2006) EPLERENONE PREVENTS ADVERSE CARDIAC REMODELLING INDUCED BY PRESSURE OVERLOAD IN ATRIAL NATRIURETIC PEPTIDE-NULL MICE. Clinical and Experimental Pharmacology and Physiology 33:9, 773-779
CrossRef714
Christopher B. Granger, John J.V. McMurray. (2006) Using Measures of Disease Progression to Determine Therapeutic Effect. Journal of the American College of Cardiology 48:3, 434-437
CrossRef715
Daniel Burkhoff, William O'Neill, Corinna Brunckhorst, Dustin Letts, David Lasorda, Howard A. Cohen. (2006) Feasibility study of the use of the TandemHeart® percutaneous ventricular assist device for treatment of cardiogenic shock. Catheterization and Cardiovascular Interventions 68:2, 211-217
CrossRef716
Yasuhiro Nakamura, Saya Suzuki, Takashi Suzuki, Katsuhiko Ono, Ikumi Miura, Fumitoshi Satoh, Takuya Moriya, Haruo Saito, Shogo Yamada, Sadayoshi Ito, Hironobu Sasano. (2006) MDM2: A Novel Mineralocorticoid-Responsive Gene Involved in Aldosterone-Induced Human Vascular Structural Remodeling. The American Journal of Pathology 169:2, 362-371
CrossRef717
Kayla D. Goodwin, Robert A. Ahokas, Syamal K. Bhattacharya, Yao Sun, Ivan C. Gerling, Karl T. Weber. (2006) Preventing Oxidative Stress in Rats with Aldosteronism by Calcitriol and Dietary Calcium and Magnesium Supplements. The American Journal of the Medical Sciences 332:2, 73-78
CrossRef718
K. ODEDRA, A. FERRO. (2006) Neurohormones and heart failure: the importance of aldosterone. International Journal of Clinical Practice 60:7, 835-846
CrossRef719
Sabu Thomas, Edward Geltman. (2006) What is the Optimal Angiotensin-Converting Enzyme Inhibitor Dose in Heart Failure?. Congestive Heart Failure 12:4, 213-218
CrossRef720
Michael A. Crouch. (2006) Pharmacotherapy Implications of Revised Chronic Heart Failure Guidelines. The Consultant Pharmacist 21:7, 576-582
CrossRef721
Larisa H. Cavallari, Vicki L. Groo, Kathryn M. Momary, Deidra Fontana, Marlos A.G. Viana, Paul Vaitkus. (2006) Racial Differences in Potassium Response to Spironolactone in Heart Failure. Congestive Heart Failure 12:4, 200-205
CrossRef722
David H Birnie, Michael Gollob, Jeffrey S Healey. (2006) Clinical trials, the renin angiotensin system and atrial fibrillation. Current Opinion in Cardiology 21:4, 368-375
CrossRef723
Susanne Böhmer, Christine Carapito, Britta Wilzewski, Emmanuelle Leize, Alain Van Dorsselaer, Rita Bernhardt. (2006) Analysis of aldosterone-induced differential receptor-independent protein patterns using 2D-electrophoresis and mass spectrometry. Biological Chemistry 387:7, 917-929
CrossRef724
Gerd Luippold, Hartmut Oßwald. (2006) Wirtschaftliche Aspekte der Therapie mit Diuretika. Einsparungen möglich?. Pharmazie in unserer Zeit 35:4, 346-352
CrossRef725
KNUT T. LAPPEGARD, HANNE BJORNSTAD. (2006) Anti-Inflammatory Effect of Cardiac Resynchronization Therapy. Pacing and Clinical Electrophysiology 29:7, 753-758
CrossRef726
María G. Crespo Leiro, María J. Paniagua Martín. (2006) Insuficiencia cardiaca. ¿Son diferentes las mujeres?. Revista Española de Cardiología 59:7, 725-735
CrossRef727
Andreas Brunschweiger, Christa Müller. (2006) Medizinische Chemie der Diuretika: Entwicklung einer erfolgreichen Wirkstoffgruppe. Pharmazie in unserer Zeit 35:4, 310-320
CrossRef728
Douglas S. Lee, Ramachandran S. Vasan. (2006) Goals and guidelines for treating hypertension in a patient with heart failure. Current Treatment Options in Cardiovascular Medicine 8:4, 334-344
CrossRef729
Bodo Cremers, Michael Böhm. (2006) Diuretika bei Hypertonie und Herzinsuffizienz: Wirkmechanismen und Therapieschemata. Pharmazie in unserer Zeit 35:4, 322-332
CrossRef730
Thomas D. Szucs, Majbrit V. Holm, Matthias Schwenkglenks, Zefeng Zhang, William S. Weintraub, Michel Burnier, Paul Erne. (2006) Cost-Effectiveness of Eplerenone in Patients with Left Ventricular Dysfunction after Myocardial Infarction—An Analysis of the EPHESUS Study from a Swiss Perspective. Cardiovascular Drugs and Therapy 20:3, 193-204
CrossRef731
Murray Epstein. (2006) Adding spironolactone to conventional antihypertensives reduces albuminuria in patients with diabetic nephropathy. Nature Clinical Practice Nephrology 2:6, 310-311
CrossRef732
Kathleen M. Knights, Arduino A. Mangoni, John O. Miners. (2006) Non-selective nonsteroidal anti-inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime?. British Journal of Clinical Pharmacology 61:6, 738-740
CrossRef733
Joël Ménard, Leigh Pascoe. (2006) Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition?. Journal of Hypertension 24:6, 993-997
CrossRef734
Rachele Adorisio, Leonardo De Luca, Joseph Rossi, Mihai Gheorghiade. (2006) Pharmacological treatment of chronic heart failure. Heart Failure Reviews 11:2, 109-123
CrossRef735
Serge Masson, Roberto Latini, Inder S. Anand, Simona Barlera, Dianne Judd, Monica Salio, Francesco Perticone, Giampaolo Perini, Gianni Tognoni, Jay N. Cohn. (2006) The Prognostic Value of Big Endothelin-1 in More Than 2,300 Patients With Heart Failure Enrolled in the Valsartan Heart Failure Trial (Val-HeFT). Journal of Cardiac Failure 12:5, 375-380
CrossRef736
Monica Colvin Adams, Syed Sohail Ali. (2006) Who should pay for home monitoring of heart failure?. Current Cardiology Reports 8:3, 191-197
CrossRef737
Gian Paolo Rossi. (2006) Aldosterone breakthrough during ras blockade: A role for endothelins and their antagonists?. Current Hypertension Reports 8:3, 262-268
CrossRef738
Scott M. MacKenzie, John M. C. Connell. (2006) Hypertension and the expanding role of aldosterone. Current Hypertension Reports 8:3, 255-261
CrossRef739
Kevin A. Courville, Hector O. Ventura. (2006) Hypertension and heart failure: Diagnosis and management. Current Hypertension Reports 8:3, 185-190
CrossRef740
SUNIL C. SHROFF, KYUNGMOO RYU, NICHOLE L. MARTOVITZ, BRIAN D. HOIT, BRUCE S. STAMBLER. (2006) Selective Aldosterone Blockade Suppresses Atrial Tachyarrhythmias in Heart Failure. Journal of Cardiovascular Electrophysiology 17:5, 534-541
CrossRef741
Judy W.M. Cheng. (2006) A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination. Clinical Therapeutics 28:5, 666-678
CrossRef742
E. M. L. Wong, E. B. Wu, W. W. M. Chan, C. M. Yu. (2006) A review of the management of patients after percutaneous coronary intervention. International Journal of Clinical Practice 60:5, 582-589
CrossRef743
Yiming Z Lit, Timothy Meyer. (2006) Managing diabetic nephropathy: recent studies. Current Opinion in Internal Medicine 5:3, 239-244
CrossRef744
Ragavendra R. Baliga, Prathiba Ranganna, Bertram Pitt, Todd M. Koelling. (2006) Spironolactone Treatment and Clinical Outcomes in Patients With Systolic Dysfunction and Mild Heart Failure Symptoms: A Retrospective Analysis. Journal of Cardiac Failure 12:4, 250-256
CrossRef745
E Ann Tallant, Carlos M Ferrario, Patricia E Gallagher. (2006) Cardioprotective role for angiotensin-(1-7) and angiotensin converting enzyme 2 in the heart. Future Cardiology 2:3, 335-342
CrossRef746
Micheline Monteiro de Resende, Katalin Kauser, José Geraldo Mill. (2006) Regulation of cardiac and renal mineralocorticoid receptor expression by captopril following myocardial infarction in rats. Life Sciences 78:26, 3066-3073
CrossRef747
Wilbert S. Aronow. (2006) Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure. Cardiology in Review 14:3, 108-124
CrossRef748
Patricia A. Howard. (2006) Cardiovascular Therapeutics - Hyperkalemia with Combined Aldosterone and Angiotensin Blockade in Patients with Heart Failure. Hospital Pharmacy 41:5, 414-418
CrossRef749
Markus Flesch, Erland Erdmann. (2006) The problem of polypharmacy in heart failure. Current Cardiology Reports 8:3, 217-225
CrossRef750
Cecilia Mattsson, William F Young. (2006) Primary aldosteronism: diagnostic and treatment strategies. Nature Clinical Practice Nephrology 2:4, 198-208
CrossRef751
Salim Janmohamed, Pierre-Marc G Bouloux. (2006) The pharmacological treatment of primary aldosteronism. Expert Opinion on Pharmacotherapy 7:5, 563-573
CrossRef752
Eric M. Williams, Richard E. Katholi, Marcey R. Karambelas. (2006) Use and side-effect profile of spironolactone in a private cardiologist's practice. Clinical Cardiology 29:4, 149-153
CrossRef753
Lawrence R Krakoff. (2006) Screening for primary aldosteronism: progress and frustration. Journal of Hypertension 24:4, 635-637
CrossRef754
Bodh I Jugdutt. (2006) Valsartan in the treatment of heart attack survivors. Vascular Health and Risk Management 2:2, 125-138
CrossRef755
Osamu Tsukamoto, Tetsuo Minamino, Shoji Sanada, Ken-ichiro Okada, Akio Hirata, Masashi Fujita, Yasunori Shintani, Liao Yulin, Yoshihiro Asano, Seiji Takashima, Satoru Yamasaki, Hitonobu Tomoike, Masatsugu Hori, Masafumi Kitakaze. (2006) The Antagonism of Aldosterone Receptor Prevents the Development of Hypertensive Heart Failure Induced by Chronic Inhibition of Nitric Oxide Synthesis in Rats. Cardiovascular Drugs and Therapy 20:2, 93-102
CrossRef756
Gastone Sabbadini, Marco Metra, Andrea Di Lenarda, Savina Nodari, Gianfranco Sinagra, Livio Dei Cas. (2006) Managing heart failure in the very old. Aging Health 2:2, 253-275
CrossRef757
Shuji Arima. (2006) Aldosterone and the kidney: Rapid regulation of renal microcirculation. Steroids 71:4, 281-285
CrossRef758
Hoang M. Thai, Bao Q. Do, Trung D. Tran, Mohamed A. Gaballa, Steven Goldman. (2006) Aldosterone Antagonism Improves Endothelial-Dependent Vasorelaxation in Heart Failure via Upregulation of Endothelial Nitric Oxide Synthase Production. Journal of Cardiac Failure 12:3, 240-245
CrossRef759
M. Böhm, N. Werner, M. Kindermann. (2006) Stand der medikamentösen Therapie bei chronischer Herzinsuffizienz. Clinical Research in Cardiology 95:S4, 36-56
CrossRef760
Dennis T. Ko, David N. Juurlink, Muhammad M. Mamdani, John J. You, Julie T. Wang, Linda R. Donovan, Jack V. Tu. (2006) Appropriateness of Spironolactone Prescribing in Heart Failure Patients: A Population-Based Study. Journal of Cardiac Failure 12:3, 205-210
CrossRef761
Christine Z Guo, Smita Kherde, Gail K Adler. (2006) Role of mineralocorticoid receptor in diabetic vascular disease. Current Opinion in Endocrinology & Diabetes 13:2, 127-134
CrossRef762
Eugene Kotlyar, Joseph A. Vita, Michael R. Winter, Eric H. Awtry, Deborah A. Siwik, John F. Keaney, Douglas B. Sawyer, L. Adrienne Cupples, Wilson S. Colucci, Flora Sam. (2006) The Relationship Between Aldosterone, Oxidative Stress, and Inflammation in Chronic, Stable Human Heart Failure. Journal of Cardiac Failure 12:2, 122-127
CrossRef763
Ilan S. Wittstein. 2006. Diuretics. , 71-98.
CrossRef764
J Ma, A Weisberg, J P Griffin, D E Vaughan, A B Fogo, N J Brown. (2006) Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney International 69:6, 1064-1072
CrossRef765
Ulrich P. Jorde. (2006) Suppression of the Renin???Angiotensin???Aldosterone System in Chronic Heart Failure. Cardiology in Review 14:2, 81-87
CrossRef766
Michael M. Givertz. 2006. Diet, Metabolic Syndrome, and Obesity. , 37-58.
CrossRef767
Aruna D Pradhan, Michael M Givertz, Kenneth L Baughman. 2006. Heart Failure and Obesity: The Risk of Development and the Treatment of Heart Failure in Obese Patients. , 403-428.
CrossRef768
David S. H. Bell, Mary Ann Lukas, Frederick K. Holdbrook, Michael B. Fowler. (2006) The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis. Current Medical Research and Opinion 22:2, 287-296
CrossRef769
Angelo Capricchione, Nathaniel Winer, James R. Sowers. (2006) Adrenocortical hypertension. Current Urology Reports 7:1, 73-79
CrossRef770
Heart Failure Society of America. (2006) Section 13: Evaluation and Therapy for Heart Failure in the Setting of Ischemic Heart Disease. Journal of Cardiac Failure 12:1, e104-e111
CrossRef771
Heart Failure Society of America. (2006) Section 9: Electrophysiologic Testing and the Use of Devices in Heart Failure. Journal of Cardiac Failure 12:1, e70-e75
CrossRef772
Heart Failure Society Of America. (2006) Executive Summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure 12:1, 10-38
CrossRef773
Heart Failure Society of America. (2006) Section 7: Heart Failure in Patients With Left Ventricular Systolic Dysfunction. Journal of Cardiac Failure 12:1, e38-e57
CrossRef774
C. Maciá-Bobes, A. Ronzón-Fernández, G. Castaño-Fernández, P. Botas-Cervero. (2006) Hiperaldosteronismo primario: ¿debemos plantearnos su detección sistemática en los centros de salud?. Atención Primaria 37:2, 104-107
CrossRef775
Rajaa F Faris, Marcus Flather, H Purcell, PA Poole-Wilson, Andrew JS Coats, Rajaa F Faris. 2006. Diuretics for heart failure. .
CrossRef776
Atsuhisa SATO, Takao SARUTA, John W. FUNDER. (2006) Combination Therapy with Aldosterone Blockade and Renin-Angiotensin Inhibitors Confers Organ Protection. Hypertension Research 29:4, 211-216
CrossRef777
Sarah Ulmschneider, Matthias Negri, Marieke Voets, Rolf W. Hartmann. (2006) Development and evaluation of a pharmacophore model for inhibitors of aldosterone synthase (CYP11B2). Bioorganic & Medicinal Chemistry Letters 16:1, 25-30
CrossRef778
Akihiro URABE, Takehiko IZUMI, Yuichi ABE, Ikuo TANIGUCHI, Seibu MOCHIZUKI. (2006) Effects of Eplerenone and Salt Intake on Left Ventricular Remodeling after Myocardial Infarction in Rats. Hypertension Research 29:8, 627-634
CrossRef779
Japanese Society of Hypertension. (2006) Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertension Research 29:Suppl, S1-S106
CrossRef780
José Azpitarte. (2006) Profilaxis primaria con desfibrilador-cardioversor implantable en la insuficiencia cardiaca: un punto de vista clínico. Revista Española de Cardiología 59, 10-22
CrossRef781
Randall E. Williams. (2006) The effect of neurohormonal antagonists in reducing heart failure hospitalizations. Current Medical Research and Opinion 22:1, 139-150
CrossRef782
George J. Philippides. (2006) Managing the Post-Myocardial Infarction Patient with Asymptomatic Left Ventricular Dysfunction. Cardiology 105:2, 95-107
CrossRef783
Gregg C. Fonarow. (2006) Hospital protocols and evidence-based therapies: The importance of integrating aldosterone blockade into the management of patients with post-acute myocardial infarction heart failure. Clinical Cardiology 29:1, 4-8
CrossRef784
Juan José Gómez-Doblas. (2006) Implementación de guías clínicas. Revista Española de Cardiología 59, 29-35
CrossRef785
Mustafa Gullulu, Ibrahim Akdag, Serdar Kahvecioglu, Gülaydan Filiz, Vahide Savci. (2006) Aldosterone Blockage in Proliferative Glomerulonephritis Prevents Not Only Fibrosis, but Proliferation as Well. Renal Failure 28:6, 509-514
CrossRef786
Wilbert S. Aronow. (2006) Treatment of Systolic and Diastolic Heart Failure in the Elderly. Journal of the American Medical Directors Association 7:1, 29-36
CrossRef787
Kohei Kikkawa. (2006) Folia Pharmacologica Japonica 127:5, 381-386
CrossRef788
Ikuo Taniguchi, Makoto Kawai, Taro Date, Satoru Yoshida, Shingo Seki, Masayuki Taniguchi, Mitsuyuki Shimizu, Seibu Mochizuki. (2006) Effects of Spironolactone During an Angiotensin II Receptor Blocker Treatment on the Left Ventricular Mass Reduction in Hypertensive Patients With Concentric Left Ventricular Hypertrophy. Circulation Journal 70:8, 995-1000
CrossRef789
Mohamed A. Bayorh, Garrett Mann, Marcus Walton, Danita Eatman. (2006) Effects of Enalapril, Tempol, and Eplerenone on Salt-Induced Hypertension in Dahl Salt-Sensitive Rats. Clinical and Experimental Hypertension 28:2, 121-132
CrossRef790
Satoshi OKAYAMA, Keiichi IMAGAWA, Noriyuki NAYA, Hajime IWAMA, Satoshi SOMEKAWA, Hiroyuki KAWATA, Manabu HORII, Tamio NAKAJIMA, Shiro UEMURA, Yoshihiko SAITO. (2006) Blocking T-Type Ca2+ Channels with Efonidipine Decreased Plasma Aldosterone Concentration in Healthy Volunteers. Hypertension Research 29:7, 493-497
CrossRef791
Ryuzea Miura, Kazufumi Nakamura, Daiji Miura, Aya Miura, Kenichi Hisamatsu, Masahito Kajiya, Katsushi Hashimoto, Satoshi Nagase, Hiroshi Morita, Kengo Fukushima Kusano, Tetsuro Emori, Kazuhiko Ishihara, Tohru Ohe. (2006) Aldosterone Synthesis and Cytokine Production in Human Peripheral Blood Mononuclear Cells. Journal of Pharmacological Sciences 102:3, 288-295
CrossRef792
Douglas P. Zipes, Michael Rubart. (2006) Neural modulation of cardiac arrhythmias and sudden cardiac death. Heart Rhythm 3:1, 108-113
CrossRef793
Michael J Lipinski, George W Vetrovec. (2006) Medical Treatment of Patients with Heart Failure or Left Ventricular Dysfunction Undergoing Percutaneous Coronary Intervention. American Journal of Cardiovascular Drugs 6:5, 313-325
CrossRef794
2006. Diuretics. , 1152-1169.
CrossRef795
Akira Nishiyama, Youichi Abe. (2006) Molecular Mechanisms and Therapeutic Strategies of Chronic Renal Injury: Renoprotective Effects of Aldosterone Blockade. Journal of Pharmacological Sciences 100:1, 9-16
CrossRef796
Elijah Sounders. (2006) Building on the Specialist's Antihypertensive Treatment Recommendation: It's Just the Beginning. The Journal of Clinical Hypertension 8:s1, 31-39
CrossRef797
Ryuzea Miura, Kazufumi Nakamura, Daiji Miura, Aya Miura, Kenichi Hisamatsu, Masahito Kajiya, Satoshi Nagase, Hiroshi Morita, Kengo Fukushima Kusano, Tohru Ohe, Kazuhiko Ishihara. (2006) Anti-inflammatory Effect of Spironolactone on Human Peripheral Blood Mononuclear Cells. Journal of Pharmacological Sciences 101:3, 256-259
CrossRef798
Clyde W. Yancy, Margarita Lopatin, Lynne Warner Stevenson, Teresa De Marco, Gregg C. Fonarow. (2006) Clinical Presentation, Management, and In-Hospital Outcomes of Patients Admitted With Acute Decompensated Heart Failure With Preserved Systolic Function. Journal of the American College of Cardiology 47:1, 76-84
CrossRef799
E. C. Miner, W. L. Miller. (2006) A Look Between the Cardiomyocytes: The Extracellular Matrix in Heart Failure. Mayo Clinic Proceedings 81:1, 71-76
CrossRef800
W. S. Aronow. (2005) Drug Treatment of Systolic and of Diastolic Heart Failure in Elderly Persons. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 60:12, 1597-1605
CrossRef801
Kevin L. Thomas, Eric J. Velazquez. (2005) Therapies to prevent heart failure post-myocardial infarction. Current Heart Failure Reports 2:4, 174-182
CrossRef802
Aldo Pietro Maggioni. (2005) Does eplerenone benefit postinfarction patients with heart failure and left ventricular systolic dysfunction?. Nature Clinical Practice Cardiovascular Medicine 2:12, 618-619
CrossRef803
A. Benetos, J. P. Gardner, M. Kimura, C. Labat, R. Nzietchueng, B. Dousset, F. Zannad, P. Lacolley, A. Aviv. (2005) Aldosterone and Telomere Length in White Blood Cells. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 60:12, 1593-1596
CrossRef804
Vijay K Verma, Steven M Hollenberg. (2005) Update on acute coronary syndromes and ST-elevation myocardial infarction. Current Opinion in Internal Medicine 4:6, 614-618
CrossRef805
W. H. W. Tang, A. C. Parameswaran, A. P. Maroo, G. S. Francis. (2005) Aldosterone Receptor Antagonists in the Medical Management of Chronic Heart Failure. Mayo Clinic Proceedings 80:12, 1623-1630
CrossRef806
Todd J. Rudo, Peter R. Kowey. (2005) Real-world algorithms for the optimal use of drugs and devices in the patient post myocardial infarction and the future of post myocardial infarction management. Clinical Cardiology 28:S1, 58-63
CrossRef807
John W Funder. (2005) Mineralocorticoid-receptor blockade, hypertension and heart failure. Nature Clinical Practice Endocrinology & Metabolism 1:1, 4-5
CrossRef808
Rebecca S. Boxer, Mark E. Dunlap. (2005) Aldosterone antagonists in the treatment and prevention of heart failure. Current Treatment Options in Cardiovascular Medicine 7:6, 431-436
CrossRef809
James A. Reiffel. (2005) Practical algorithms for pharmacologic management of the post myocardial infarction patient. Clinical Cardiology 28:S1, 28-37
CrossRef810
Vishal Bhatia, Ruchi Bhatia, Boban Mathew. (2005) Angiotensin Receptor Blockers in Congestive Heart Failure. Cardiology in Review 13:6, 297-303
CrossRef811
Keith C Ferdinand. (2005) Isosorbide dinitrate and hydralazine hydrochloride: a review of efficacy and safety. Expert Review of Cardiovascular Therapy 3:6, 993-1001
CrossRef812
Robert D. Toto. (2005) Heart Disease in Diabetic Patients. Seminars in Nephrology 25:6, 372-378
CrossRef813
Jonathan Sackner-Bernstein. (2005) Reducing the risks of sudden death and heart failure post myocardial infarction: Utility of optimized pharmacotherapy. Clinical Cardiology 28:S1, 19-27
CrossRef814
JOHN J V MCMURRAY. (2005) Chronic kidney disease in patients with cardiac disease: A review of evidence-based treatment. Kidney International 68:4, 1419-1426
CrossRef815
Iain Squire. (2005) Neurohormonal Intervention to Reduce Sudden Cardiac Death in Heart Failure: What is the Optimal Pharmacologic Strategy?. Heart Failure Reviews 9:4, 337-345
CrossRef816
Dee Ann Rivera, Michael R. Bristow. (2005) Cardiac Resynchronization-A Heart Failure Perspective. Annals of Noninvasive Electrocardiology 10:s4, 16-23
CrossRef817
Steven G. Coca, Mark A. Perazella. (2005) The Role of Aldosterone Blockers in the Management of Chronic Heart Failure. The American Journal of the Medical Sciences 330:4, 176-183
CrossRef818
LORENZO A CALÒ, DECIO ARMANINI. (2005) Aldosterone-mediated endothelial remodeling and oxidative stress. Kidney International 68:4, 1899-1899
CrossRef819
James D. Neaton, Gerry Gray, Bram D. Zuckerman, Marvin A. Konstam. (2005) Key Issues in End Point Selection for Heart Failure Trials: Composite End Points. Journal of Cardiac Failure 11:8, 567-575
CrossRef820
Toru Sugiyama, Takanobu Yoshimoto, Yuki Hirono, Noriko Suzuki, Maya Sakurada, Kyoichiro Tsuchiya, Isao Minami, Fumiko Iwashima, Haruna Sakai, Toru Tateno, Ryuji Sato, Yukio Hirata. (2005) Aldosterone increases osteopontin gene expression in rat endothelial cells. Biochemical and Biophysical Research Communications 336:1, 163-167
CrossRef821
Clyde W. Yancy. (2005) Heart Failure in African Americans. The American Journal of Cardiology 96:7, 3-12
CrossRef822
Lisa Mielniczuk, Lynne Warner Stevenson. (2005) Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers in the management of congestive heart failure patients: what have we learned from recent clinical trials?. Current Opinion in Internal Medicine 4:5, 529-534
CrossRef823
(2005) Sudden Death in Patients with Myocardial Infarction. New England Journal of Medicine 353:12, 1294-1297
Full Text824
Pravin Singhal, Joseph Mattana, Hitesh Shah. 2005. Diuretics. , 305-315.
CrossRef825
John V Terrovitis, Maria I Anastasiou-Nana, John N Nanas. (2005) Out-patient management of chronic heart failure. Expert Opinion on Pharmacotherapy 6:11, 1857-1881
CrossRef826
Kenneth Dickstein. (2005) Is eplerenone a cost-effective therapy for heart failure patients after myocardial infarction?. Nature Clinical Practice Cardiovascular Medicine 2:9, 440-441
CrossRef827
Arantxa González, Begoña López, Javier Díez. (2005) New directions in the assessment and treatment of hypertensive heart disease. Current Opinion in Nephrology and Hypertension 14:5, 428-434
CrossRef828
Michael A. Crouch. (2005) Chronic Heart Failure: Developments and Perspectives. The Consultant Pharmacist 20:9, 751-765
CrossRef829
Hector F. Lozano, Cesar A. Conde, Todd Florin, Gervasio A. Lamas. (2005) Treatment and prevention of atrial fibrillation with nonantiarrhythmic pharmacologic therapy. Heart Rhythm 2:9, 1000-1007
CrossRef830
(2005) Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la insuficiencia cardíaca crónica. Versión resumida (actualización 2005). Revista Española de Cardiología 58:9, 1062-1092
CrossRef831
Frank A. Cuoco, Steven N. Singh. (2005) Nonsustained ventricular tachycardia in dilated cardiomyopathy. Current Cardiology Reports 7:5, 368-375
CrossRef832
Philip B. Adamson. (2005) Ambulatory Hemodynamics in Patients With Chronic Heart Failure: Implications for Volume Management in Elderly Patients. The American Journal of Geriatric Cardiology 14:5, 236-241
CrossRef833
Lars Køber, Christian Torp-Pedersen. (2005) Valsartan: the past, present and future. Future Cardiology 1:5, 591-598
CrossRef834
Keyur B. Shah, Krishnamurti Rao, Robert Sawyer, Stephen S. Gottlieb. (2005) The Adequacy of Laboratory Monitoring in Patients Treated With Spironolactone for Congestive Heart Failure. Journal of the American College of Cardiology 46:5, 845-849
CrossRef835
Sandeep A. Kamath, Clyde W. Yancy. (2005) Treatment of the african-american patient with congestive heart failure. Current Treatment Options in Cardiovascular Medicine 7:4, 307-315
CrossRef836
Shyam Bhakta, Mark E. Dunlap. (2005) Treatment of heart failure with a normal ejection fraction. Current Treatment Options in Cardiovascular Medicine 7:4, 317-325
CrossRef837
John L. Jefferies, Anthony C. Chang. (2005) The neurohormonal axis and biochemical markers of heart failure. Cardiology in the Young 15:4, 333-344
CrossRef838
Bertram Pitt, Harvey White, Jose Nicolau, Felipe Martinez, Mihai Gheorghiade, Michael Aschermann, Dirk J. van Veldhuisen, Faiez Zannad, Henry Krum, Robin Mukherjee, John Vincent. (2005) Eplerenone Reduces Mortality 30 Days After Randomization Following Acute Myocardial Infarction in Patients With Left Ventricular Systolic Dysfunction and Heart Failure. Journal of the American College of Cardiology 46:3, 425-431
CrossRef839
C. Richard Conti. (2005) Heart failure after acute ST-segment elevation myocardial infarction: What should we do about it?. Clinical Cardiology 28:8, 360-361
CrossRef840
Daniel J. Garry, Sean C. Goetsch, Amanda J. McGrath, Pradeep P.A. Mammen. (2005) Alternative Therapies for Orthotopic Heart Transplantation. The American Journal of the Medical Sciences 330:2, 88-101
CrossRef841
Nancy J Brown. (2005) Aldosterone and end-organ damage. Current Opinion in Internal Medicine 4:4, 381-387
CrossRef842
Ursula Müller-Vieira, Marc Angotti, Rolf W. Hartmann. (2005) The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11β-hydroxylase) inhibitors. The Journal of Steroid Biochemistry and Molecular Biology 96:3-4, 259-270
CrossRef843
U. C. Hoppe, M. Böhm, R. Dietz, P. Hanrath, H. K. Kroemer, A. Osterspey, A. A. Schmaltz, E. Erdmann. (2005) Leitlinien zur Therapie der chronischen Herzinsuffizienz. Zeitschrift für Kardiologie 94:8, 488-509
CrossRef844
Douglas L. Jennings, James S. Kalus, Kate M. O'Dell. (2005) Aldosterone Receptor Antagonism in Heart Failure. Pharmacotherapy 25:8, 1126-1133
CrossRef845
Roxy Senior, Gavin Galasko. (2005) Cost-Effective Strategies to Screen for Left Ventricular Systolic Dysfunction in the Community?A Concept. Congestive Heart Failure 11:4, 194-211
CrossRef846
Evan Gross, Marcos Rothstein, Susan Dombek, Henrikas Irmantas Juknis. (2005) Effect of Spironolactone on Blood Pressure and the Renin-Angiotensin-Aldosterone System in Oligo-Anuric Hemodialysis Patients. American Journal of Kidney Diseases 46:1, 94-101
CrossRef847
Wenxia Chai, Ingrid M Garrelds, Udayasankar Arulmani, Regien G Schoemaker, Jos M J Lamers, A H Jan Danser. (2005) Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective?. British Journal of Pharmacology 145:5, 664-671
CrossRef848
Constança S Cruz, Luzia S Cruz, Gustavo S Domingues, Carlos A Marcílio de Souza. (2005) New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia. Expert Opinion on Drug Safety 4:4, 677-688
CrossRef849
Frederick A. Spencer, Theo Meyer. (2005) Heart failure and shock complicating acute coronary syndromes. Current Cardiology Reports 7:4, 276-282
CrossRef850
Tae-Yon Chun, J. Howard Pratt. (2005) Aldosterone increases plasminogen activator inhibitor-1 synthesis in rat cardiomyocytes. Molecular and Cellular Endocrinology 239:1-2, 55-61
CrossRef851
Xiaobing Guo, Harjot K Saini, Jingwei Wang, Suresh K Gupta, Ramesh K Goyal, Naranjan S Dhalla. (2005) Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of the renin–angiotensin system. Expert Review of Cardiovascular Therapy 3:4, 717-732
CrossRef852
Franz H. Messerli, Ehud Grossman. (2005) Therapeutic Controversies in Hypertension. Seminars in Nephrology 25:4, 227-235
CrossRef853
Peter H. Law, Yao Sun, Syamal K. Bhattacharya, Vikram S. Chhokar, Karl T. Weber. (2005) Diuretics and Bone Loss in Rats With Aldosteronism. Journal of the American College of Cardiology 46:1, 142-146
CrossRef854
Edward D Frohlich. (2005) Recent advances in hypertension, stroke, and cardiorenal disease. Current Opinion in Cardiology 20:4, 258-263
CrossRef855
Douglas L. Mann. (2005) Cardiac Remodeling as Therapeutic Target: Treating Heart Failure with Cardiac Support Devices. Heart Failure Reviews 10:2, 93-94
CrossRef856
Domenic A. Sica. (2005) The risks and benefits of aldosterone antagonists. Current Heart Failure Reports 2:2, 65-71
CrossRef857
Ariel J. Reyes, William P. Leary, Giuseppe Crippa, Mário F.C. Maranhão, Rafael Hernández-Hernández. (2005) The aldosterone antagonist and facultative diuretic eplerenone: A critical review. European Journal of Internal Medicine 16:3, 145-153
CrossRef858
Osama A. Ibrahim, Mark E. Dunlap. (2005) Combination pharmacologic therapies for heart failure: What next after angiotensin-converting enzyme inhibitors and beta-blockers?. Current Heart Failure Reports 2:2, 89-93
CrossRef859
John W Funder. (2005) Cardiac synthesis of aldosterone: con. Current Opinion in Endocrinology & Diabetes 12:3, 215-218
CrossRef860
Paolo Magni, Marcella Motta. (2005) Aldosterone receptor antagonists: Biology and novel therapeutic applications. Current Hypertension Reports 7:3, 206-211
CrossRef861
Gregg C. Fonarow. (2005) When to initiate beta-blockers in heart failure: Is it ever too early?. Current Heart Failure Reports 2:2, 94-99
CrossRef862
Mary Rose Fabi, John R. Teerlink. (2005) The addition of angiotensin receptor blockers to angiotens-inconverting enzyme inhibitors—What has time told us?. Current Heart Failure Reports 2:2, 59-64
CrossRef863
Martin Wehling. (2005) Cardiac and vascular synthesis of aldosterone: yes, but???. Current Opinion in Endocrinology & Diabetes 12:3, 211-214
CrossRef864
T. Jared Bunch, Stephen C. Hammill, Roger D. White. (2005) Outcomes After Ventricular Fibrillation Out-of-Hospital Cardiac Arrest: Expanding the Chain of Survival. Mayo Clinic Proceedings 80:6, 774-782
CrossRef865
J. Davies, A. Gavin, M. Band, A. Morris, A. Struthers. (2005) Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients. British Journal of Clinical Pharmacology 59:5, 520-523
CrossRef866
Paul R. Conlin. (2005) Interactions of High Salt Intake and the Response of the Cardiovascular System to Aldosterone. Cardiology in Review 13:3, 118-124
CrossRef867
U. Wenzel, G. Wolf. (2005) Blutdruckunabhängige Wirkungen von Antihypertensiva. Der Internist 46:5, 548-556
CrossRef868
David S. Geller. (2005) Mineralocorticoid resistance. Clinical Endocrinology 62:5, 513-520
CrossRef869
Nancy J Brown. (2005) Aldosterone and end-organ damage. Current Opinion in Nephrology and Hypertension 14:3, 235-241
CrossRef870
L. R. Erhardt. (2005) A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure. International Journal of Clinical Practice 59:5, 571-578
CrossRef871
Steven G Coca, Mark A Perazella. (2005) Adverse cardiorenal effects of aldosterone: is aldosterone antagonism beneficial?. Expert Review of Cardiovascular Therapy 3:3, 497-512
CrossRef872
John JV McMurray, Marc A Pfeffer. (2005) Heart failure. The Lancet 365:9474, 1877-1889
CrossRef873
Michael W. Rich. (2005) Heart Failure in the Oldest Patients: The Impact of Comorbid Conditions. The American Journal of Geriatric Cardiology 14:3, 134-141
CrossRef874
E. Erdmann. (2005) Effekte der RALE-Studie. Der Internist 46:4, 466-468
CrossRef875
Gary S. Francis, W.H. Wilson Tang. (2005) Should we consider aldosterone as the primary screening target for preventing cardiovascular events?**Editorials published in the Journal of American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 45:8, 1249-1250
CrossRef876
Gerald V. Naccarelli, Mary Ann Lukas. (2005) Carvedilol's antiarrhythmic properties: Therapeutic implications in patients with left ventricular dysfunction. Clinical Cardiology 28:4, 165-173
CrossRef877
GianPaolo Rossi, Marco Boscaro, Vanessa Ronconi, John W. Funder. (2005) Aldosterone as a cardiovascular risk factor. Trends in Endocrinology & Metabolism 16:3, 104-107
CrossRef878
Richard D. Gordon, John H. Laragh, John W. Funder. (2005) Low renin hypertensive states: perspectives, unsolved problems, future research. Trends in Endocrinology & Metabolism 16:3, 108-113
CrossRef879
(2005) Implantable Cardioverter–Defibrillator Therapy after Myocardial Infarction. New England Journal of Medicine 352:10, 1039-1041
Full Text880
Eyal Herzog, Cathleen Varley, Marrick Kukin. (2005) Pathway for the Management of Acute Heart Failure. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 4:1, 37-42
CrossRef881
Aldo Pietro Maggioni, Gianna Fabbri. (2005) VALIANT (VALsartan In Acute myocardial iNfarcTion) trial. Expert Opinion on Pharmacotherapy 6:3, 507-512
CrossRef882
Eva Delpón, Ricardo Caballero, Ricardo Gómez, Lucía Núñez, Juan Tamargo. (2005) Angiotensin II, angiotensin II antagonists and spironolactone and their modulation of cardiac repolarization. Trends in Pharmacological Sciences 26:3, 155-161
CrossRef883
Timothy D. Brennan, Garrie J. Haas. (2005) The role of prophylactic implantable cardioverter defibrillators in heart failure: Recent trials usher in a new era of device therapy. Current Heart Failure Reports 2:1, 40-45
CrossRef884
Vikram Kalra, Sandeep Mahajan, Sanjay Kumar Agarwal, Suresh Chander Tiwari. (2005) Cardiorenal Disease: A Clinical Intersection. International Urology and Nephrology 37:1, 175-184
CrossRef885
Robert P Giugliano, Eugene Braunwald. (2005) 2004 ACC/AHA guideline for the management of patients with STEMI: the implications for clinicians. Nature Clinical Practice Cardiovascular Medicine 2:3, 114-115
CrossRef886
John W. Funder. (2005) RALES, EPHESUS and redox. The Journal of Steroid Biochemistry and Molecular Biology 93:2-5, 121-125
CrossRef887
John McMurray, Lars Køber, Michele Robertson, Henry Dargie, Wilson Colucci, Jose Lopez-Sendon, Willem Remme, D. Norman Sharpe, Ian Ford. (2005) Antiarrhythmic effect of carvedilol after acute myocardial infarction. Journal of the American College of Cardiology 45:4, 525-530
CrossRef888
R. Dale Brown, S. Kelly Ambler, M. Darren Mitchell, Carlin S. Long. (2005) THE CARDIAC FIBROBLAST: Therapeutic Target in Myocardial Remodeling and Failure. Annual Review of Pharmacology and Toxicology 45:1, 657-687
CrossRef889
Steven G. Coca, Mark A. Perazella, Gregory K. Buller. (2005) The cardiovascular implications of hypokalemia. American Journal of Kidney Diseases 45:2, 233-247
CrossRef890
Bertram Pitt. (2005) Should chronic heart failure patients with reduced left-ventricular ejection fraction receive angiotensin-receptor blockers?. Nature Clinical Practice Cardiovascular Medicine 2:2, 70-71
CrossRef891
Gurbir Bhatia, Michael Sosin, John F Leahy, Derek L Connolly, Russell C Davis, Gregory YH Lip. (2005) Hibernating myocardium in heart failure. Expert Review of Cardiovascular Therapy 3:1, 111-122
CrossRef892
Kevin D. O'Brien, Daniel P. Fishbein. (2005) Mitral valve abnormalities in congestive heart failure. Journal of the American College of Cardiology 45:1, 62-64
CrossRef893
Kaoru YOSHIDA, Shokei KIM-MITSUYAMA, Ryotaro WAKE, Yasuhiro IZUMIYA, Yasukatsu IZUMI, Tokihito YUKIMURA, Makiko UEDA, Minoru YOSHIYAMA, Hiroshi IWAO. (2005) Excess Aldosterone under Normal Salt Diet Induces Cardiac Hypertrophy and Infiltration via Oxidative Stress. Hypertension Research 28:5, 447-455
CrossRef894
Xiaoyan Zhou, Edward D. Frohlich. (2005) Differential Effects of Antihypertensive Drugs on Renal and Glomerular Hemodynamics and Injury in the Chronic Nitric-Oxide-Suppressed Rat. American Journal of Nephrology 25:2, 138-152
CrossRef895
Christian J.F. Holubarsch. (2005) Evidenz-basierte Medizin mit Wei
dorn-Extrakt: Ein Phytopharmakon ist einen weiten Weg gegangen. Pharmazie in unserer Zeit 34:1, 58-64
CrossRef896
Michael Domanski, Eliot Peyster. (2005) Heart failure with preserved systolic function. Current Treatment Options in Cardiovascular Medicine 7:1, 55-59
CrossRef897
Hylton V. Joffe, Gail K. Adler. (2005) Effect of Aldosterone and Mineralocorticoid Receptor Blockade on Vascular Inflammation. Heart Failure Reviews 10:1, 31-37
CrossRef898
C. Richard Conti. (2005) Management of heart failure and left ventricular systolic dysfunction following acute myocardial infarction. Clinical Cardiology 28:1, 1-2
CrossRef899
Masahiro Yoshida, Jun Ma, Tsutomu Tomita, Norihiro Morikawa, Nobuyoshi Tanaka, Katsuhiko Masamura, Yasuyuki Kawai, Isamu Miyamori. (2005) Mineralocorticoid Receptor Is Overexpressed in Cardiomyocytes of Patients With Congestive Heart Failure. Congestive Heart Failure 11:1, 12-16
CrossRef900
Olaf Hedrich, Richard D. Patten, David Nofrio. (2005) Current treatment options for CHF management: Focus on the renin-angiotensin-aldosterone system. Current Treatment Options in Cardiovascular Medicine 7:1, 3-13
CrossRef901
Mir Imam Ibne Wahed, Kenichi Watanabe, Meilei Ma, Kenichi Yamaguchi, Toshihiro Takahashi, Hitoshi Tachikawa, Makoto Kodama, Yushifusa Aizawa. (2005) Effects of Eplerenone, a Selective Aldosterone Blocker, on the Progression of Left Ventricular Dysfunction and Remodeling in Rats with Dilated Cardiomyopathy. Pharmacology 73:2, 81-88
CrossRef902
Domenic A. Sica. (2005) Pharmacokinetics and Pharmacodynamics of Mineralocorticoid Blocking Agents and their Effects on Potassium Homeostasis. Heart Failure Reviews 10:1, 23-29
CrossRef903
Shigefumi NAKANO, Naohiko KOBAYASHI, Kohtaro YOSHIDA, Tomoyuki OHNO, Hiroaki MATSUOKA. (2005) Cardioprotective Mechanisms of Spironolactone Associated with the Angiotensin-Converting Enzyme/Epidermal Growth Factor Receptor/Extracellular Signal-Regulated Kinases, NAD(P)H Oxidase/Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1, and Rho-Kinase Pathways in Aldosterone/Salt-Induced Hypertensive Rats. Hypertension Research 28:11, 925-936
CrossRef904
Charles T. Stier, Ricardo Rocha, Praveen N. Chander. (2005) Effect of Aldosterone and MR Blockade on the Brain and the Kidney. Heart Failure Reviews 10:1, 53-62
CrossRef905
Andrew J. Burger. (2005) A Review of the Renal and Neurohormonal Effects of B-Type Natriuretic Peptide. Congestive Heart Failure 11:1, 30-38
CrossRef906
Toshio Ogihara, Hiromi Rakugi. (2005) Hypertension in the Elderly. Drugs & Aging 22:4, 297-314
CrossRef907
Bertram Pitt. (2005) The Role of Aldosterone Blockade in Patients with Heart Failure. Heart Failure Reviews 10:1, 79-83
CrossRef908
Michihiro Yoshimura. (2005) Folia Pharmacologica Japonica 126:6, 377-380
CrossRef909
Gisli Jonsson, Michael Abdelnoor, Carl Müller, Sverre Erik Kjeldsen, Ingrid Os, Arne Westheim. (2005) A Comparison of the Two β-Blockers Carvedilol and Atenolol on Left Ventricular Ejection Fraction and Clinical Endpoints after Myocardial Infarction. Cardiology 103:3, 148-155
CrossRef910
Maria Vittoria Pitzalis, Massimo Iacoviello, Roberta Romito, Pietro Guida, Elisabetta De Tommasi, Giovanni Luzzi, Matteo Anaclerio, Cinzia Forleo, Paolo Rizzon. (2005) Ventricular asynchrony predicts a better outcome in patients with chronic heart failure receiving cardiac resynchronization therapy. Journal of the American College of Cardiology 45:1, 65-69
CrossRef911
Romain Bos, Nathalie Mougenot, Laurent Findji, Odile M??diani, Paul M. Vanhoutte, Philippe Lechat. (2005) Inhibition of Catecholamine-Induced Cardiac Fibrosis by an Aldosterone Antagonist. Journal of Cardiovascular Pharmacology 45:1, 8-13
CrossRef912
Sandeep A. Kamath, S. Raja Laskar, Clyde W. Yancy. (2005) Novel Therapies for Heart Failure: Vasopressin and Selective Aldosterone Antagonists. Congestive Heart Failure 11:1, 21-29
CrossRef913
C. Leclercq. (2005) La resynchronisation cardiaque : quel type d’appareil utiliser ?. Annales de Cardiologie et d'Angéiologie 54:1, 12-16
CrossRef914
Justine I. Davies, Miles D. Witham, Allan D. Struthers. (2005) Autonomic Effects of Spironolactone and MR Blockers in Heart Failure. Heart Failure Reviews 10:1, 63-69
CrossRef915
Faiez Zannad, Anca Radauceanu. (2005) Effect of MR Blockade on Collagen Formation and Cardiovascular Disease with a Specific Emphasis on Heart Failure. Heart Failure Reviews 10:1, 71-78
CrossRef916
Sergio Richter, Gabor Duray, Gerian Grönefeld, Carsten W Israel, Stefan H Hohnloser. (2005) Prevention of Sudden Cardiac Death. Circulation Journal 69:6, 625-629
CrossRef917
John W. Funder. (2005) ACE inhibitors and mineralocorticoid receptor blockade in patients with congestive heart failure. Current Diabetes Reports 5:1, 36-40
CrossRef918
John W. Funder. (2005) Mineralocorticoid Receptors: Distribution and Activation. Heart Failure Reviews 10:1, 15-22
CrossRef919
Nagahiro Nishikawa, Kazuhiro Yamamoto, Yasushi Sakata, Toshiaki Mano, Junichi Yoshida, Seiko Umekawa1, Masatsugu Hori, Yuki Yasuhara, Teruyuki Sonoyama, Akimitsu Harada, Tohru Masuyama. (2005) Long-Term Effect of Spironolactone on Cardiac Structure as Assessed by Analysis of Ultrasonic Radio-Frequency Signals in Patients With Ventricular Hypertrophy. Circulation Journal 69:11, 1394-1400
CrossRef920
Allan D. Struthers. (2004) Aldosterone in heart failure: Pathophysiology and treatment. Current Heart Failure Reports 1:4, 171-175
CrossRef921
Kumaraswamy Nanthakumar, Andrew E. Epstein, G. Neal Kay, Vance J. Plumb, Douglas S. Lee. (2004) Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction. Journal of the American College of Cardiology 44:11, 2166-2172
CrossRef922
Ellen Burgess. (2004) Eplerenone in hypertension. Expert Opinion on Pharmacotherapy 5:12, 2573-2581
CrossRef923
John J.V. McMurray, Marc A. Pfeffer. (2004) The year in heart failure. Journal of the American College of Cardiology 44:12, 2398-2405
CrossRef924
David Rosenthal, Maryanne R.K. Chrisant, Erik Edens, Lynn Mahony, Charles Canter, Steven Colan, Anne Dubin, Jacque Lamour, Robert Ross, Robert Shaddy, Linda Addonizio, Lee Beerman, Stuart Berger, Daniel Bernstein, Elizabeth Blume, Mark Boucek, Paul Checchia, Anne Dipchand, Jonathan Drummond-Webb, Jay Fricker, Richard Friedman, Sara Hallowell, Robert Jaquiss, Seema Mital, Elfriede Pahl, Bennett Pearce, Larry Rhodes, Kathy Rotondo, Paolo Rusconi, Janet Scheel, Tajinder Pal Singh, Jeffrey Towbin. (2004) International Society for Heart and Lung Transplantation: Practice guidelines for management of heart failure in children. The Journal of Heart and Lung Transplantation 23:12, 1313-1333
CrossRef925
P. Cía Gómez, A. Martínez Berganza, J.I. Pérez Calvo. (2004) Tratamiento farmacológico de la hipertensión arterial. Medicine - Programa de Formación Médica Continuada Acreditado 9:23, 1481-1493
CrossRef926
Keyur B. Shah, Stephen S. Gottlieb. (2004) Current concepts for the neurohormonal management of left ventricular dysfunction after myocardial infarction. Current Heart Failure Reports 1:4, 161-167
CrossRef927
(2004) Aldosterone Revisited. New England Journal of Medicine 351:20, 2131-2133
Full Text928
Mary Clare Derfler, Mark Jacob, Robert E. Wolf, Frank Bleyer, Paul J. Hauptman. (2004) Mode of Death From Congestive Heart Failure: Implications for Clinical Management. The American Journal of Geriatric Cardiology 13:6, 299-304
CrossRef929
Robert E Hobbs. (2004) Guidelines for the Diagnosis and Management of Heart Failure. American Journal of Therapeutics 11:6, 467-472
CrossRef930
Allison M. Pritchett, Douglas L. Mann. (2004) Neurohormonal therapy for congestive heart failure. Current Treatment Options in Cardiovascular Medicine 6:6, 499-507
CrossRef931
van de Wal Rma, Voors AA, Plokker HWM, van Gilst WH, van Veldhuisen DJ. (2004) New Pharmacological Strategies in Chronic Heart Failure. Cardiovascular Drugs and Therapy 18:6, 491-501
CrossRef932
John IP, Sricharan Kantipudi, Atul Khasnis, Anand Cholia, Michael Dickinson. (2004) Statin Therapy Is Associated With Improved Survival in Ischemic and Non-Ischemic Heart Failure. Rates of Hyperkalemia After Publication of the Randomized Aldactone Evaluation Study. Congestive Heart Failure 10:6, 313-315
CrossRef933
Myron H. Weinberger. (2004) The Use of Aldosterone Receptor Blockers in the Treatment of Hypertension. The Journal of Clinical Hypertension 6:11, 632-635
CrossRef934
John C Somberg, Janos Molnar. (2004) The Pharmacologic Treatment of Heart Failure. American Journal of Therapeutics 11:6, 480-488
CrossRef935
Maziar Azadpour, Gervasio A Lamas. (2004) AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction. Expert Review of Cardiovascular Therapy 2:6, 891-902
CrossRef936
Angie Veverka, Jamie L Jolly. (2004) Recent advances in the secondary prevention of coronary heart disease. Expert Review of Cardiovascular Therapy 2:6, 877-889
CrossRef937
PETER GROSS. (2004) Renal transport proteins in excreted urine: Gold mine or gold dust?. Kidney International 66:4, 1707-1708
CrossRef938
Steven N. Singh, Jonathan Patrick. (2004) Antiarrhythmic drugs. Current Treatment Options in Cardiovascular Medicine 6:5, 357-364
CrossRef939
Ji-Guang Wang, Lifang Liu, Laura Zagato, Jinxiang Xie, Robert Fagard, Kugen Jin, Jinxiang Wang, Yan Li, Giuseppe Bianchi, Jan A. Staessen, Lisheng Liu. (2004) Renal function in relation to three candidate genes in a Chinese population. Journal of Molecular Medicine 82:10, 715-722
CrossRef940
Victor N. Uebele, Cindy E. Nuss, John J. Renger, Thomas M. Connolly. (2004) Role of voltage-gated calcium channels in potassium-stimulated aldosterone secretion from rat adrenal zona glomerulosa cells. The Journal of Steroid Biochemistry and Molecular Biology 92:3, 209-218
CrossRef941
Serge Masson, Lidia Staszewsky, Giorgio Annoni, Eleonora Carlo, Beatrice Arosio, Antonio Bai, Carmen Calabresi, Elena Martinoli, Monica Salio, Fabio Fiordaliso, Eugenio Scanziani, Amy E. Rudolph, Roberto Latini. (2004) Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction. Journal of Cardiac Failure 10:5, 433-441
CrossRef942
Fraser M Rogerson, Yizhou Yao, Brian J Smith, Peter J Fuller. (2004) Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor*. Clinical and Experimental Pharmacology and Physiology 31:10, 704-709
CrossRef943
J. Bauersachs. (2004) Aldosterone antagonism in heart failure: improvement of cardiac remodelling, endothelial dysfunction and platelet activation. European Journal of Clinical Investigation 34:10, 649-652
CrossRef944
J. I. Davies, M. Band, A. Morris, A. D. Struthers. (2004) Spironolactone impairs endothelial function and heart rate variability in patients with Type 2 diabetes. Diabetologia 47:10, 1687-1694
CrossRef945
Lars H. Lund, Donna Mancini. (2004) Heart failure in women. Medical Clinics of North America 88:5, 1321-1345
CrossRef946
Liviu Klein, Mihai Gheorghiade. (2004) Coronary artery disease and prevention of heart failure. Medical Clinics of North America 88:5, 1209-1235
CrossRef947
Jocelyn D. Jones, Keecia D. King, Frank S. Emanuel. (2004) Hypertension: A Clinical Pharmacist's Synopsis of JNC 7. American Journal of Pharmaceutical Education 68:3, 71
CrossRef948
ML Ambroisine, P Milliez, J Nehme, AL Pasquier, N De Angelis, P Mansier, B Swynghedauw, C Delcayre. (2004) Aldosterone and anti-aldosterone effects in cardiovascular diseases and diabetic nephropathy. Diabetes & Metabolism 30:4, 311-318
CrossRef949
Niels H. Andersen, Carl E. Mogensen. (2004) Dual blockade of the renin angiotensin system in diabetic and nondiabetic kidney disease. Current Hypertension Reports 6:5, 369-376
CrossRef950
Leonard I. Ganz. (2004) Primary prevention of sudden cardiac death. Current Cardiology Reports 6:5, 339-347
CrossRef951
Marc A. Silver, Alan Maisel, Clyde W. Yancy, Peter A. McCullough, John C. Burnett, Gary S. Francis, Mandeep R. Mehra, Gregg Fonarow, W. Brian Gibler, David A. Morrow, Judd Hollander. (2004) BNP Consensus Panel 2004: A Clinical Approach for the Diagnostic, Prognostic, Screening, Treatment Monitoring, and Therapeutic Roles of Natriuretic Peptides in Cardiovascular Diseases. Congestive Heart Failure 10:s5, 1-30
CrossRef952
Guido Boerrigter, John C. Burnett. (2004) Cardiorenal syndrome in decompensated heart failure: Prognostic and therapeutic implications. Current Heart Failure Reports 1:3, 113-120
CrossRef953
Myron H. Weinberger. (2004) The use of selective aldosterone antagonists. Current Hypertension Reports 6:5, 342-345
CrossRef954
Sidney Goldstein. (2004) The changing epidemiology of sudden death in heart failure. Current Heart Failure Reports 1:3, 93-97
CrossRef955
Domenic A. Sica, Michael Hess. (2004) Aldosterone Receptor Antagonism: Interface With Hyperkalemia in Heart Failure. Congestive Heart Failure 10:5, 259-264
CrossRef956
P. Gross. (2004) Hyperkalaemia: again. Nephrology Dialysis Transplantation 19:9, 2163-2166
CrossRef957
Palmer, Biff F., . (2004) Managing Hyperkalemia Caused by Inhibitors of the Renin–Angiotensin–Aldosterone System. New England Journal of Medicine 351:6, 585-592
Full Text958
Elliott M. Antman, Daniel T. Anbe, Paul Wayne Armstrong, Eric R. Bates, Lee A. Green, Mary Hand, Judith S. Hochman, Harlan M. Krumholz, Frederick G. Kushner, Gervasio A. Lamas, Charles J. Mullany, Joseph P. Ornato, David L. Pearle, Michael A. Sloan, Sidney C. Smith, Elliott M. Antman, Sidney C. Smith, Joseph S. Alpert, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Raymond J. Gibbons, Gabriel Gregoratos, Jonathan L. Halperin, Loren F. Hiratzka, Sharon Ann Hunt, Alice K. Jacobs, Joseph P. Ornato. (2004) ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary. Journal of the American College of Cardiology 44:3, 671-719
CrossRef959
David G. Warnock, Stephen C. Textor. (2004) Hypertension. American Journal of Kidney Diseases 44:2, 369-375
CrossRef960
C Sierra, Luis M Ruilope. (2004) Novel antihypertensive agents. Expert Opinion on Investigational Drugs 13:8, 987-998
CrossRef961
Morten Svensson, Finn Gustafsson, SØren Galatius, Per R Hildebrandt, Dan Atar. (2004) How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?. Journal of Cardiac Failure 10:4, 297-303
CrossRef962
Alex Adler, Barry H. Greenberg. (2004) Use of beta blockers in patients with post-MI left ventricular dysfunction. Current Treatment Options in Cardiovascular Medicine 6:4, 335-343
CrossRef963
Anita Deswal, David Yao. (2004) Aldosterone receptor blockers in the treatment of heart failure. Current Treatment Options in Cardiovascular Medicine 6:4, 327-334
CrossRef964
Ari Mosenkis, Raymond R. Townsend. (2004) Gynecomastia and Antihypertensive Therapy. The Journal of Clinical Hypertension 6:8, 122-130
CrossRef965
Richard D. Patten, Prem Soman. (2004) Prevention and reversal of LV remodeling with neurohormonal inhibitors. Current Treatment Options in Cardiovascular Medicine 6:4, 313-325
CrossRef966
Joanne Moncrieff, M Mitchell Lindsay, Francis G Dunn. (2004) Hypertensive heart disease and fibrosis. Current Opinion in Cardiology 19:4, 326-331
CrossRef967
Vinay Thohan, Guillermo Torre-Amione, Micheal M Koerner. (2004) Aldosterone antagonism and congestive heart failure: a new look at an old therapy. Current Opinion in Cardiology 19:4, 301-308
CrossRef968
W.H Wilson Tang, Anjli Maroo, James B Young. (2004) Ischemic heart disease and congestive heart failure in diabetic patients. Medical Clinics of North America 88:4, 1037-1061
CrossRef969
Nanette K. Wenger, Gabriel Gregoratos, Dalane W. Kitzman, Stephen Scheidt, Michael A. Weber, Joseph S. Alpert. (2004) Guidelines of the Cardiogeriatrics Department of the Brazilian Cardiology Society: Commentary by Editorial Board Members of The American Journal of Geriatric Cardiology. CARDIAC ARRHYTHMIAS. HEART FAILURE. CORONARY ARTERY DISEASE (CHRONIC STABLE ANGINA, ACUTE CORONARY SYNDROME, ACUTE MI). SYSTEMIC ARTERIAL HYPERTENSION. VALVULOPATHIES. CARDIOVASCULAR RISK PREVENTION. The American Journal of Geriatric Cardiology 13:4, 209-209
CrossRef970
Felix J Frey, A Odermatt, Brigitte M Frey. (2004) Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension. Current Opinion in Nephrology and Hypertension 13:4, 451-458
CrossRef971
Olga Gumieniak, Gordon H. Williams. (2004) Mineralocorticoid receptor antagonists and hypertension: Is there a rationale?. Current Hypertension Reports 6:4, 279-287
CrossRef972
David J. Meier, Bertram Pitt, Sanjay Rajagopalan. (2004) Eplerenone: Will it have a role in the treatment of acute coronary syndromes?. Current Cardiology Reports 6:4, 259-263
CrossRef973
Karl T. Weber. (2004) Efficacy of aldosterone receptor antagonism in heart failure: Potential mechanisms. Current Heart Failure Reports 1:2, 51-56
CrossRef974
Pablo Navarro, Robert Moskowitz, Thierry H. Le Jemtel. (2004) Inhibition of RAAS—When is it too much?. Current Heart Failure Reports 1:2, 57-64
CrossRef975
Monica R Shah, Lynne W Stevenson. (2004) Searching for evidence: refractory questions in advanced heart failure. Journal of Cardiac Failure 10:3, 210-218
CrossRef976
Brian F. McBride, C. Michael White. (2004) Anemia Management in Heart Failure: A Thick Review of Thin Data. Pharmacotherapy 24:6, 757-767
CrossRef977
Steven R. Goldsmith. (2004) Interactions between the sympathetic nervous system and the RAAS in heart failure. Current Heart Failure Reports 1:2, 45-50
CrossRef978
Carl V. Leier. (2004) Advanced Heart Failure: A Practical Management Algorithm and Therapeutic Options. The American Heart Hospital Journal 2:3, 142-148
CrossRef979
Kadish, Alan, Dyer, Alan, Daubert, James P., Quigg, Rebecca, Estes, N.A. Mark, Anderson, Kelley P., Calkins, Hugh, Hoch, David, Goldberger, Jeffrey, Shalaby, Alaa, Sanders, William E., Schaechter, Andi, Levine, Joseph H., . (2004) Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy. New England Journal of Medicine 350:21, 2151-2158
Full Text980
J.R Payne, S.S Dhamrait, I.S Toor, J Cooper, A Jones, G.J Miller, S.E Humphries, H.E Montgomery. (2004) The −344T>C promoter variant of the gene for aldosterone synthase (CYP11B2) is not associated with cardiovascular risk in a prospective study of UK healthy men. Atherosclerosis 174:1, 81-86
CrossRef981
(2004) References. American Journal of Kidney Diseases 43, 268-290
CrossRef982
Angelo Capricchione, Nathaniel Winer, James R. Sowers. (2004) Adrenocortical hypertension. Current Hypertension Reports 6:3, 224-229
CrossRef983
W.H. Wilson Tang, Gary S. Francis. (2004) Evolving concepts in left ventricular systolic and diastolic remodeling: Implications for therapy. Current Cardiology Reports 6:3, 200-204
CrossRef984
Peter J. Fuller. (2004) Aldosterone and DNA: the 50th anniversary. Trends in Endocrinology & Metabolism 15:4, 143-146
CrossRef985
William H. Frishman, Charles T. Stier. (2004) Aldosterone and aldosterone antagonism in systemic hypertension. Current Hypertension Reports 6:3, 195-200
CrossRef986
Henry Krum, Danny Liew. (2004) Eplerenone in the treatment of chronic heart failure. Expert Review of Cardiovascular Therapy 2:3, 315-320
CrossRef987
Maylene Wong, Luigi Tavazzi. (2004) Effect of Drug Therapy for Heart Failure on Quality of Life. The Journal of Clinical Hypertension 6:5, 256-261
CrossRef988
John W. Funder. (2004) Is aldosterone bad for the heart?. Trends in Endocrinology & Metabolism 15:4, 139-142
CrossRef989
Rachel Hughes-Doichev, Mark E. Dunlap. (2004) Is heart failure different on the two continents (North America and Europe)?. Current Cardiology Reports 6:3, 182-188
CrossRef990
Clyde W. Yancy. (2004) Improving Outcomes in the Post-Myocardial Infarction Setting. The Journal of Clinical Hypertension 6:s4, 34-41
CrossRef991
J. M. Trujillo, M. J. Gonyeau, M. V. DiVall, S. L. Alexander. (2004) Spironolactone use in patients with heart failure. Journal of Clinical Pharmacy and Therapeutics 29:2, 165-170
CrossRef992
Domenic Sica. (2004) Hypertension and End-Organ Disease in African Americans: Case Presentations. The Journal of Clinical Hypertension 6:s4, 48-53
CrossRef993
Janine Fletcher, Ashesh N Buch, Helen C Routledge, Saqib Chowdhary, John H Coote, Jonathan N Townend. (2004) Acute aldosterone antagonism improves cardiac vagal control in humans. Journal of the American College of Cardiology 43:7, 1270-1275
CrossRef994
Susan M Garthwaite, Ellen G McMahon. (2004) The evolution of aldosterone antagonists. Molecular and Cellular Endocrinology 217:1-2, 27-31
CrossRef995
Jo??l M??nard, Michel Azizi. (2004) Renin???angiotensin system blockade. Journal of Hypertension 22:3, 459-462
CrossRef996
Joël Ménard. (2004) The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Molecular and Cellular Endocrinology 217:1-2, 45-52
CrossRef997
Donald Silverberg, Dov Wexler, Miriam Blum, Doron Schwartz, Adrian Iaina. (2004) The association between congestive heart failure and chronic renal disease. Current Opinion in Nephrology and Hypertension 13:2, 163-170
CrossRef998
Elise P Gomez-Sanchez. (2004) Brain mineralocorticoid receptors: orchestrators of hypertension and end-organ disease. Current Opinion in Nephrology and Hypertension 13:2, 191-196
CrossRef999
Norman Sharpe. (2004) Pharmacologic effects on cardiac remodeling. Current Heart Failure Reports 1:1, 9-13
CrossRef1000
C Heymes, A Garnier, S Fuchs, J.K Bendall, J Nehme, M.L Ambroisine, E Robidel, B Swynghedauw, P Milliez, C Delcayre. (2004) Aldosterone-synthase overexpression in heart: a tool to explore aldosterone’s effects. Molecular and Cellular Endocrinology 217:1-2, 213-219
CrossRef1001
John D Baxter, John W Funder, James W Apriletti, Paul Webb. (2004) Towards selectively modulating mineralocorticoid receptor function: lessons from other systems. Molecular and Cellular Endocrinology 217:1-2, 151-165
CrossRef1002
Amy E. Rudolph, Ricardo Rocha, Ellen G. McMahon. (2004) Aldosterone target organ protection by eplerenone. Molecular and Cellular Endocrinology 217:1-2, 229-238
CrossRef1003
Damien Le Menuet, Say Viengchareun, Martine Muffat-Joly, Maria-Christina Zennaro, Marc Lombès. (2004) Expression and function of the human mineralocorticoid receptor: lessons from transgenic mouse models. Molecular and Cellular Endocrinology 217:1-2, 127-136
CrossRef1004
Dahai Wang, Yun-He Liu, Xiao-Ping Yang, Nour-Eddine Rhaleb, Jiang Xu, Edward Peterson, Amy E Rudolph, Oscar A Carretero. (2004) Role of a selective aldosterone blocker in mice with chronic heart failure. Journal of Cardiac Failure 10:1, 67-73
CrossRef1005
Gian Paolo Rossi. (2004) Primary aldosteronism: A needle in a haystack or a yellow cab on fifth avenue?. Current Hypertension Reports 6:1, 1-4
CrossRef1006
Yoshiyu TAKEDA. (2004) Pleiotropic Actions of Aldosterone and the Effects of Eplerenone, a Selective Mineralocorticoid Receptor Antagonist. Hypertension Research 27:11, 781-789
CrossRef1007
Atsuhisa SATO, Takao SARUTA. (2004) Aldosterone-Induced Organ Damage: Plasma Aldosterone Level and Inappropriate Salt Status. Hypertension Research 27:5, 303-310
CrossRef1008
Roberto Latini, Serge Masson, Lidia Staszewsky, Aldo P Maggioni. (2004) Valsartan for the treatment of heart failure. Expert Opinion on Pharmacotherapy 5:1, 181-193
CrossRef1009
Nicholas L M Cruden, David E Newby. (2004) Angiotensin Antagonism in Patients with Heart Failure. American Journal of Cardiovascular Drugs 4:6, 345-353
CrossRef1010
Georg Ertl, Johann Bauersachs. (2004) Endothelin Receptor Antagonists in Heart Failure. Drugs 64:10, 1029-1040
CrossRef1011
Takayoshi TSUTAMOTO. (2004) Mineralocorticoid receptor antagonist spironolactone improves left ventricular remodeling in patients with congestive heart failure and acute myocardial infarction. Folia Pharmacologica Japonica 124:2, 90-100
CrossRef1012
Adelle Dawson, Justine I Davies, Allan D Struthers. (2004) The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade. Expert Review of Cardiovascular Therapy 2:1, 29-36
CrossRef1013
Massimo Volpe. (2004) Evidence-Based Indications in Hypertensive Patients. High Blood Pressure & Cardiovascular Prevention 11:1, 1-7
CrossRef1014
Minoru YOSHIYAMA, Takashi OMURA, Jyunichi YOSHIKAWA. (2004) Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin II type 1 receptor antagonist in rats with myocardial infarction. Folia Pharmacologica Japonica 124:2, 83-89
CrossRef1015
Gillian M Keating, Greg L Plosker. (2004) Eplerenone. Drugs 64:23, 2689-2707
CrossRef1016
Makoto KODAMA, Hitoshi TACHIKAWA, Takeshi KASHIMURA, Manabu HAYASHI, Tsuyoshi YOSHIDA, Haruo HANAWA, Yoshifusa AIZAWA, Mikio NAKAZAWA, Kenichi WATANABE. (2004) Effects of humoral factors on left ventricular remodeling under chronic heart failure.. Folia Pharmacologica Japonica 123:2, 63-70
CrossRef1017
John E. Macdonald, Allan D. Struthers. (2004) What is the optimal serum potassium level in cardiovascular patients?. Journal of the American College of Cardiology 43:2, 155-161
CrossRef1018
John W Funder. (2003) The role of mineralocorticoid receptor antagonists in the treatment of cardiac failure. Expert Opinion on Investigational Drugs 12:12, 1963-1969
CrossRef1019
Rajan Krishnamani, Mohamad El-Zaru, David DeNofrio. (2003) Contemporary medical, surgical, and device therapies for end-stage heart failure. Current Treatment Options in Cardiovascular Medicine 5:6, 487-499
CrossRef1020
Michael Stowasser, Richard D Gordon. (2003) Primary aldosteronism. Best Practice & Research Clinical Endocrinology & Metabolism 17:4, 591-605
CrossRef1021
Mann, Douglas L., Deswal, Anita, . (2003) Angiotensin-Receptor Blockade in Acute Myocardial Infarction — A Matter of Dose. New England Journal of Medicine 349:20, 1963-1965
Full Text1022
Scott D. Solomon, Marc A. Pfeffer. (2003) Aldosterone antagonism and myocardial infarction. Journal of the American College of Cardiology 42:9, 1674-1676
CrossRef1023
Stefan Viktor Vormfelde, Gerhard Burckhardt, Alexandra Zirk, Leszek Wojnowski, Jürgen Brockmöller. (2003) Pharmacogenomics of diuretic drugs: data on rare monogenic disorders and on polymorphisms and requirements for further research. Pharmacogenomics 4:6, 701-734
CrossRef1024
Sheila A Doggrell. (2003) Are implantable cardioverter-defribrillators always superior to amiodarone?. Expert Opinion on Pharmacotherapy 4:11, 2111-2114
CrossRef1025
Kelli L. Davis, Jean M. Nappi. (2003) The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist. Clinical Therapeutics 25:11, 2647-2668
CrossRef1026
WH Wilson Tang, Gary S Francis. (2003) Novel pharmacological treatments for heart failure. Expert Opinion on Investigational Drugs 12:11, 1791-1801
CrossRef1027
Jay Lakkis, Wei X. Lu, Matthew R. Weir. (2003) RAAS escape: A real clinical entity that may be important in the progression of cardiovascular and renal disease. Current Hypertension Reports 5:5, 408-417
CrossRef1028
Charles T. Stier. (2003) Eplerenone: A Selective Aldosterone Blocker. Cardiovascular Drug Reviews 21:3, 169-184
CrossRef1029
Tera D. Moore, James J. Nawarskas, Joe R. Anderson. (2003) Eplerenone. Heart Disease 5:5, 354-363
CrossRef1030
Peter Sleight, Salim Yusuf. (2003) New evidence on the importance of the renin???angiotensin system in the treatment of higher-risk patients with hypertension. Journal of Hypertension 21:9, 1599-1608
CrossRef1031
A. JOHN CAMM. (2003) Translation of Clinical Trials into Clinical Practice:. Journal of Cardiovascular Electrophysiology 14, S9-S14
CrossRef1032
Sheila Doggrell. (2003) Should the aldosterone-receptor antagonist – eplerenone – be used after acute myocardial infarction with left ventricular dysfunction?. Expert Opinion on Pharmacotherapy 4:9, 1605-1607
CrossRef1033
William E. Chavey, Barry E. Bleske, John M. Nicklas. (2003) Controversies in the Use of Beta Blockers in Heart Failure. Congestive Heart Failure 9:5, 255-262
CrossRef1034
Amar Mohammad Salam. (2003) Selective aldosterone blockade with eplerenone in patients with congestive heart failure. Expert Opinion on Investigational Drugs 12:8, 1423-1427
CrossRef1035
Brian F. McBride, C. Michael White. (2003) Acute Decompensated Heart Failure: A Contemporary Approach to Pharmacotherapeutic Management. Pharmacotherapy 23:8, 997-1020
CrossRef1036
Steven J. Hussein, John R. Teerlink. (2003) Novel pharmacologic therapy of heart failure. Current Treatment Options in Cardiovascular Medicine 5:4, 321-335
CrossRef1037
Adrian F Hernandez, Christopher M O'Connor. (2003) Sparing a little may save a lot. Journal of the American College of Cardiology 42:4, 709-711
CrossRef1038
(2003) Eplerenone in Patients with Left Ventricular Dysfunction. New England Journal of Medicine 349:1, 88-89
Full Text1039
. (2003) Nieuwe hoop voor patiënten met hartfalen. Medisch-Farmaceutische Mededelingen 41:7, 194-195
CrossRef1040
Domemic A. Sica, Todd W.B. Gehr, Clyde Yancy. (2003) Hyperkalemia, Congestive Heart Failure, and Aldosterone Receptor Antagonism. Congestive Heart Failure 9:4, 224-229
CrossRef1041
W. H. Wilson Tang, Gary S. Francis. (2003) Trends and Treatment of Heart Failure Developing After Acute Myocardial Infarction. The American Heart Hospital Journal 1:3, 216-218
CrossRef1042
Todd S. Perlstein, Eveline M. Oestreicher, Gail K. Adler. (2003) Role for aldosterone in cardiovascular injury. Current Opinion in Endocrinology and Diabetes 10:3, 191-196
CrossRef1043
Henry Krum, Danny Liew. (2003) New developments in the pharmacological treatment of chronic heart failure. Expert Opinion on Investigational Drugs 12:5, 751-757
CrossRef1044
Jessup, Mariell, . (2003) Aldosterone Blockade and Heart Failure. New England Journal of Medicine 348:14, 1380-1382
Full Text1045
Danny Liew, Henry Krum. (2003) Aldosterone Receptor Antagonists for Hypertension. Drugs 63:19, 1963-1972
CrossRef1046
C SHIRODARIA. (2002) What's new in & Ischaemic heart disease and MI. Medicine 30:5, 1-4
CrossRef
- Letters
